aeid,acid,assay_component_endpoint_name,export_ready,internal_ready,assay_component_endpoint_desc,assay_function_type,normalized_data_type,analysis_direction,burst_assay,key_positive_control,signal_direction,intended_target_type,intended_target_type_sub,intended_target_family,intended_target_family_sub,fit_all
1,1,ACEA_T47D_80hr_Negative,1,1,"Data from the assay component ACEA_T47D_80hr was analyzed into 2 assay endpoints. This assay endpoint, ACEA_T47D_80hr_Negative, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,negative,1,"MG 132",loss,cellular,cellular,"cell cycle",cytotoxicity,0
2,1,ACEA_T47D_80hr_Positive,1,1,"Data from the assay component ACEA_T47D_80hr was analyzed into 2 assay endpoints. 
This assay endpoint, ACEA_T47D_80hr_Positive, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, measures of the cells for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.",signaling,percent_activity,positive,0,17b-estradiol,gain,pathway,pathway-specified,"nuclear receptor",steroidal,0
3,2,APR_HepG2_CellCycleArrest_1h_dn,1,1,"Data from the assay component APR_HepG2_CellCycleArrest_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'proliferation'.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,"cell cycle",proliferation,0
4,2,APR_HepG2_CellCycleArrest_1h_up,1,1,"Data from the assay component APR_HepG2_CellCycleArrest_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'arrest'.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,"cell cycle",arrest,0
5,3,APR_HepG2_CellLoss_1h_dn,1,1,"Data from the assay component APR_HepG2_CellLoss_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log2_fold_induction,negative,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,loss,cellular,cellular,"cell cycle",cytotoxicity,0
6,3,APR_HepG2_CellLoss_1h_up,1,1,"Data from the assay component APR_HepG2_CellLoss_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for gain-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'proliferation'.",viability,log2_fold_induction,positive,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,gain,cellular,cellular,"cell cycle",proliferation,0
7,4,APR_HepG2_MicrotubuleCSK_1h_dn,1,1,"Data from the assay component APR_HepG2_MicrotubuleCSK_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MicrotubuleCSK_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of conformation reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,loss,cellular,cellular,"cell morphology","cell conformation",0
8,4,APR_HepG2_MicrotubuleCSK_1h_up,1,1,"Data from the assay component APR_HepG2_MicrotubuleCSK_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MicrotubuleCSK_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of conformation reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,gain,cellular,cellular,"cell morphology","cell conformation",0
9,5,APR_HepG2_MitoMass_1h_dn,1,1,"Data from the assay component APR_HepG2_MitoMass_1hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMass_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'organelle conformation'.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,loss,cellular,mitochondria,"cell morphology","organelle conformation",0
10,5,APR_HepG2_MitoMass_1h_up,1,1,"Data from the assay component APR_HepG2_MitoMass_1hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMass_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'organelle conformation'.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,gain,cellular,mitochondria,"cell morphology","organelle conformation",0
11,6,APR_HepG2_MitoMembPot_1h_dn,1,1,"Data from the assay component APR_HepG2_MitoMembPot_1hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMembPot_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'organelle conformation'.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,loss,cellular,mitochondria,"cell morphology","organelle conformation",0
12,6,APR_HepG2_MitoMembPot_1h_up,1,1,"Data from the assay component APR_HepG2_MitoMembPot_1hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMembPot_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of membrane potential reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'organelle conformation'.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,gain,cellular,mitochondria,"cell morphology","organelle conformation",0
13,7,APR_HepG2_MitoticArrest_1h_dn,1,1,"Data from the assay component APR_HepG2_MitoticArrest_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'proliferation'.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,loss,pathway,pathway-specified,"cell cycle",proliferation,0
14,7,APR_HepG2_MitoticArrest_1h_up,1,1,"Data from the assay component APR_HepG2_MitoticArrest_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'arrest'.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,gain,pathway,pathway-specified,"cell cycle",arrest,0
15,8,APR_HepG2_NuclearSize_1h_dn,1,1,"Data from the assay component APR_HepG2_NuclearSize_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_NuclearSize_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the nuclear-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'organelle conformation'.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,loss,cellular,nucleus,"cell morphology","organelle conformation",0
16,8,APR_HepG2_NuclearSize_1h_up,1,1,"Data from the assay component APR_HepG2_NuclearSize_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_NuclearSize_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for gain-of-signal activity can be used to understand the signaling at the nuclear-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'organelle conformation'.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,gain,cellular,nucleus,"cell morphology","organelle conformation",0
17,9,APR_HepG2_OxidativeStress_1h_dn,1,1,"Data from the assay component APR_HepG2_OxidativeStress_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_OxidativeStress_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'stress response'.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,"cell cycle","stress response",0
18,9,APR_HepG2_OxidativeStress_1h_up,1,1,"Data from the assay component APR_HepG2_OxidativeStress_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_OxidativeStress_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'stress response'.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,"cell cycle","stress response",0
19,10,APR_HepG2_p53Act_1h_dn,1,1,"Data from the assay component APR_HepG2_p53Act_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'tumor suppressor'.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,"dna binding","tumor suppressor",0
20,10,APR_HepG2_p53Act_1h_up,1,1,"Data from the assay component APR_HepG2_p53Act_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'tumor suppressor'.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,"dna binding","tumor suppressor",0
21,11,APR_HepG2_StressKinase_1h_dn,1,1,"Data from the assay component APR_HepG2_StressKinase_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_StressKinase_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'stress response'.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,"cell cycle","stress response",0
22,11,APR_HepG2_StressKinase_1h_up,1,1,"Data from the assay component APR_HepG2_StressKinase_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_StressKinase_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'stress response'.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,"cell cycle","stress response",0
23,12,APR_HepG2_CellCycleArrest_24h_dn,1,1,"Data from the assay component APR_HepG2_CellCycleArrest_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'proliferation'.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,"cell cycle",proliferation,0
24,12,APR_HepG2_CellCycleArrest_24h_up,1,1,"Data from the assay component APR_HepG2_CellCycleArrest_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'arrest'.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,"cell cycle",arrest,0
25,13,APR_HepG2_CellLoss_24h_dn,1,1,"Data from the assay component APR_HepG2_CellLoss_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log2_fold_induction,negative,1,Camptothecin;Anisomycin;Paclitaxel;CCCP,loss,cellular,cellular,"cell cycle",cytotoxicity,0
26,13,APR_HepG2_CellLoss_24h_up,1,1,"Data from the assay component APR_HepG2_CellLoss_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for gain-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'proliferation'.",viability,log2_fold_induction,positive,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,gain,cellular,cellular,"cell cycle",proliferation,0
27,14,APR_HepG2_MicrotubuleCSK_24h_dn,1,1,"Data from the assay component APR_HepG2_MicrotubuleCSK_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MicrotubuleCSK_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of conformation reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,cellular,cellular,"cell morphology","cell conformation",0
28,14,APR_HepG2_MicrotubuleCSK_24h_up,1,1,"Data from the assay component APR_HepG2_MicrotubuleCSK_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MicrotubuleCSK_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of conformation reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,cellular,cellular,"cell morphology","cell conformation",0
29,15,APR_HepG2_MitoMass_24h_dn,1,1,"Data from the assay component APR_HepG2_MitoMass_24hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMass_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'organelle conformation'.",signaling,log2_fold_induction,negative,0,Paclitaxel;CCCP,loss,cellular,mitochondria,"cell morphology","organelle conformation",0
30,15,APR_HepG2_MitoMass_24h_up,1,1,"Data from the assay component APR_HepG2_MitoMass_24hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMass_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'organelle conformation'.",signaling,log2_fold_induction,positive,0,Paclitaxel;CCCP,gain,cellular,mitochondria,"cell morphology","organelle conformation",0
31,16,APR_HepG2_MitoMembPot_24h_dn,1,1,"Data from the assay component APR_HepG2_MitoMembPot_24hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMembPot_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'organelle conformation'.",signaling,log2_fold_induction,negative,0,Paclitaxel;CCCP,loss,cellular,mitochondria,"cell morphology","organelle conformation",0
32,16,APR_HepG2_MitoMembPot_24h_up,1,1,"Data from the assay component APR_HepG2_MitoMembPot_24hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMembPot_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of membrane potential reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'organelle conformation'.",signaling,log2_fold_induction,positive,0,Paclitaxel;CCCP,gain,cellular,mitochondria,"cell morphology","organelle conformation",0
33,17,APR_HepG2_MitoticArrest_24h_dn,1,1,"Data from the assay component APR_HepG2_MitoticArrest_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'proliferation'.",signaling,log2_fold_induction,negative,0,Paclitaxel;CCCP,loss,pathway,pathway-specified,"cell cycle",proliferation,0
34,17,APR_HepG2_MitoticArrest_24h_up,1,1,"Data from the assay component APR_HepG2_MitoticArrest_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'arrest'.",signaling,log2_fold_induction,positive,0,Paclitaxel;CCCP,gain,pathway,pathway-specified,"cell cycle",arrest,0
35,18,APR_HepG2_NuclearSize_24h_dn,1,1,"Data from the assay component APR_HepG2_NuclearSize_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_NuclearSize_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the nuclear-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'organelle conformation'.",signaling,log2_fold_induction,negative,0,Paclitaxel;CCCP,loss,cellular,nucleus,"cell morphology","organelle conformation",0
36,18,APR_HepG2_NuclearSize_24h_up,1,1,"Data from the assay component APR_HepG2_NuclearSize_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_NuclearSize_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for gain-of-signal activity can be used to understand the signaling at the nuclear-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'organelle conformation'.",signaling,log2_fold_induction,positive,0,Paclitaxel;CCCP,gain,cellular,nucleus,"cell morphology","organelle conformation",0
37,19,APR_HepG2_OxidativeStress_24h_dn,1,1,"Data from the assay component APR_HepG2_OxidativeStress_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_OxidativeStress_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'stress response'.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,"cell cycle","stress response",0
38,19,APR_HepG2_OxidativeStress_24h_up,1,1,"Data from the assay component APR_HepG2_OxidativeStress_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_OxidativeStress_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'stress response'.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,"cell cycle","stress response",0
39,20,APR_HepG2_p53Act_24h_dn,1,1,"Data from the assay component APR_HepG2_p53Act_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'tumor suppressor'.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,"dna binding","tumor suppressor",0
40,20,APR_HepG2_p53Act_24h_up,1,1,"Data from the assay component APR_HepG2_p53Act_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'tumor suppressor'.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,"dna binding","tumor suppressor",0
41,21,APR_HepG2_StressKinase_24h_dn,1,1,"Data from the assay component APR_HepG2_StressKinase_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_StressKinase_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'stress response'.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,"cell cycle","stress response",0
42,21,APR_HepG2_StressKinase_24h_up,1,1,"Data from the assay component APR_HepG2_StressKinase_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_StressKinase_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'stress response'.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,"cell cycle","stress response",0
43,22,APR_HepG2_CellCycleArrest_72h_dn,1,1,"Data from the assay component APR_HepG2_CellCycleArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'proliferation'.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,"cell cycle",proliferation,0
44,22,APR_HepG2_CellCycleArrest_72h_up,1,1,"Data from the assay component APR_HepG2_CellCycleArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellCycleArrest_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'arrest'.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,"cell cycle",arrest,0
45,23,APR_HepG2_CellLoss_72h_dn,1,1,"Data from the assay component APR_HepG2_CellLoss_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log2_fold_induction,negative,1,Camptothecin;Anisomycin;Paclitaxel;CCCP,loss,cellular,cellular,"cell cycle",cytotoxicity,0
46,23,APR_HepG2_CellLoss_72h_up,1,1,"Data from the assay component APR_HepG2_CellLoss_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for gain-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'proliferation'.",viability,log2_fold_induction,positive,0,Camptothecin;Anisomycin;Paclitaxel;CCCP,gain,cellular,cellular,"cell cycle",proliferation,0
47,24,APR_HepG2_MicrotubuleCSK_72h_dn,1,1,"Data from the assay component APR_HepG2_MicrotubuleCSK_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MicrotubuleCSK_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of conformation reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,cellular,cellular,"cell morphology","cell conformation",0
48,24,APR_HepG2_MicrotubuleCSK_72h_up,1,1,"Data from the assay component APR_HepG2_MicrotubuleCSK_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MicrotubuleCSK_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of conformation reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,cellular,cellular,"cell morphology","cell conformation",0
49,25,APR_HepG2_MitoMass_72h_dn,1,1,"Data from the assay component APR_HepG2_MitoMass_72hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMass_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'organelle conformation'.",signaling,log2_fold_induction,negative,0,Paclitaxel;CCCP,loss,cellular,mitochondria,"cell morphology","organelle conformation",0
50,25,APR_HepG2_MitoMass_72h_up,1,1,"Data from the assay component APR_HepG2_MitoMass_72hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMass_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'organelle conformation'.",signaling,log2_fold_induction,positive,0,Paclitaxel;CCCP,gain,cellular,mitochondria,"cell morphology","organelle conformation",0
51,26,APR_HepG2_MitoMembPot_72h_dn,1,1,"Data from the assay component APR_HepG2_MitoMembPot_72hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMembPot_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'organelle conformation'.",signaling,log2_fold_induction,negative,0,Paclitaxel;CCCP,loss,cellular,mitochondria,"cell morphology","organelle conformation",0
52,26,APR_HepG2_MitoMembPot_72h_up,1,1,"Data from the assay component APR_HepG2_MitoMembPot_72hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMembPot_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of membrane potential reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'organelle conformation'.",signaling,log2_fold_induction,positive,0,Paclitaxel;CCCP,gain,cellular,mitochondria,"cell morphology","organelle conformation",0
53,27,APR_HepG2_MitoticArrest_72h_dn,1,1,"Data from the assay component APR_HepG2_MitoticArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'proliferation'.",signaling,log2_fold_induction,negative,0,Paclitaxel;CCCP,loss,pathway,pathway-specified,"cell cycle",proliferation,0
54,27,APR_HepG2_MitoticArrest_72h_up,1,1,"Data from the assay component APR_HepG2_MitoticArrest_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MitoticArrest_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'arrest'.",signaling,log2_fold_induction,positive,0,Paclitaxel;CCCP,gain,pathway,pathway-specified,"cell cycle",arrest,0
55,28,APR_HepG2_NuclearSize_72h_dn,1,1,"Data from the assay component APR_HepG2_NuclearSize_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_NuclearSize_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the nuclear-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'organelle conformation'.",signaling,log2_fold_induction,negative,0,Paclitaxel;CCCP,loss,cellular,nucleus,"cell morphology","organelle conformation",0
56,28,APR_HepG2_NuclearSize_72h_up,1,1,"Data from the assay component APR_HepG2_NuclearSize_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_NuclearSize_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for gain-of-signal activity can be used to understand the signaling at the nuclear-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'organelle conformation'.",signaling,log2_fold_induction,positive,0,Paclitaxel;CCCP,gain,cellular,nucleus,"cell morphology","organelle conformation",0
57,29,APR_HepG2_OxidativeStress_72h_dn,1,1,"Data from the assay component APR_HepG2_OxidativeStress_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_OxidativeStress_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'stress response'.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,"cell cycle","stress response",0
58,29,APR_HepG2_OxidativeStress_72h_up,1,1,"Data from the assay component APR_HepG2_OxidativeStress_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_OxidativeStress_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'stress response'.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,"cell cycle","stress response",0
59,30,APR_HepG2_p53Act_72h_dn,1,1,"Data from the assay component APR_HepG2_p53Act_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'tumor suppressor'.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,"dna binding","tumor suppressor",0
60,30,APR_HepG2_p53Act_72h_up,1,1,"Data from the assay component APR_HepG2_p53Act_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'tumor suppressor'.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,"dna binding","tumor suppressor",0
61,31,APR_HepG2_StressKinase_72h_dn,1,1,"Data from the assay component APR_HepG2_StressKinase_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_StressKinase_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'stress response'.",signaling,log2_fold_induction,negative,0,Camptothecin;Anisomycin,loss,pathway,pathway-specified,"cell cycle","stress response",0
62,31,APR_HepG2_StressKinase_72h_up,1,1,"Data from the assay component APR_HepG2_StressKinase_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_StressKinase_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'stress response'.",signaling,log2_fold_induction,positive,0,Camptothecin;Anisomycin,gain,pathway,pathway-specified,"cell cycle","stress response",0
63,32,ATG_Ahr_CIS_up,1,1,"Data from the assay component ATG_Ahr_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Ahr_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AHR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'basic helix-loop-helix protein'.","reporter gene",log2_fold_induction,positive,0,"6-formylindolo carbazole",gain,protein,"transcription factor","dna binding","basic helix-loop-helix protein",0
64,33,ATG_AP_1_CIS_up,1,1,"Data from the assay component ATG_AP_1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AP_1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOS and JUN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'basic leucine zipper'.","reporter gene",log2_fold_induction,positive,0,4-Hydroxynonenal,gain,protein,"transcription factor","dna binding","basic leucine zipper",0
65,34,ATG_AP_2_CIS_up,1,1,"Data from the assay component ATG_AP_2_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AP_2_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TFAP2A and TFAP2B and TFAP2D. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'basic helix-turn-helix leucine zipper'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","basic helix-turn-helix leucine zipper",0
66,35,ATG_BRE_CIS_up,1,1,"Data from the assay component ATG_BRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_BRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SMAD1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'Smad protein'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","Smad protein",0
67,36,ATG_C_EBP_CIS_up,1,1,"Data from the assay component ATG_C_EBP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_C_EBP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CEBPB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'basic leucine zipper'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","basic leucine zipper",0
68,37,ATG_CMV_CIS_up,1,1,"Data from the assay component ATG_CMV_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_CMV_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'internal marker'.","background control",log2_fold_induction,positive,0,4-Hydroxynonenal,gain,protein,"transcription factor","background measurement","internal marker",0
69,38,ATG_CRE_CIS_up,1,1,"Data from the assay component ATG_CRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_CRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene CREB3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'basic leucine zipper'.","reporter gene",log2_fold_induction,positive,0,Forskolin,gain,protein,"transcription factor","dna binding","basic leucine zipper",0
70,39,ATG_DR4_LXR_CIS_up,1,1,"Data from the assay component ATG_DR4_LXR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_DR4_LXR_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H2 and NR1H3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
71,40,ATG_DR5_CIS_up,1,1,"Data from the assay component ATG_DR5_RAR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_DR5_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA and RARB and RARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,"9-cis-Retinoic Acid",gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
72,41,ATG_E_Box_CIS_up,1,1,"Data from the assay component ATG_E_Box_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_E_Box_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene USF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'basic helix-loop-helix protein'.","reporter gene",log2_fold_induction,positive,0,4-Hydroxynonenal,gain,protein,"transcription factor","dna binding","basic helix-loop-helix protein",0
73,42,ATG_E2F_CIS_up,1,1,"Data from the assay component ATG_E2F_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_E2F_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene E2F1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'E2F transcription factor'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","E2F transcription factor",0
74,43,ATG_EGR_CIS_up,1,1,"Data from the assay component ATG_EGR_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_EGR_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene EGR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'zinc finger'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","zinc finger",0
75,44,ATG_ERE_CIS_up,1,1,"Data from the assay component ATG_ERE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.","reporter gene",log2_fold_induction,positive,0,17b-estradiol,gain,protein,"transcription factor","nuclear receptor",steroidal,0
76,45,ATG_Ets_CIS_up,1,1,"Data from the assay component ATG_Ets_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Ets_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ETS1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'winged helix-turn-helix'.","reporter gene",log2_fold_induction,positive,0,4-Hydroxynonenal,gain,protein,"transcription factor","dna binding","winged helix-turn-helix",0
77,46,ATG_FoxA2_CIS_up,1,1,"Data from the assay component ATG_FoxA2_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_FoxA2_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOXA2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'forkhead box protein'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","forkhead box protein",0
78,47,ATG_FoxO_CIS_up,1,1,"Data from the assay component ATG_FoxO_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_FoxO_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene FOXO1 and FOXO3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'forkhead box protein'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","forkhead box protein",0
79,48,ATG_GATA_CIS_up,1,1,"Data from the assay component ATG_GATA_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_GATA_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GATA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'GATA proteins'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","GATA proteins",0
80,49,ATG_GLI_CIS_up,1,1,"Data from the assay component ATG_GLI_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_GLI_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene GLI1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'zinc finger'.","reporter gene",log2_fold_induction,positive,0,4-Hydroxynonenal,gain,protein,"transcription factor","dna binding","zinc finger",0
81,50,ATG_GRE_CIS_up,1,1,"Data from the assay component ATG_GRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_GRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR3C1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.","reporter gene",log2_fold_induction,positive,0,Dexamethasone,gain,protein,"transcription factor","nuclear receptor",steroidal,0
82,51,ATG_HIF1a_CIS_up,1,1,"Data from the assay component ATG_HIF1a_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HIF1a_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HIF1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'basic helix-loop-helix protein'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","basic helix-loop-helix protein",0
83,52,ATG_HNF6_CIS_up,1,1,"Data from the assay component ATG_HNF6_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HNF6_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ONECUT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'homeobox protein'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","homeobox protein",0
84,53,ATG_HSE_CIS_up,1,1,"Data from the assay component ATG_HSE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HSE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'heat shock protein'.","reporter gene",log2_fold_induction,positive,0,4-Hydroxynonenal,gain,protein,"transcription factor","dna binding","heat shock protein",0
85,54,ATG_IR1_CIS_up,1,1,"Data from the assay component ATG_IR1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_IR1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
86,55,ATG_ISRE_CIS_up,1,1,"Data from the assay component ATG_ISRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ISRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene IRF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'interferon regulatory factors'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","interferon regulatory factors",0
87,56,ATG_M_06_CIS_up,1,1,"Data from the assay component ATG_M_06_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_M_06_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'internal marker'.","background control",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","background measurement","internal marker",0
88,57,ATG_M_19_CIS_up,1,1,"Data from the assay component ATG_M_19_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_M_19_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'internal marker'.","background control",log2_fold_induction,positive,0,4-Hydroxynonenal,gain,protein,"transcription factor","background measurement","internal marker",0
89,58,ATG_M_32_CIS_up,1,1,"Data from the assay component ATG_M_32_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_M_32_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'internal marker'.","background control",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","background measurement","internal marker",0
90,59,ATG_M_61_CIS_up,1,1,"Data from the assay component ATG_M_61_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_M_61_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'internal marker'.","background control",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","background measurement","internal marker",0
91,60,ATG_MRE_CIS_up,1,1,"Data from the assay component ATG_MRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_MRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MTF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'zinc finger'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","zinc finger",0
92,61,ATG_Myb_CIS_up,1,1,"Data from the assay component ATG_Myb_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Myb_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MYB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'MYB proteins'.","reporter gene",log2_fold_induction,positive,0,4-Hydroxynonenal,gain,protein,"transcription factor","dna binding","MYB proteins",0
93,62,ATG_Myc_CIS_up,1,1,"Data from the assay component ATG_Myc_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Myc_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene MYC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'basic helix-loop-helix leucine zipper'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","basic helix-loop-helix leucine zipper",0
94,63,ATG_NF_kB_CIS_up,1,1,"Data from the assay component ATG_NF_kB_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NF_kB_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFKB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'NF-kappa B'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","NF-kappa B",0
95,64,ATG_NFI_CIS_up,1,1,"Data from the assay component ATG_NFI_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NFI_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFIA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'nuclear factor I'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","nuclear factor I",0
96,65,ATG_NRF1_CIS_up,1,1,"Data from the assay component ATG_NRF1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NRF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'nuclear respiratory factors'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","nuclear respiratory factors",0
97,66,ATG_NRF2_ARE_CIS_up,1,1,"Data from the assay component ATG_NRF2_ARE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NRF2_ARE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NFE2L2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'basic leucine zipper'.","reporter gene",log2_fold_induction,positive,0,4-Hydroxynonenal,gain,protein,"transcription factor","dna binding","basic leucine zipper",0
98,67,ATG_Oct_MLP_CIS_up,1,1,"Data from the assay component ATG_Oct_MLP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Oct_MLP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene POU2F1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'POU domain protein'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","POU domain protein",0
99,68,ATG_p53_CIS_up,1,1,"Data from the assay component ATG_p53_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_p53_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'tumor suppressor'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","tumor suppressor",0
100,69,ATG_Pax6_CIS_up,1,1,"Data from the assay component ATG_Pax6_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Pax6_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PAX6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'paired box protein'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","paired box protein",0
101,70,ATG_PBREM_CIS_up,1,1,"Data from the assay component ATG_PBREM_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PBREM_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,4-Hydroxynonenal,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
102,71,ATG_PPRE_CIS_up,1,1,"Data from the assay component ATG_PPRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA and PPARD and PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,Rosiglitazone,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
103,72,ATG_PXRE_CIS_up,1,1,"Data from the assay component ATG_PXRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PXRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,Rifampicin,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
104,73,ATG_RORE_CIS_up,1,1,"Data from the assay component ATG_RORE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RORE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORA and RORB and RORC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'orphan'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
105,74,ATG_Sox_CIS_up,1,1,"Data from the assay component ATG_Sox_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Sox_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SOX1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'HMG box protein'.","reporter gene",log2_fold_induction,positive,0,4-Hydroxynonenal,gain,protein,"transcription factor","dna binding","HMG box protein",0
106,75,ATG_Sp1_CIS_up,1,1,"Data from the assay component ATG_Sp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Sp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'zinc finger'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","zinc finger",0
107,76,ATG_SREBP_CIS_up,1,1,"Data from the assay component ATG_SREBP_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_SREBP_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene SREBF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'basic helix-loop-helix leucine zipper'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","basic helix-loop-helix leucine zipper",0
108,77,ATG_STAT3_CIS_up,1,1,"Data from the assay component ATG_STAT3_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_STAT3_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene STAT3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'stat protein'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","stat protein",0
109,78,ATG_TA_CIS_up,1,1,"Data from the assay component ATG_TA_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_TA_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'internal marker'.","background control",log2_fold_induction,positive,0,4-Hydroxynonenal,gain,protein,"transcription factor","background measurement","internal marker",0
110,79,ATG_TAL_CIS_up,1,1,"Data from the assay component ATG_TAL_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_TAL_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'internal marker'.","background control",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","background measurement","internal marker",0
111,80,ATG_TCF_b_cat_CIS_up,1,1,"Data from the assay component ATG_TCF_b_cat_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_TCF_b_cat_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TCF7 and TCF7L2 and LEF1 and TCF7L1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'HMG box protein'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","HMG box protein",0
112,81,ATG_TGFb_CIS_up,1,1,"Data from the assay component ATG_TGFb_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_TGFb_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'growth factor' intended target family, where the subfamily is 'transforming growth factor beta'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","growth factor","transforming growth factor beta",0
113,82,ATG_VDRE_CIS_up,1,1,"Data from the assay component ATG_VDRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_VDRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,4-Hydroxynonenal,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
114,83,ATG_Xbp1_CIS_up,1,1,"Data from the assay component ATG_Xbp1_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Xbp1_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene XBP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'basic leucine zipper'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","dna binding","basic leucine zipper",0
115,84,ATG_AR_TRANS_up,1,1,"Data from the assay component ATG_AR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_AR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",steroidal,0
116,85,ATG_CAR_TRANS_up,1,1,"Data from the assay component ATG_CAR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_CAR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
117,86,ATG_ERa_TRANS_up,1,1,"Data from the assay component ATG_ERa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.","reporter gene",log2_fold_induction,positive,0,17b-estradiol,gain,protein,"transcription factor","nuclear receptor",steroidal,0
118,87,ATG_ERRa_TRANS_up,1,1,"Data from the assay component ATG_ERRa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERRa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESRRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",steroidal,0
119,88,ATG_ERRg_TRANS_up,1,1,"Data from the assay component ATG_ERRg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_ERRg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene ESRRG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",steroidal,0
120,89,ATG_FXR_TRANS_up,1,1,"Data from the assay component ATG_FXR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_FXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,CDCA,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
121,90,ATG_GAL4_TRANS_up,1,1,"Data from the assay component ATG_GAL4_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_GAL4_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'baseline control'.","background control",log2_fold_induction,positive,0,4-Hydroxynonenal,gain,protein,"transcription factor","background measurement","baseline control",0
122,91,ATG_GR_TRANS_up,1,1,"Data from the assay component ATG_GR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_GR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR3C1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",steroidal,0
123,92,ATG_HNF4a_TRANS_up,1,1,"Data from the assay component ATG_HNF4a_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_HNF4a_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene HNF4A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'orphan'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
124,93,ATG_Hpa5_TRANS_up,1,1,"Data from the assay component ATG_Hpa5_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_Hpa5_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'internal marker'.","background control",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","background measurement","internal marker",0
125,94,ATG_LXRa_TRANS_up,1,1,"Data from the assay component ATG_LXRa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_LXRa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,T9,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
126,95,ATG_LXRb_TRANS_up,1,1,"Data from the assay component ATG_LXRb_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_LXRb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1H2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,T9;4-Hydroxynonenal,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
127,96,ATG_M_06_TRANS_up,1,1,"Data from the assay component ATG_M_06_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_M_06_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'internal marker'.","background control",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","background measurement","internal marker",0
128,97,ATG_M_19_TRANS_up,1,1,"Data from the assay component ATG_M_19_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_M_19_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'internal marker'.","background control",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","background measurement","internal marker",0
129,98,ATG_M_32_TRANS_up,1,1,"Data from the assay component ATG_M_32_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_M_32_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'internal marker'.","background control",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","background measurement","internal marker",0
130,99,ATG_M_61_TRANS_up,1,1,"Data from the assay component ATG_M_61_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_M_61_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the background control at the transcription factor-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'internal marker'.","background control",log2_fold_induction,positive,0,4-Hydroxynonenal,gain,protein,"transcription factor","background measurement","internal marker",0
131,100,ATG_NURR1_TRANS_up,1,1,"Data from the assay component ATG_NURR1_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_NURR1_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR4A2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'orphan'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
132,101,ATG_PPARa_TRANS_up,1,1,"Data from the assay component ATG_PPARa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,GW7647,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
133,102,ATG_PPARd_TRANS_up,1,1,"Data from the assay component ATG_PPARd_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARd_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,GW7647,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
134,103,ATG_PPARg_TRANS_up,1,1,"Data from the assay component ATG_PPARg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PPARg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,GW7647,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
135,104,ATG_PXR_TRANS_up,1,1,"Data from the assay component ATG_PXR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PXR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,4-Hydroxynonenal,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
136,105,ATG_RARa_TRANS_up,1,1,"Data from the assay component ATG_RARa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RARa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
137,106,ATG_RARb_TRANS_up,1,1,"Data from the assay component ATG_RARb_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RARb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
138,107,ATG_RARg_TRANS_up,1,1,"Data from the assay component ATG_RARg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RARg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
139,108,ATG_RORb_TRANS_up,1,1,"Data from the assay component ATG_RORb_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RORb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'orphan'.","reporter gene",log2_fold_induction,positive,0,4-Hydroxynonenal,gain,protein,"transcription factor","nuclear receptor",orphan,0
140,109,ATG_RORg_TRANS_up,1,1,"Data from the assay component ATG_RORg_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RORg_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RORC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'orphan'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
141,110,ATG_RXRa_TRANS_up,1,1,"Data from the assay component ATG_RXRa_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RXRa_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
142,111,ATG_RXRb_TRANS_up,1,1,"Data from the assay component ATG_RXRb_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_RXRb_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene RXRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
143,112,ATG_THRa1_TRANS_up,1,1,"Data from the assay component ATG_THRa1_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_THRa1_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene THRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,4-Hydroxynonenal,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
144,113,ATG_VDR_TRANS_up,1,1,"Data from the assay component ATG_VDR_TRANS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_VDR_TRANS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene VDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
145,114,BSK_3C_Eselectin_down,1,1,"Data from the assay component BSK_3C_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'selectins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"cell adhesion molecules",selectins,0
146,114,BSK_3C_Eselectin_up,1,1,"Data from the assay component BSK_3C_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Eselectin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'selectins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"cell adhesion molecules",selectins,0
147,115,BSK_3C_HLADR_down,1,1,"Data from the assay component BSK_3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'MHC Class II'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"cell adhesion molecules","MHC Class II",0
148,115,BSK_3C_HLADR_up,1,1,"Data from the assay component BSK_3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_HLADR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'MHC Class II'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"cell adhesion molecules","MHC Class II",0
149,116,BSK_3C_ICAM1_down,1,1,"Data from the assay component BSK_3C_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_ICAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"cell adhesion molecules","Immunoglobulin CAM",0
150,116,BSK_3C_ICAM1_up,1,1,"Data from the assay component BSK_3C_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_ICAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"cell adhesion molecules","Immunoglobulin CAM",0
151,117,BSK_3C_IL8_down,1,1,"Data from the assay component BSK_3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0
152,117,BSK_3C_IL8_up,1,1,"Data from the assay component BSK_3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_IL8_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0
153,118,BSK_3C_MCP1_down,1,1,"Data from the assay component BSK_3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"chemotactic factor",0
154,118,BSK_3C_MCP1_up,1,1,"Data from the assay component BSK_3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"chemotactic factor",0
155,119,BSK_3C_MIG_down,1,1,"Data from the assay component BSK_3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"chemotactic factor",0
156,119,BSK_3C_MIG_up,1,1,"Data from the assay component BSK_3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MIG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"chemotactic factor",0
157,120,BSK_3C_Proliferation_down,1,1,"Data from the assay component BSK_3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,"cell cycle",cytotoxicity,0
158,120,BSK_3C_Proliferation_up,1,1,"Data from the assay component BSK_3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_Proliferation_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for gain-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'proliferation'.",viability,log10_fold_induction,positive,0,colchicine,gain,cellular,cellular,"cell cycle",proliferation,0
159,121,BSK_3C_SRB_down,1,1,"Data from the assay component BSK_3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,"cell cycle",cytotoxicity,0
160,121,BSK_3C_SRB_up,1,1,"Data from the assay component BSK_3C_SRB was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_SRB_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-unspecified,"cell morphology","cell conformation",0
161,122,BSK_3C_Thrombomodulin_down,1,1,"Data from the assay component BSK_3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Thrombomodulin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,gpcr,"rhodopsin-like receptor",0
162,122,BSK_3C_Thrombomodulin_up,1,1,"Data from the assay component BSK_3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Thrombomodulin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,gpcr,"rhodopsin-like receptor",0
163,123,BSK_3C_TissueFactor_down,1,1,"Data from the assay component BSK_3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'coagulation factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"coagulation factor",0
164,123,BSK_3C_TissueFactor_up,1,1,"Data from the assay component BSK_3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_TissueFactor_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'coagulation factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"coagulation factor",0
165,124,BSK_3C_uPAR_down,1,1,"Data from the assay component BSK_3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"plasmogen activator",0
166,124,BSK_3C_uPAR_up,1,1,"Data from the assay component BSK_3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_uPAR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"plasmogen activator",0
167,125,BSK_3C_VCAM1_down,1,1,"Data from the assay component BSK_3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"cell adhesion molecules","Immunoglobulin CAM",0
168,125,BSK_3C_VCAM1_up,1,1,"Data from the assay component BSK_3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_VCAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"cell adhesion molecules","Immunoglobulin CAM",0
169,126,BSK_3C_Vis_down,1,1,"Data from the assay component BSK_3C_Vis was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Vis_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, loss-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.","background control",log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,"cell morphology","cell conformation",0
170,126,BSK_3C_Vis_up,1,1,"Data from the assay component BSK_3C_Vis was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Vis_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.","background control",log10_fold_induction,positive,0,colchicine,gain,cellular,cellular,"cell morphology","cell conformation",0
171,127,BSK_4H_Eotaxin3_down,1,1,"Data from the assay component BSK_4H_Eotaxin3 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Eotaxin3_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL26. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"chemotactic factor",0
172,127,BSK_4H_Eotaxin3_up,1,1,"Data from the assay component BSK_4H_Eotaxin3 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Eotaxin3_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL26. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"chemotactic factor",0
173,128,BSK_4H_MCP1_down,1,1,"Data from the assay component BSK_4H_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"chemotactic factor",0
174,128,BSK_4H_MCP1_up,1,1,"Data from the assay component BSK_4H_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"chemotactic factor",0
175,129,BSK_4H_Pselectin_down,1,1,"Data from the assay component BSK_4H_Pselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Pselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELP. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'selectins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"cell adhesion molecules",selectins,0
176,129,BSK_4H_Pselectin_up,1,1,"Data from the assay component BSK_4H_Pselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Pselectin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELP. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'selectins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"cell adhesion molecules",selectins,0
177,130,BSK_4H_SRB_down,1,1,"Data from the assay component BSK_4H_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_4H_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,"cell cycle",cytotoxicity,0
178,130,BSK_4H_SRB_up,1,1,"Data from the assay component BSK_4H_SRB was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_SRB_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-unspecified,"cell morphology","cell conformation",0
179,131,BSK_4H_uPAR_down,1,1,"Data from the assay component BSK_4H_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"plasmogen activator",0
180,131,BSK_4H_uPAR_up,1,1,"Data from the assay component BSK_4H_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_uPAR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"plasmogen activator",0
181,132,BSK_4H_VCAM1_down,1,1,"Data from the assay component BSK_4H_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"cell adhesion molecules","Immunoglobulin CAM",0
182,132,BSK_4H_VCAM1_up,1,1,"Data from the assay component BSK_4H_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VCAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"cell adhesion molecules","Immunoglobulin CAM",0
183,133,BSK_4H_VEGFRII_down,1,1,"Data from the assay component BSK_4H_VEGFRII was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VEGFRII_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene KDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,receptor,kinase,"receptor tyrosine kinase",0
184,133,BSK_4H_VEGFRII_up,1,1,"Data from the assay component BSK_4H_VEGFRII was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VEGFRII_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene KDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,receptor,kinase,"receptor tyrosine kinase",0
185,134,BSK_BE3C_HLADR_down,1,1,"Data from the assay component BSK_BE3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'MHC Class II'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"cell adhesion molecules","MHC Class II",0
186,134,BSK_BE3C_HLADR_up,1,1,"Data from the assay component BSK_BE3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_HLADR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'MHC Class II'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"cell adhesion molecules","MHC Class II",0
187,135,BSK_BE3C_IL1a_down,1,1,"Data from the assay component BSK_BE3C_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0
188,135,BSK_BE3C_IL1a_up,1,1,"Data from the assay component BSK_BE3C_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IL1a_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0
189,136,BSK_BE3C_IP10_down,1,1,"Data from the assay component BSK_BE3C_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"chemotactic factor",0
190,136,BSK_BE3C_IP10_up,1,1,"Data from the assay component BSK_BE3C_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IP10_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"chemotactic factor",0
191,137,BSK_BE3C_MIG_down,1,1,"Data from the assay component BSK_BE3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"chemotactic factor",0
192,137,BSK_BE3C_MIG_up,1,1,"Data from the assay component BSK_BE3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MIG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"chemotactic factor",0
193,138,BSK_BE3C_MMP1_down,1,1,"Data from the assay component BSK_BE3C_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,"matrix metalloproteinase",0
194,138,BSK_BE3C_MMP1_up,1,1,"Data from the assay component BSK_BE3C_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MMP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,"matrix metalloproteinase",0
195,139,BSK_BE3C_PAI1_down,1,1,"Data from the assay component BSK_BE3C_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_PAI1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"plasmogen activator inhibitor",0
196,139,BSK_BE3C_PAI1_up,1,1,"Data from the assay component BSK_BE3C_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_PAI1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"plasmogen activator inhibitor",0
197,140,BSK_BE3C_SRB_down,1,1,"Data from the assay component BSK_BE3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_BE3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,"cell cycle",cytotoxicity,0
198,140,BSK_BE3C_SRB_up,1,1,"Data from the assay component BSK_BE3C_SRB was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_SRB_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-unspecified,"cell morphology","cell conformation",0
199,141,BSK_BE3C_TGFb1_down,1,1,"Data from the assay component BSK_BE3C_TGFb1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_TGFb1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'growth factor' intended target family, where the subfamily is 'transforming growth factor beta'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"growth factor","transforming growth factor beta",0
200,141,BSK_BE3C_TGFb1_up,1,1,"Data from the assay component BSK_BE3C_TGFb1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_TGFb1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'growth factor' intended target family, where the subfamily is 'transforming growth factor beta'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"growth factor","transforming growth factor beta",0
201,142,BSK_BE3C_tPA_down,1,1,"Data from the assay component BSK_BE3C_tPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_tPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAT. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'serine protease'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,"serine protease",0
202,142,BSK_BE3C_tPA_up,1,1,"Data from the assay component BSK_BE3C_tPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_tPA_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAT. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'serine protease'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,"serine protease",0
203,143,BSK_BE3C_uPA_down,1,1,"Data from the assay component BSK_BE3C_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'serine protease'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,"serine protease",0
204,143,BSK_BE3C_uPA_up,1,1,"Data from the assay component BSK_BE3C_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPA_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'serine protease'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,"serine protease",0
205,144,BSK_BE3C_uPAR_down,1,1,"Data from the assay component BSK_BE3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"plasmogen activator",0
206,144,BSK_BE3C_uPAR_up,1,1,"Data from the assay component BSK_BE3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPAR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"plasmogen activator",0
207,145,BSK_CASM3C_HLADR_down,1,1,"Data from the assay component BSK_CASM3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'MHC Class II'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"cell adhesion molecules","MHC Class II",0
208,145,BSK_CASM3C_HLADR_up,1,1,"Data from the assay component BSK_CASM3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_HLADR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'MHC Class II'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"cell adhesion molecules","MHC Class II",0
209,146,BSK_CASM3C_IL6_down,1,1,"Data from the assay component BSK_CASM3C_IL6 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_IL6_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0
210,146,BSK_CASM3C_IL6_up,1,1,"Data from the assay component BSK_CASM3C_IL6 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_IL6_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0
211,147,BSK_CASM3C_IL8_down,1,1,"Data from the assay component BSK_CASM3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0
212,147,BSK_CASM3C_IL8_up,1,1,"Data from the assay component BSK_CASM3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_IL8_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0
213,148,BSK_CASM3C_LDLR_down,1,1,"Data from the assay component BSK_CASM3C_LDLR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_LDLR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene LDLR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'misc protein' intended target family, where the subfamily is 'LDL receptor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"misc protein","LDL receptor",0
214,148,BSK_CASM3C_LDLR_up,1,1,"Data from the assay component BSK_CASM3C_LDLR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_LDLR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene LDLR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'misc protein' intended target family, where the subfamily is 'LDL receptor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"misc protein","LDL receptor",0
215,149,BSK_CASM3C_MCP1_down,1,1,"Data from the assay component BSK_CASM3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"chemotactic factor",0
216,149,BSK_CASM3C_MCP1_up,1,1,"Data from the assay component BSK_CASM3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"chemotactic factor",0
217,150,BSK_CASM3C_MCSF_down,1,1,"Data from the assay component BSK_CASM3C_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'colony stimulating factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"colony stimulating factor",0
218,150,BSK_CASM3C_MCSF_up,1,1,"Data from the assay component BSK_CASM3C_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCSF_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'colony stimulating factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"colony stimulating factor",0
219,151,BSK_CASM3C_MIG_down,1,1,"Data from the assay component BSK_CASM3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"chemotactic factor",0
220,151,BSK_CASM3C_MIG_up,1,1,"Data from the assay component BSK_CASM3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MIG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"chemotactic factor",0
221,152,BSK_CASM3C_Proliferation_down,1,1,"Data from the assay component BSK_CASM3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_CASM3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,"cell cycle",cytotoxicity,0
222,152,BSK_CASM3C_Proliferation_up,1,1,"Data from the assay component BSK_CASM3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_CASM3C_Proliferation_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for gain-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'proliferation'.",viability,log10_fold_induction,positive,0,colchicine,gain,cellular,cellular,"cell cycle",proliferation,0
223,153,BSK_CASM3C_SAA_down,1,1,"Data from the assay component BSK_CASM3C_SAA was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_SAA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SAA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'apolipoproteins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"cell adhesion molecules",apolipoproteins,0
224,153,BSK_CASM3C_SAA_up,1,1,"Data from the assay component BSK_CASM3C_SAA was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_SAA_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SAA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'apolipoproteins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"cell adhesion molecules",apolipoproteins,0
225,154,BSK_CASM3C_SRB_down,1,1,"Data from the assay component BSK_CASM3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_CASM3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,"cell cycle",cytotoxicity,0
226,154,BSK_CASM3C_SRB_up,1,1,"Data from the assay component BSK_CASM3C_SRB was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_SRB_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-unspecified,"cell morphology","cell conformation",0
227,155,BSK_CASM3C_Thrombomodulin_down,1,1,"Data from the assay component BSK_CASM3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_Thrombomodulin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,gpcr,"rhodopsin-like receptor",0
228,155,BSK_CASM3C_Thrombomodulin_up,1,1,"Data from the assay component BSK_CASM3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_Thrombomodulin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,gpcr,"rhodopsin-like receptor",0
229,156,BSK_CASM3C_TissueFactor_down,1,1,"Data from the assay component BSK_CASM3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'coagulation factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"coagulation factor",0
230,156,BSK_CASM3C_TissueFactor_up,1,1,"Data from the assay component BSK_CASM3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_TissueFactor_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'coagulation factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"coagulation factor",0
231,157,BSK_CASM3C_uPAR_down,1,1,"Data from the assay component BSK_CASM3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"plasmogen activator",0
232,157,BSK_CASM3C_uPAR_up,1,1,"Data from the assay component BSK_CASM3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_uPAR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"plasmogen activator",0
233,158,BSK_CASM3C_VCAM1_down,1,1,"Data from the assay component BSK_CASM3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"cell adhesion molecules","Immunoglobulin CAM",0
234,158,BSK_CASM3C_VCAM1_up,1,1,"Data from the assay component BSK_CASM3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_VCAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"cell adhesion molecules","Immunoglobulin CAM",0
235,159,BSK_hDFCGF_CollagenIII_down,1,1,"Data from the assay component BSK_hDFCGF_CollagenIII was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_CollagenIII_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene COL3A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"cell adhesion molecules",collagen,0
236,159,BSK_hDFCGF_CollagenIII_up,1,1,"Data from the assay component BSK_hDFCGF_CollagenIII was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_CollagenIII_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene COL3A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'collagen'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"cell adhesion molecules",collagen,0
237,160,BSK_hDFCGF_EGFR_down,1,1,"Data from the assay component BSK_hDFCGF_EGFR was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_EGFR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene EGFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,receptor,kinase,"receptor tyrosine kinase",0
238,160,BSK_hDFCGF_EGFR_up,1,1,"Data from the assay component BSK_hDFCGF_EGFR was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_EGFR_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene EGFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,receptor,kinase,"receptor tyrosine kinase",0
239,161,BSK_hDFCGF_IL8_down,1,1,"Data from the assay component BSK_hDFCGF_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0
240,161,BSK_hDFCGF_IL8_up,1,1,"Data from the assay component BSK_hDFCGF_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IL8_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0
241,162,BSK_hDFCGF_IP10_down,1,1,"Data from the assay component BSK_hDFCGF_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"chemotactic factor",0
242,162,BSK_hDFCGF_IP10_up,1,1,"Data from the assay component BSK_hDFCGF_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IP10_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"chemotactic factor",0
243,163,BSK_hDFCGF_MCSF_down,1,1,"Data from the assay component BSK_hDFCGF_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'colony stimulating factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"colony stimulating factor",0
244,163,BSK_hDFCGF_MCSF_up,1,1,"Data from the assay component BSK_hDFCGF_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MCSF_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'colony stimulating factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"colony stimulating factor",0
245,164,BSK_hDFCGF_MIG_down,1,1,"Data from the assay component BSK_hDFCGF_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"chemotactic factor",0
246,164,BSK_hDFCGF_MIG_up,1,1,"Data from the assay component BSK_hDFCGF_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MIG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"chemotactic factor",0
247,165,BSK_hDFCGF_MMP1_down,1,1,"Data from the assay component BSK_hDFCGF_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,"matrix metalloproteinase",0
248,165,BSK_hDFCGF_MMP1_up,1,1,"Data from the assay component BSK_hDFCGF_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MMP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,"matrix metalloproteinase",0
249,166,BSK_hDFCGF_PAI1_down,1,1,"Data from the assay component BSK_hDFCGF_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_PAI1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"plasmogen activator inhibitor",0
250,166,BSK_hDFCGF_PAI1_up,1,1,"Data from the assay component BSK_hDFCGF_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_PAI1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'plasmogen activator inhibitor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"plasmogen activator inhibitor",0
251,167,BSK_hDFCGF_Proliferation_down,1,1,"Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,"cell cycle",cytotoxicity,0
252,167,BSK_hDFCGF_Proliferation_up,1,1,"Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_Proliferation_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for gain-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'proliferation'.",viability,log10_fold_induction,positive,0,colchicine,gain,cellular,cellular,"cell cycle",proliferation,0
253,168,BSK_hDFCGF_SRB_down,1,1,"Data from the assay component BSK_hDFCGF_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,"cell cycle",cytotoxicity,0
254,168,BSK_hDFCGF_SRB_up,1,1,"Data from the assay component BSK_hDFCGF_SRB was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_SRB_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-unspecified,"cell morphology","cell conformation",0
255,169,BSK_hDFCGF_TIMP1_down,1,1,"Data from the assay component BSK_hDFCGF_TIMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_TIMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease inhibitor' intended target family, where the subfamily is 'metalloproteinase inhibitor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"protease inhibitor","metalloproteinase inhibitor",0
256,169,BSK_hDFCGF_TIMP1_up,1,1,"Data from the assay component BSK_hDFCGF_TIMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_TIMP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease inhibitor' intended target family, where the subfamily is 'metalloproteinase inhibitor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"protease inhibitor","metalloproteinase inhibitor",0
257,170,BSK_hDFCGF_VCAM1_down,1,1,"Data from the assay component BSK_hDFCGF_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"cell adhesion molecules","Immunoglobulin CAM",0
258,170,BSK_hDFCGF_VCAM1_up,1,1,"Data from the assay component BSK_hDFCGF_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_VCAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"cell adhesion molecules","Immunoglobulin CAM",0
259,171,BSK_KF3CT_ICAM1_down,1,1,"Data from the assay component BSK_KF3CT_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_ICAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"cell adhesion molecules","Immunoglobulin CAM",0
260,171,BSK_KF3CT_ICAM1_up,1,1,"Data from the assay component BSK_KF3CT_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_ICAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"cell adhesion molecules","Immunoglobulin CAM",0
261,172,BSK_KF3CT_IL1a_down,1,1,"Data from the assay component BSK_KF3CT_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0
262,172,BSK_KF3CT_IL1a_up,1,1,"Data from the assay component BSK_KF3CT_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IL1a_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0
263,173,BSK_KF3CT_IP10_down,1,1,"Data from the assay component BSK_KF3CT_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"chemotactic factor",0
264,173,BSK_KF3CT_IP10_up,1,1,"Data from the assay component BSK_KF3CT_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IP10_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"chemotactic factor",0
265,174,BSK_KF3CT_MCP1_down,1,1,"Data from the assay component BSK_KF3CT_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"chemotactic factor",0
266,174,BSK_KF3CT_MCP1_up,1,1,"Data from the assay component BSK_KF3CT_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"chemotactic factor",0
267,175,BSK_KF3CT_MMP9_down,1,1,"Data from the assay component BSK_KF3CT_MMP9 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MMP9_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,"matrix metalloproteinase",0
268,175,BSK_KF3CT_MMP9_up,1,1,"Data from the assay component BSK_KF3CT_MMP9 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MMP9_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,"matrix metalloproteinase",0
269,176,BSK_KF3CT_SRB_down,1,1,"Data from the assay component BSK_KF3CT_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_KF3CT_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,"cell cycle",cytotoxicity,0
270,176,BSK_KF3CT_SRB_up,1,1,"Data from the assay component BSK_KF3CT_SRB was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_SRB_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-unspecified,"cell morphology","cell conformation",0
271,177,BSK_KF3CT_TGFb1_down,1,1,"Data from the assay component BSK_KF3CT_TGFb1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TGFb1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'growth factor' intended target family, where the subfamily is 'transforming growth factor beta'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"growth factor","transforming growth factor beta",0
272,177,BSK_KF3CT_TGFb1_up,1,1,"Data from the assay component BSK_KF3CT_TGFb1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TGFb1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'growth factor' intended target family, where the subfamily is 'transforming growth factor beta'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"growth factor","transforming growth factor beta",0
273,178,BSK_KF3CT_TIMP2_down,1,1,"Data from the assay component BSK_KF3CT_TIMP2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TIMP2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease inhibitor' intended target family, where the subfamily is 'metalloproteinase inhibitor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"protease inhibitor","metalloproteinase inhibitor",0
274,178,BSK_KF3CT_TIMP2_up,1,1,"Data from the assay component BSK_KF3CT_TIMP2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TIMP2_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease inhibitor' intended target family, where the subfamily is 'metalloproteinase inhibitor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"protease inhibitor","metalloproteinase inhibitor",0
275,179,BSK_KF3CT_uPA_down,1,1,"Data from the assay component BSK_KF3CT_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_uPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'serine protease'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,protease,"serine protease",0
276,179,BSK_KF3CT_uPA_up,1,1,"Data from the assay component BSK_KF3CT_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_uPA_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'serine protease'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,protease,"serine protease",0
277,180,BSK_LPS_CD40_down,1,1,"Data from the assay component BSK_LPS_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"inflammatory factor",0
278,180,BSK_LPS_CD40_up,1,1,"Data from the assay component BSK_LPS_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_CD40_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"inflammatory factor",0
279,181,BSK_LPS_Eselectin_down,1,1,"Data from the assay component BSK_LPS_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'selectins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"cell adhesion molecules",selectins,0
280,181,BSK_LPS_Eselectin_up,1,1,"Data from the assay component BSK_LPS_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_Eselectin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'selectins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"cell adhesion molecules",selectins,0
281,182,BSK_LPS_IL1a_down,1,1,"Data from the assay component BSK_LPS_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0
282,182,BSK_LPS_IL1a_up,1,1,"Data from the assay component BSK_LPS_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL1a_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0
283,183,BSK_LPS_IL8_down,1,1,"Data from the assay component BSK_LPS_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0
284,183,BSK_LPS_IL8_up,1,1,"Data from the assay component BSK_LPS_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL8_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0
285,184,BSK_LPS_MCP1_down,1,1,"Data from the assay component BSK_LPS_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"chemotactic factor",0
286,184,BSK_LPS_MCP1_up,1,1,"Data from the assay component BSK_LPS_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"chemotactic factor",0
287,185,BSK_LPS_MCSF_down,1,1,"Data from the assay component BSK_LPS_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'colony stimulating factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"colony stimulating factor",0
288,185,BSK_LPS_MCSF_up,1,1,"Data from the assay component BSK_LPS_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCSF_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'colony stimulating factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"colony stimulating factor",0
289,186,BSK_LPS_PGE2_down,1,1,"Data from the assay component BSK_LPS_PGE2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_PGE2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PTGER2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,gpcr,"rhodopsin-like receptor",0
290,186,BSK_LPS_PGE2_up,1,1,"Data from the assay component BSK_LPS_PGE2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_PGE2_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene PTGER2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,gpcr,"rhodopsin-like receptor",0
291,187,BSK_LPS_SRB_down,1,1,"Data from the assay component BSK_LPS_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_LPS_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,"cell cycle",cytotoxicity,0
292,187,BSK_LPS_SRB_up,1,1,"Data from the assay component BSK_LPS_SRB was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_SRB_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-unspecified,"cell morphology","cell conformation",0
293,188,BSK_LPS_TissueFactor_down,1,1,"Data from the assay component BSK_LPS_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'coagulation factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"coagulation factor",0
294,188,BSK_LPS_TissueFactor_up,1,1,"Data from the assay component BSK_LPS_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TissueFactor_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'coagulation factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"coagulation factor",0
295,189,BSK_LPS_TNFa_down,1,1,"Data from the assay component BSK_LPS_TNFa was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TNFa_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TNF. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"inflammatory factor",0
296,189,BSK_LPS_TNFa_up,1,1,"Data from the assay component BSK_LPS_TNFa was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TNFa_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene TNF. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"inflammatory factor",0
297,190,BSK_LPS_VCAM1_down,1,1,"Data from the assay component BSK_LPS_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"cell adhesion molecules","Immunoglobulin CAM",0
298,190,BSK_LPS_VCAM1_up,1,1,"Data from the assay component BSK_LPS_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_VCAM1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'Immunoglobulin CAM'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"cell adhesion molecules","Immunoglobulin CAM",0
299,191,BSK_SAg_CD38_down,1,1,"Data from the assay component BSK_SAg_CD38 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD38_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'other cytokine'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"other cytokine",0
300,191,BSK_SAg_CD38_up,1,1,"Data from the assay component BSK_SAg_CD38 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD38_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'other cytokine'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"other cytokine",0
301,192,BSK_SAg_CD40_down,1,1,"Data from the assay component BSK_SAg_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"inflammatory factor",0
302,192,BSK_SAg_CD40_up,1,1,"Data from the assay component BSK_SAg_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD40_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"inflammatory factor",0
303,193,BSK_SAg_CD69_down,1,1,"Data from the assay component BSK_SAg_CD69 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD69_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD69. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"inflammatory factor",0
304,193,BSK_SAg_CD69_up,1,1,"Data from the assay component BSK_SAg_CD69 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD69_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD69. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'inflammatory factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"inflammatory factor",0
305,194,BSK_SAg_Eselectin_down,1,1,"Data from the assay component BSK_SAg_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'selectins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,"cell adhesion molecules",selectins,0
306,194,BSK_SAg_Eselectin_up,1,1,"Data from the assay component BSK_SAg_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_Eselectin_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell adhesion molecules' intended target family, where the subfamily is 'selectins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,"cell adhesion molecules",selectins,0
307,195,BSK_SAg_IL8_down,1,1,"Data from the assay component BSK_SAg_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,interleukins,0
308,195,BSK_SAg_IL8_up,1,1,"Data from the assay component BSK_SAg_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_IL8_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'interleukins'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,interleukins,0
309,196,BSK_SAg_MCP1_down,1,1,"Data from the assay component BSK_SAg_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"chemotactic factor",0
310,196,BSK_SAg_MCP1_up,1,1,"Data from the assay component BSK_SAg_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MCP1_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"chemotactic factor",0
311,197,BSK_SAg_MIG_down,1,1,"Data from the assay component BSK_SAg_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,negative,0,colchicine,loss,protein,protein-specified,cytokine,"chemotactic factor",0
312,197,BSK_SAg_MIG_up,1,1,"Data from the assay component BSK_SAg_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MIG_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, gain-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cytokine' intended target family, where the subfamily is 'chemotactic factor'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-specified,cytokine,"chemotactic factor",0
313,198,BSK_SAg_PBMCCytotoxicity_down,1,1,"Data from the assay component BSK_SAg_PBMCCytotoxicity was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_PBMCCytotoxicity_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'proliferation'.",signaling,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,"cell cycle",proliferation,0
314,198,BSK_SAg_PBMCCytotoxicity_up,1,1,"Data from the assay component BSK_SAg_PBMCCytotoxicity was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_PBMCCytotoxicity_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, gain-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log10_fold_induction,positive,0,colchicine,gain,cellular,cellular,"cell cycle",cytotoxicity,0
315,199,BSK_SAg_Proliferation_down,1,1,"Data from the assay component BSK_SAg_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,"cell cycle",cytotoxicity,0
316,199,BSK_SAg_Proliferation_up,1,1,"Data from the assay component BSK_SAg_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_Proliferation_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for gain-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'proliferation'.",viability,log10_fold_induction,positive,0,colchicine,gain,cellular,cellular,"cell cycle",proliferation,0
317,200,BSK_SAg_SRB_down,1,1,"Data from the assay component BSK_SAg_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,log10_fold_induction,negative,1,colchicine,loss,cellular,cellular,"cell cycle",cytotoxicity,0
318,200,BSK_SAg_SRB_up,1,1,"Data from the assay component BSK_SAg_SRB was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_SRB_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'cell conformation'.",signaling,log10_fold_induction,positive,0,colchicine,gain,protein,protein-unspecified,"cell morphology","cell conformation",0
319,201,NVS_ADME_hCYP19A1,1,1,"Data from the assay component NVS_ADME_hCYP19A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP19A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP19A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'steroidogenesis-related'.","enzymatic activity",percent_activity,positive,0,Ketoconazole,loss,protein,enzyme,cyp,steroidogenesis-related,0
320,201,NVS_ADME_hCYP19A1_Activator,1,1,"Data from the assay component NVS_ADME_hCYP19A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP19A1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP19A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'steroidogenesis-related'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Ketoconazole,gain,protein,enzyme,cyp,steroidogenesis-related,0
321,202,NVS_ADME_hCYP1A1,1,1,"Data from the assay component NVS_ADME_hCYP1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,Ketoconazole;Ketanserin,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
322,202,NVS_ADME_hCYP1A1_Activator,1,1,"Data from the assay component NVS_ADME_hCYP1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1A1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Ketoconazole;Ketanserin,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
323,203,NVS_ADME_hCYP1A2,1,1,"Data from the assay component NVS_ADME_hCYP1A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1A2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,Furafylline,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
324,203,NVS_ADME_hCYP1A2_Activator,1,1,"Data from the assay component NVS_ADME_hCYP1A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1A2_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1A2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Furafylline,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
325,204,NVS_ADME_hCYP1B1,1,1,"Data from the assay component NVS_ADME_hCYP1B1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1B1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1B1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,Alpha-Naphthoflavone,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
326,204,NVS_ADME_hCYP1B1_Activator,1,1,"Data from the assay component NVS_ADME_hCYP1B1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP1B1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP1B1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Alpha-Naphthoflavone,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
327,205,NVS_ADME_hCYP2A6,1,1,"Data from the assay component NVS_ADME_hCYP2A6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2A6, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2A6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,Tranylcypromine,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
328,205,NVS_ADME_hCYP2A6_Activator,1,1,"Data from the assay component NVS_ADME_hCYP2A6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2A6_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2A6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Tranylcypromine,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
329,206,NVS_ADME_hCYP2B6,1,1,"Data from the assay component NVS_ADME_hCYP2B6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2B6, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2B6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,Clotrimazole,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
330,206,NVS_ADME_hCYP2B6_Activator,1,1,"Data from the assay component NVS_ADME_hCYP2B6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2B6_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2B6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Clotrimazole,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
331,207,NVS_ADME_hCYP2C18,1,1,"Data from the assay component NVS_ADME_hCYP2C18 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C18, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C18. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,Tranylcypromine,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
332,207,NVS_ADME_hCYP2C18_Activator,1,1,"Data from the assay component NVS_ADME_hCYP2C18 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C18_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C18. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Tranylcypromine,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
333,208,NVS_ADME_hCYP2C19,1,1,"Data from the assay component NVS_ADME_hCYP2C19 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C19, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C19. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,Tranylcypromine,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
334,208,NVS_ADME_hCYP2C19_Activator,1,1,"Data from the assay component NVS_ADME_hCYP2C19 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C19_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C19. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Tranylcypromine,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
335,209,NVS_ADME_hCYP2C8,1,1,"Data from the assay component NVS_ADME_hCYP2C8 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C8, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,quercetin,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
336,209,NVS_ADME_hCYP2C8_Activator,1,1,"Data from the assay component NVS_ADME_hCYP2C8 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C8_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,quercetin,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
337,210,NVS_ADME_hCYP2C9,1,1,"Data from the assay component NVS_ADME_hCYP2C9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C9, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,Sulfaphenazole,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
338,210,NVS_ADME_hCYP2C9_Activator,1,1,"Data from the assay component NVS_ADME_hCYP2C9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C9_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,sulfaphenazole,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
339,211,NVS_ADME_hCYP2D6,1,1,"Data from the assay component NVS_ADME_hCYP2D6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2D6, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2D6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,quinidine,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
340,211,NVS_ADME_hCYP2D6_Activator,1,1,"Data from the assay component NVS_ADME_hCYP2D6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2D6_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2D6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,quinidine,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
341,212,NVS_ADME_hCYP2E1,1,1,"Data from the assay component NVS_ADME_hCYP2E1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2E1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2E1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,chlormethiazole,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
342,212,NVS_ADME_hCYP2E1_Activator,1,1,"Data from the assay component NVS_ADME_hCYP2E1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2E1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2E1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,chlormethiazole,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
343,213,NVS_ADME_hCYP2J2,1,1,"Data from the assay component NVS_ADME_hCYP2J2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2J2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2J2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,Ketoconazole,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
344,213,NVS_ADME_hCYP2J2_Activator,1,1,"Data from the assay component NVS_ADME_hCYP2J2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2J2_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2J2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Ketoconazole,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
345,214,NVS_ADME_hCYP3A4,1,1,"Data from the assay component NVS_ADME_hCYP3A4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP3A4, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP3A4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,Ketoconazole,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
346,214,NVS_ADME_hCYP3A4_Activator,1,1,"Data from the assay component NVS_ADME_hCYP3A4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP3A4_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP3A4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Ketoconazole,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
347,215,NVS_ADME_hCYP3A5,1,1,"Data from the assay component NVS_ADME_hCYP3A5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP3A5, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP3A5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,Ketoconazole,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
348,215,NVS_ADME_hCYP3A5_Activator,1,1,"Data from the assay component NVS_ADME_hCYP3A5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP3A5_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP3A5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Ketoconazole,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
349,216,NVS_ADME_hCYP4F12,1,1,"Data from the assay component NVS_ADME_hCYP4F12 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP4F12, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP4F12. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,Ketoconazole,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
350,216,NVS_ADME_hCYP4F12_Activator,1,1,"Data from the assay component NVS_ADME_hCYP4F12 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP4F12_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP4F12. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Ketoconazole,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
351,217,NVS_ADME_rCYP1A1,1,1,"Data from the assay component NVS_ADME_rCYP1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP1A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp1a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,ellipticine,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
352,217,NVS_ADME_rCYP1A1_Activator,1,1,"Data from the assay component NVS_ADME_rCYP1A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP1A1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp1a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,ellipticine,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
353,218,NVS_ADME_rCYP1A2,1,1,"Data from the assay component NVS_ADME_rCYP1A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP1A2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp1a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,Alpha-Naphthoflavone,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
354,218,NVS_ADME_rCYP1A2_Activator,1,1,"Data from the assay component NVS_ADME_rCYP1A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP1A2_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp1a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Alpha-Naphthoflavone,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
355,219,NVS_ADME_rCYP2A1,1,1,"Data from the assay component NVS_ADME_rCYP2A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,Clotrimazole,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
356,219,NVS_ADME_rCYP2A1_Activator,1,1,"Data from the assay component NVS_ADME_rCYP2A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2A1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Clotrimazole,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
357,220,NVS_ADME_rCYP2A2,1,1,"Data from the assay component NVS_ADME_rCYP2A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2A2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,Ketoconazole;Tranylcypromine,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
358,220,NVS_ADME_rCYP2A2_Activator,1,1,"Data from the assay component NVS_ADME_rCYP2A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2A2_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Ketoconazole;Tranylcypromine,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
359,221,NVS_ADME_rCYP2B1,1,1,"Data from the assay component NVS_ADME_rCYP2B1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2B1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2b1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,Ketoconazole,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
360,221,NVS_ADME_rCYP2B1_Activator,1,1,"Data from the assay component NVS_ADME_rCYP2B1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2B1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2b1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Ketoconazole,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
361,222,NVS_ADME_rCYP2C11,1,1,"Data from the assay component NVS_ADME_rCYP2C11 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C11, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c11. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,Ketoconazole,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
362,222,NVS_ADME_rCYP2C11_Activator,1,1,"Data from the assay component NVS_ADME_rCYP2C11 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C11_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c11. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Ketoconazole,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
363,223,NVS_ADME_rCYP2C12,1,1,"Data from the assay component NVS_ADME_rCYP2C12 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C12, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c12. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,Tranylcypromine,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
364,223,NVS_ADME_rCYP2C12_Activator,1,1,"Data from the assay component NVS_ADME_rCYP2C12 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C12_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c12. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Tranylcypromine,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
365,224,NVS_ADME_rCYP2C13,1,1,"Data from the assay component NVS_ADME_rCYP2C13 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C13, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c13. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,Clotrimazole,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
366,224,NVS_ADME_rCYP2C13_Activator,1,1,"Data from the assay component NVS_ADME_rCYP2C13 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C13_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c13. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Clotrimazole,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
367,225,NVS_ADME_rCYP2C6,1,1,"Data from the assay component NVS_ADME_rCYP2C6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C6, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c6v1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,Ketoconazole,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
368,225,NVS_ADME_rCYP2C6_Activator,1,1,"Data from the assay component NVS_ADME_rCYP2C6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2C6_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2c6v1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Ketoconazole,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
369,226,NVS_ADME_rCYP2D1,1,1,"Data from the assay component NVS_ADME_rCYP2D1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2D1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2d1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,"Propranolol HCl",loss,protein,enzyme,cyp,"xenobiotic metabolism",0
370,226,NVS_ADME_rCYP2D1_Activator,1,1,"Data from the assay component NVS_ADME_rCYP2D1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2D1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2d1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Propranolol HCl",gain,protein,enzyme,cyp,"xenobiotic metabolism",0
371,227,NVS_ADME_rCYP2D2,1,1,"Data from the assay component NVS_ADME_rCYP2D2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2D2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2d2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,"Propranolol HCl",loss,protein,enzyme,cyp,"xenobiotic metabolism",0
372,227,NVS_ADME_rCYP2D2_Activator,1,1,"Data from the assay component NVS_ADME_rCYP2D2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2D2_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2d2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Propranolol HCl",gain,protein,enzyme,cyp,"xenobiotic metabolism",0
373,228,NVS_ADME_rCYP2E1,1,1,"Data from the assay component NVS_ADME_rCYP2E1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2E1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2e1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,chlormethiazole,loss,protein,enzyme,cyp,"xenobiotic metabolism",0
374,228,NVS_ADME_rCYP2E1_Activator,1,1,"Data from the assay component NVS_ADME_rCYP2E1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP2E1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp2e1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,chlormethiazole,gain,protein,enzyme,cyp,"xenobiotic metabolism",0
375,229,NVS_ADME_rCYP3A1,1,1,"Data from the assay component NVS_ADME_rCYP3A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP3A1, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp3a23/3a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,"(+/-) Verapamil HCl",loss,protein,enzyme,cyp,"xenobiotic metabolism",0
376,229,NVS_ADME_rCYP3A1_Activator,1,1,"Data from the assay component NVS_ADME_rCYP3A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP3A1_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp3a23/3a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"(+/-) Verapamil HCl",gain,protein,enzyme,cyp,"xenobiotic metabolism",0
377,230,NVS_ADME_rCYP3A2,1,1,"Data from the assay component NVS_ADME_rCYP3A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP3A2, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp3a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","enzymatic activity",percent_activity,positive,0,"(+/-) Verapamil HCl",loss,protein,enzyme,cyp,"xenobiotic metabolism",0
378,230,NVS_ADME_rCYP3A2_Activator,1,1,"Data from the assay component NVS_ADME_rCYP3A2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_rCYP3A2_Activator, was analyzed in the negative fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Cyp3a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"(+/-) Verapamil HCl",gain,protein,enzyme,cyp,"xenobiotic metabolism",0
379,231,NVS_ENZ_hAbl,1,1,"Data from the assay component NVS_ENZ_hAbl was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAbl, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ABL1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
380,231,NVS_ENZ_hAbl_Activator,1,1,"Data from the assay component NVS_ENZ_hAbl was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAbl_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ABL1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
381,232,NVS_ENZ_hAChE,1,1,"Data from the assay component NVS_ENZ_hAChE was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAChE, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ACHE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'esterase' intended target family, where the subfamily is 'acetylcholinesterase'.","enzymatic activity",percent_activity,positive,0,physostigmine,loss,protein,enzyme,esterase,acetylcholinesterase,0
382,232,NVS_ENZ_hAChE_Activator,1,1,"Data from the assay component NVS_ENZ_hAChE was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAChE_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ACHE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'esterase' intended target family, where the subfamily is 'acetylcholinesterase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,physostigmine,gain,protein,enzyme,esterase,acetylcholinesterase,0
383,233,NVS_ENZ_hACP1,1,1,"Data from the assay component NVS_ENZ_hACP1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hACP1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ACP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'acid phosphatase'.","enzymatic activity",percent_activity,positive,0,"Ammonium Molybdate (NH4MoO4)",loss,protein,enzyme,phosphatase,"acid phosphatase",0
384,233,NVS_ENZ_hACP1_Activator,1,1,"Data from the assay component NVS_ENZ_hACP1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hACP1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ACP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'acid phosphatase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Ammonium Molybdate (NH4MoO4)",gain,protein,enzyme,phosphatase,"acid phosphatase",0
385,234,NVS_ENZ_hAKT1,1,1,"Data from the assay component NVS_ENZ_hAKT1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAKT1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
386,234,NVS_ENZ_hAKT1_Activator,1,1,"Data from the assay component NVS_ENZ_hAKT1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAKT1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
387,235,NVS_ENZ_hAKT2,1,1,"Data from the assay component NVS_ENZ_hAKT2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAKT2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
388,235,NVS_ENZ_hAKT2_Activator,1,1,"Data from the assay component NVS_ENZ_hAKT2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAKT2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
389,236,NVS_ENZ_hAKT3,1,1,"Data from the assay component NVS_ENZ_hAKT3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAKT3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
390,236,NVS_ENZ_hAKT3_Activator,1,1,"Data from the assay component NVS_ENZ_hAKT3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAKT3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AKT3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
391,237,NVS_ENZ_hAMPKa1,1,1,"Data from the assay component NVS_ENZ_hAMPKa1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAMPKa1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKAA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
392,237,NVS_ENZ_hAMPKa1_Activator,1,1,"Data from the assay component NVS_ENZ_hAMPKa1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAMPKa1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKAA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
393,238,NVS_ENZ_hAurA,1,1,"Data from the assay component NVS_ENZ_hAurA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAurA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AURKA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
394,238,NVS_ENZ_hAurA_Activator,1,1,"Data from the assay component NVS_ENZ_hAurA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hAurA_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene AURKA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
395,239,NVS_ENZ_hBACE,1,1,"Data from the assay component NVS_ENZ_hBACE was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hBACE, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BACE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'aspartate protease'.","enzymatic activity",percent_activity,positive,0,OM99-02,loss,protein,enzyme,protease,"aspartate protease",0
396,239,NVS_ENZ_hBACE_Activator,1,1,"Data from the assay component NVS_ENZ_hBACE was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hBACE_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BACE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'aspartate protease'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,OM99-02,gain,protein,enzyme,protease,"aspartate protease",0
397,240,NVS_ENZ_hBTK,1,1,"Data from the assay component NVS_ENZ_hBTK was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hBTK, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BTK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
398,240,NVS_ENZ_hBTK_Activator,1,1,"Data from the assay component NVS_ENZ_hBTK was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hBTK_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BTK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
399,241,NVS_ENZ_hCASP1,1,1,"Data from the assay component NVS_ENZ_hCASP1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'cysteine protease'.","enzymatic activity",percent_activity,positive,0,Ac-YVAD-CHO,loss,protein,enzyme,protease,"cysteine protease",0
400,241,NVS_ENZ_hCASP1_Activator,1,1,"Data from the assay component NVS_ENZ_hCASP1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'cysteine protease'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Ac-YVAD-CHO,gain,protein,enzyme,protease,"cysteine protease",0
401,242,NVS_ENZ_hCASP10,1,1,"Data from the assay component NVS_ENZ_hCASP10 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP10, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'cysteine protease'.","enzymatic activity",percent_activity,positive,0,Ac-DEVD-CHO,loss,protein,enzyme,protease,"cysteine protease",0
402,242,NVS_ENZ_hCASP10_Activator,1,1,"Data from the assay component NVS_ENZ_hCASP10 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP10_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'cysteine protease'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Ac-DEVD-CHO,gain,protein,enzyme,protease,"cysteine protease",0
403,243,NVS_ENZ_hCASP2,1,1,"Data from the assay component NVS_ENZ_hCASP2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'cysteine protease'.","enzymatic activity",percent_activity,positive,0,z-VDVAD-CHO,loss,protein,enzyme,protease,"cysteine protease",0
404,243,NVS_ENZ_hCASP2_Activator,1,1,"Data from the assay component NVS_ENZ_hCASP2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'cysteine protease'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,z-VDVAD-CHO,gain,protein,enzyme,protease,"cysteine protease",0
405,244,NVS_ENZ_hCASP3,1,1,"Data from the assay component NVS_ENZ_hCASP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'cysteine protease'.","enzymatic activity",percent_activity,positive,0,Ac-DEVD-CHO,loss,protein,enzyme,protease,"cysteine protease",0
406,244,NVS_ENZ_hCASP3_Activator,1,1,"Data from the assay component NVS_ENZ_hCASP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'cysteine protease'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Ac-DEVD-CHO,gain,protein,enzyme,protease,"cysteine protease",0
407,245,NVS_ENZ_hCASP4,1,1,"Data from the assay component NVS_ENZ_hCASP4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'cysteine protease'.","enzymatic activity",percent_activity,positive,0,Ac-LEHD-CHO,loss,protein,enzyme,protease,"cysteine protease",0
408,245,NVS_ENZ_hCASP4_Activator,1,1,"Data from the assay component NVS_ENZ_hCASP4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP4_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'cysteine protease'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Ac-LEHD-CHO,gain,protein,enzyme,protease,"cysteine protease",0
409,246,NVS_ENZ_hCASP5,1,1,"Data from the assay component NVS_ENZ_hCASP5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP5, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'cysteine protease'.","enzymatic activity",percent_activity,positive,0,Ac-LEHD-CHO,loss,protein,enzyme,protease,"cysteine protease",0
410,246,NVS_ENZ_hCASP5_Activator,1,1,"Data from the assay component NVS_ENZ_hCASP5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP5_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'cysteine protease'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Ac-LEHD-CHO,gain,protein,enzyme,protease,"cysteine protease",0
411,247,NVS_ENZ_hCASP8,1,1,"Data from the assay component NVS_ENZ_hCASP8 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP8, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'cysteine protease'.","enzymatic activity",percent_activity,positive,0,Ac-DEVD-CHO,loss,protein,enzyme,protease,"cysteine protease",0
412,247,NVS_ENZ_hCASP8_Activator,1,1,"Data from the assay component NVS_ENZ_hCASP8 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCASP8_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CASP8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'cysteine protease'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Ac-DEVD-CHO,gain,protein,enzyme,protease,"cysteine protease",0
413,248,NVS_ENZ_hCDK2,1,1,"Data from the assay component NVS_ENZ_hCDK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCDK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CDK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
414,248,NVS_ENZ_hCDK2_Activator,1,1,"Data from the assay component NVS_ENZ_hCDK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCDK2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CDK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
415,249,NVS_ENZ_hCDK6,1,1,"Data from the assay component NVS_ENZ_hCDK6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCDK6, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CDK6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
416,249,NVS_ENZ_hCDK6_Activator,1,1,"Data from the assay component NVS_ENZ_hCDK6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCDK6_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CDK6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
417,250,NVS_ENZ_hCHK1,1,1,"Data from the assay component NVS_ENZ_hCHK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCHK1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CHEK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
418,250,NVS_ENZ_hCHK1_Activator,1,1,"Data from the assay component NVS_ENZ_hCHK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCHK1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CHEK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
419,251,NVS_ENZ_hCK1a,1,1,"Data from the assay component NVS_ENZ_hCK1a was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCK1a, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,5-iodotubericidin,loss,protein,enzyme,kinase,"serine/threonine kinase",0
420,251,NVS_ENZ_hCK1a_Activator,1,1,"Data from the assay component NVS_ENZ_hCK1a was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCK1a_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK1A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,5-iodotubericidin,gain,protein,enzyme,kinase,"serine/threonine kinase",0
421,252,NVS_ENZ_hCK1D,1,1,"Data from the assay component NVS_ENZ_hCK1D was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCK1D, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK1D. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,5-iodotubericidin,loss,protein,enzyme,kinase,"serine/threonine kinase",0
422,252,NVS_ENZ_hCK1D_Activator,1,1,"Data from the assay component NVS_ENZ_hCK1D was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCK1D_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK1D. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,5-iodotubericidin,gain,protein,enzyme,kinase,"serine/threonine kinase",0
423,253,NVS_ENZ_hCK2a2b2,1,1,"Data from the assay component NVS_ENZ_hCK2a2b2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCK2a2b2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK2A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
424,253,NVS_ENZ_hCK2a2b2_Activator,1,1,"Data from the assay component NVS_ENZ_hCK2a2b2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCK2a2b2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSNK2A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
425,254,NVS_ENZ_hCSF1R,1,1,"Data from the assay component NVS_ENZ_hCSF1R was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCSF1R, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSF1R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,"receptor tyrosine kinase",0
426,254,NVS_ENZ_hCSF1R_Activator,1,1,"Data from the assay component NVS_ENZ_hCSF1R was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hCSF1R_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CSF1R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,"receptor tyrosine kinase",0
427,255,NVS_ENZ_hDUSP3,1,1,"Data from the assay component NVS_ENZ_hDUSP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hDUSP3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DUSP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'dual-specific phosphatase'.","enzymatic activity",percent_activity,positive,0,"Ammonium Molybdate (NH4MoO4)",loss,protein,enzyme,phosphatase,"dual-specific phosphatase",0
428,255,NVS_ENZ_hDUSP3_Activator,1,1,"Data from the assay component NVS_ENZ_hDUSP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hDUSP3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DUSP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'dual-specific phosphatase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Ammonium Molybdate (NH4MoO4)",gain,protein,enzyme,phosphatase,"dual-specific phosphatase",0
429,256,NVS_ENZ_hEGFR,1,1,"Data from the assay component NVS_ENZ_hEGFR was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEGFR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EGFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,"receptor tyrosine kinase",0
430,256,NVS_ENZ_hEGFR_Activator,1,1,"Data from the assay component NVS_ENZ_hEGFR was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEGFR_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EGFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,"receptor tyrosine kinase",0
431,257,NVS_ENZ_hElastase,1,1,"Data from the assay component NVS_ENZ_hElastase was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hElastase, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ELANE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'serine protease'.","enzymatic activity",percent_activity,positive,0,"Ursolic acid",loss,protein,enzyme,protease,"serine protease",0
432,257,NVS_ENZ_hElastase_Activator,1,1,"Data from the assay component NVS_ENZ_hElastase was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hElastase_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ELANE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'serine protease'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Ursolic acid",gain,protein,enzyme,protease,"serine protease",0
433,258,NVS_ENZ_hEphA1,1,1,"Data from the assay component NVS_ENZ_hEphA1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphA1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,"receptor tyrosine kinase",0
434,258,NVS_ENZ_hEphA1_Activator,1,1,"Data from the assay component NVS_ENZ_hEphA1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphA1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,"receptor tyrosine kinase",0
435,259,NVS_ENZ_hEphA2,1,1,"Data from the assay component NVS_ENZ_hEphA2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphA2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHA2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,"receptor tyrosine kinase",0
436,259,NVS_ENZ_hEphA2_Activator,1,1,"Data from the assay component NVS_ENZ_hEphA2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphA2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHA2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,"receptor tyrosine kinase",0
437,260,NVS_ENZ_hEphB1,1,1,"Data from the assay component NVS_ENZ_hEphB1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphB1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,"receptor tyrosine kinase",0
438,260,NVS_ENZ_hEphB1_Activator,1,1,"Data from the assay component NVS_ENZ_hEphB1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphB1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,"receptor tyrosine kinase",0
439,261,NVS_ENZ_hEphB2,1,1,"Data from the assay component NVS_ENZ_hEphB2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphB2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHB2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,"receptor tyrosine kinase",0
440,261,NVS_ENZ_hEphB2_Activator,1,1,"Data from the assay component NVS_ENZ_hEphB2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hEphB2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene EPHB2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,"receptor tyrosine kinase",0
441,262,NVS_ENZ_hES,1,1,"Data from the assay component NVS_ENZ_hES was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hES, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BCHE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'esterase' intended target family, where the subfamily is 'pseudocholinesterase'.","enzymatic activity",percent_activity,positive,0,physostigmine,loss,protein,enzyme,esterase,pseudocholinesterase,0
442,262,NVS_ENZ_hES_Activator,1,1,"Data from the assay component NVS_ENZ_hES was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hES_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene BCHE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'esterase' intended target family, where the subfamily is 'pseudocholinesterase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,physostigmine,gain,protein,enzyme,esterase,pseudocholinesterase,0
443,263,NVS_ENZ_hFGFR1,1,1,"Data from the assay component NVS_ENZ_hFGFR1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hFGFR1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FGFR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,K252a,loss,protein,receptor,kinase,"receptor tyrosine kinase",0
444,263,NVS_ENZ_hFGFR1_Activator,1,1,"Data from the assay component NVS_ENZ_hFGFR1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hFGFR1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FGFR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,K252a,gain,protein,receptor,kinase,"receptor tyrosine kinase",0
445,264,NVS_ENZ_hFGFR3,1,1,"Data from the assay component NVS_ENZ_hFGFR3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hFGFR3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FGFR3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,"receptor tyrosine kinase",0
446,264,NVS_ENZ_hFGFR3_Activator,1,1,"Data from the assay component NVS_ENZ_hFGFR3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hFGFR3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FGFR3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,"receptor tyrosine kinase",0
447,265,NVS_ENZ_hFyn,1,1,"Data from the assay component NVS_ENZ_hFyn was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hFyn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FYN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
448,265,NVS_ENZ_hFyn_Activator,1,1,"Data from the assay component NVS_ENZ_hFyn was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hFyn_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FYN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
449,266,NVS_ENZ_hGSK3b,1,1,"Data from the assay component NVS_ENZ_hGSK3b was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hGSK3b, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene GSK3B. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
450,266,NVS_ENZ_hGSK3b_Activator,1,1,"Data from the assay component NVS_ENZ_hGSK3b was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hGSK3b_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene GSK3B. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
451,267,NVS_ENZ_hHDAC3,1,1,"Data from the assay component NVS_ENZ_hHDAC3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hHDAC3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene HDAC3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'hydrolase' intended target family, where the subfamily is 'histone deacetylase'.","enzymatic activity",percent_activity,positive,0,trichostatin,loss,protein,enzyme,hydrolase,"histone deacetylase",0
452,267,NVS_ENZ_hHDAC3_Activator,1,1,"Data from the assay component NVS_ENZ_hHDAC3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hHDAC3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene HDAC3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'hydrolase' intended target family, where the subfamily is 'histone deacetylase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,trichostatin,gain,protein,enzyme,hydrolase,"histone deacetylase",0
453,268,NVS_ENZ_hHDAC6,1,1,"Data from the assay component NVS_ENZ_hHDAC6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hHDAC6, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene HDAC6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'hydrolase' intended target family, where the subfamily is 'histone deacetylase'.","enzymatic activity",percent_activity,positive,0,trichostatin,loss,protein,enzyme,hydrolase,"histone deacetylase",0
454,268,NVS_ENZ_hHDAC6_Activator,1,1,"Data from the assay component NVS_ENZ_hHDAC6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hHDAC6_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene HDAC6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'hydrolase' intended target family, where the subfamily is 'histone deacetylase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,trichostatin,gain,protein,enzyme,hydrolase,"histone deacetylase",0
455,269,NVS_ENZ_hIGF1R,1,1,"Data from the assay component NVS_ENZ_hIGF1R was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hIGF1R, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene IGF1R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,"receptor tyrosine kinase",0
456,269,NVS_ENZ_hIGF1R_Activator,1,1,"Data from the assay component NVS_ENZ_hIGF1R was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hIGF1R_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene IGF1R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,"receptor tyrosine kinase",0
457,270,NVS_ENZ_hIKKa,1,1,"Data from the assay component NVS_ENZ_hIKKa was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hIKKa, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CHUK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
458,270,NVS_ENZ_hIKKa_Activator,1,1,"Data from the assay component NVS_ENZ_hIKKa was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hIKKa_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CHUK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
459,271,NVS_ENZ_hInsR,1,1,"Data from the assay component NVS_ENZ_hInsR was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hInsR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene INSR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,"receptor tyrosine kinase",0
460,271,NVS_ENZ_hInsR_Activator,1,1,"Data from the assay component NVS_ENZ_hInsR was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hInsR_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene INSR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,"receptor tyrosine kinase",0
461,272,NVS_ENZ_hIRAK4,1,1,"Data from the assay component NVS_ENZ_hIRAK4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hIRAK4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene IRAK4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
462,272,NVS_ENZ_hIRAK4_Activator,1,1,"Data from the assay component NVS_ENZ_hIRAK4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hIRAK4_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene IRAK4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
463,273,NVS_ENZ_hJak2,1,1,"Data from the assay component NVS_ENZ_hJak2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hJak2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene JAK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
464,273,NVS_ENZ_hJak2_Activator,1,1,"Data from the assay component NVS_ENZ_hJak2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hJak2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene JAK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
465,274,NVS_ENZ_hJNK2,1,1,"Data from the assay component NVS_ENZ_hJNK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hJNK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,SB203580,loss,protein,enzyme,kinase,"serine/threonine kinase",0
466,274,NVS_ENZ_hJNK2_Activator,1,1,"Data from the assay component NVS_ENZ_hJNK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hJNK2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,SB203580,gain,protein,enzyme,kinase,"serine/threonine kinase",0
467,275,NVS_ENZ_hLck,1,1,"Data from the assay component NVS_ENZ_hLck was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hLck, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LCK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
468,275,NVS_ENZ_hLck_Activator,1,1,"Data from the assay component NVS_ENZ_hLck was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hLck_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LCK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
469,276,NVS_ENZ_hLynA,1,1,"Data from the assay component NVS_ENZ_hLynA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hLynA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LYN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
470,276,NVS_ENZ_hLynA_Activator,1,1,"Data from the assay component NVS_ENZ_hLynA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hLynA_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LYN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
471,277,NVS_ENZ_hLynB,1,1,"Data from the assay component NVS_ENZ_hLynB was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hLynB, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LYN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
472,277,NVS_ENZ_hLynB_Activator,1,1,"Data from the assay component NVS_ENZ_hLynB was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hLynB_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene LYN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
473,278,NVS_ENZ_hMAPK1,1,1,"Data from the assay component NVS_ENZ_hMAPK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPK1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,K252a,loss,protein,enzyme,kinase,"serine/threonine kinase",0
474,278,NVS_ENZ_hMAPK1_Activator,1,1,"Data from the assay component NVS_ENZ_hMAPK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPK1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,K252a,gain,protein,enzyme,kinase,"serine/threonine kinase",0
475,279,NVS_ENZ_hMAPK11,1,1,"Data from the assay component NVS_ENZ_hMAPK11 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPK11, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK11. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,SB203580,loss,protein,enzyme,kinase,"serine/threonine kinase",0
476,279,NVS_ENZ_hMAPK11_Activator,1,1,"Data from the assay component NVS_ENZ_hMAPK11 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPK11_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK11. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,SB203580,gain,protein,enzyme,kinase,"serine/threonine kinase",0
477,280,NVS_ENZ_hMAPK3,1,1,"Data from the assay component NVS_ENZ_hMAPK3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPK3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
478,280,NVS_ENZ_hMAPK3_Activator,1,1,"Data from the assay component NVS_ENZ_hMAPK3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPK3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPK3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
479,281,NVS_ENZ_hMAPKAPK2,1,1,"Data from the assay component NVS_ENZ_hMAPKAPK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPKAPK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPKAPK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
480,281,NVS_ENZ_hMAPKAPK2_Activator,1,1,"Data from the assay component NVS_ENZ_hMAPKAPK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPKAPK2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPKAPK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
481,282,NVS_ENZ_hMAPKAPK5,1,1,"Data from the assay component NVS_ENZ_hMAPKAPK5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPKAPK5, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPKAPK5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
482,282,NVS_ENZ_hMAPKAPK5_Activator,1,1,"Data from the assay component NVS_ENZ_hMAPKAPK5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMAPKAPK5_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MAPKAPK5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
483,283,NVS_ENZ_hMARK1,1,1,"Data from the assay component NVS_ENZ_hMARK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMARK1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MARK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
484,283,NVS_ENZ_hMARK1_Activator,1,1,"Data from the assay component NVS_ENZ_hMARK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMARK1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MARK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
485,284,NVS_ENZ_hMet,1,1,"Data from the assay component NVS_ENZ_hMet was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMet, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MET. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,"receptor tyrosine kinase",0
486,284,NVS_ENZ_hMet_Activator,1,1,"Data from the assay component NVS_ENZ_hMet was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMet_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MET. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,"receptor tyrosine kinase",0
487,285,NVS_ENZ_hMMP1,1,1,"Data from the assay component NVS_ENZ_hMMP1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.","enzymatic activity",percent_activity,positive,0,"Galardin (GM6001)",loss,protein,enzyme,protease,"matrix metalloproteinase",0
488,285,NVS_ENZ_hMMP1_Activator,1,1,"Data from the assay component NVS_ENZ_hMMP1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Galardin (GM6001)",gain,protein,enzyme,protease,"matrix metalloproteinase",0
489,286,NVS_ENZ_hMMP13,1,1,"Data from the assay component NVS_ENZ_hMMP13 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP13, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP13. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.","enzymatic activity",percent_activity,positive,0,"Tyr-Hydroxamic acid",loss,protein,enzyme,protease,"matrix metalloproteinase",0
490,286,NVS_ENZ_hMMP13_Activator,1,1,"Data from the assay component NVS_ENZ_hMMP13 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP13_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP13. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Tyr-Hydroxamic acid",gain,protein,enzyme,protease,"matrix metalloproteinase",0
491,287,NVS_ENZ_hMMP2,1,1,"Data from the assay component NVS_ENZ_hMMP2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.","enzymatic activity",percent_activity,positive,0,"Galardin (GM6001)",loss,protein,enzyme,protease,"matrix metalloproteinase",0
492,287,NVS_ENZ_hMMP2_Activator,1,1,"Data from the assay component NVS_ENZ_hMMP2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Galardin (GM6001)",gain,protein,enzyme,protease,"matrix metalloproteinase",0
493,288,NVS_ENZ_hMMP3,1,1,"Data from the assay component NVS_ENZ_hMMP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.","enzymatic activity",percent_activity,positive,0,"Galardin (GM6001)",loss,protein,enzyme,protease,"matrix metalloproteinase",0
494,288,NVS_ENZ_hMMP3_Activator,1,1,"Data from the assay component NVS_ENZ_hMMP3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Galardin (GM6001)",gain,protein,enzyme,protease,"matrix metalloproteinase",0
495,289,NVS_ENZ_hMMP7,1,1,"Data from the assay component NVS_ENZ_hMMP7 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP7, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP7. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.","enzymatic activity",percent_activity,positive,0,"Galardin (GM6001)",loss,protein,enzyme,protease,"matrix metalloproteinase",0
496,289,NVS_ENZ_hMMP7_Activator,1,1,"Data from the assay component NVS_ENZ_hMMP7 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP7_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP7. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Galardin (GM6001)",gain,protein,enzyme,protease,"matrix metalloproteinase",0
497,290,NVS_ENZ_hMMP9,1,1,"Data from the assay component NVS_ENZ_hMMP9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP9, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'.","enzymatic activity",percent_activity,positive,0,"Galardin (GM6001)",loss,protein,enzyme,protease,"matrix metalloproteinase",0
498,290,NVS_ENZ_hMMP9_Activator,1,1,"Data from the assay component NVS_ENZ_hMMP9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMMP9_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MMP9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'protease' intended target family, where the subfamily is 'matrix metalloproteinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Galardin (GM6001)",gain,protein,enzyme,protease,"matrix metalloproteinase",0
499,291,NVS_ENZ_hMsk1,1,1,"Data from the assay component NVS_ENZ_hMsk1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMsk1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene RPS6KA5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
500,291,NVS_ENZ_hMsk1_Activator,1,1,"Data from the assay component NVS_ENZ_hMsk1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hMsk1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene RPS6KA5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
501,292,NVS_ENZ_hNEK2,1,1,"Data from the assay component NVS_ENZ_hNEK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hNEK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene NEK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
502,292,NVS_ENZ_hNEK2_Activator,1,1,"Data from the assay component NVS_ENZ_hNEK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hNEK2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene NEK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
503,293,NVS_ENZ_hPAK2,1,1,"Data from the assay component NVS_ENZ_hPAK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPAK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PAK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
504,293,NVS_ENZ_hPAK2_Activator,1,1,"Data from the assay component NVS_ENZ_hPAK2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPAK2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PAK2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
505,294,NVS_ENZ_hPAK4,1,1,"Data from the assay component NVS_ENZ_hPAK4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPAK4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PAK4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
506,294,NVS_ENZ_hPAK4_Activator,1,1,"Data from the assay component NVS_ENZ_hPAK4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPAK4_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PAK4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
507,295,NVS_ENZ_hPDE10,1,1,"Data from the assay component NVS_ENZ_hPDE10 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE10, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE10A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'esterase' intended target family, where the subfamily is 'phosphodiesterase'.","enzymatic activity",percent_activity,positive,0,trequinsin,loss,protein,enzyme,esterase,phosphodiesterase,0
508,295,NVS_ENZ_hPDE10_Activator,1,1,"Data from the assay component NVS_ENZ_hPDE10 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE10_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE10A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'esterase' intended target family, where the subfamily is 'phosphodiesterase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,trequinsin,gain,protein,enzyme,esterase,phosphodiesterase,0
509,296,NVS_ENZ_hPDE4A1,1,1,"Data from the assay component NVS_ENZ_hPDE4A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE4A1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE4A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'esterase' intended target family, where the subfamily is 'phosphodiesterase'.","enzymatic activity",percent_activity,positive,0,trequinsin,loss,protein,enzyme,esterase,phosphodiesterase,0
510,296,NVS_ENZ_hPDE4A1_Activator,1,1,"Data from the assay component NVS_ENZ_hPDE4A1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE4A1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE4A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'esterase' intended target family, where the subfamily is 'phosphodiesterase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,trequinsin,gain,protein,enzyme,esterase,phosphodiesterase,0
511,297,NVS_ENZ_hPDE5,1,1,"Data from the assay component NVS_ENZ_hPDE5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE5, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE5A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'esterase' intended target family, where the subfamily is 'phosphodiesterase'.","enzymatic activity",percent_activity,positive,0,Dipyridamole,loss,protein,enzyme,esterase,phosphodiesterase,0
512,297,NVS_ENZ_hPDE5_Activator,1,1,"Data from the assay component NVS_ENZ_hPDE5 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPDE5_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PDE5A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'esterase' intended target family, where the subfamily is 'phosphodiesterase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Dipyridamole,gain,protein,enzyme,esterase,phosphodiesterase,0
513,298,NVS_ENZ_hPI3Ka,1,1,"Data from the assay component NVS_ENZ_hPI3Ka was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPI3Ka, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PIK3CA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'phosphoinositol kinase'.","enzymatic activity",percent_activity,positive,0,PI-103,loss,protein,enzyme,kinase,"phosphoinositol kinase",0
514,298,NVS_ENZ_hPI3Ka_Activator,1,1,"Data from the assay component NVS_ENZ_hPI3Ka was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPI3Ka_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PIK3CA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'phosphoinositol kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,PI-103,gain,protein,enzyme,kinase,"phosphoinositol kinase",0
515,299,NVS_ENZ_hPKA,1,1,"Data from the assay component NVS_ENZ_hPKA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPKA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKACA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,"H 89",loss,protein,enzyme,kinase,"serine/threonine kinase",0
516,299,NVS_ENZ_hPKA_Activator,1,1,"Data from the assay component NVS_ENZ_hPKA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPKA_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKACA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"H 89",gain,protein,enzyme,kinase,"serine/threonine kinase",0
517,300,NVS_ENZ_hPKCz,1,1,"Data from the assay component NVS_ENZ_hPKCz was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPKCz, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKCZ. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
518,300,NVS_ENZ_hPKCz_Activator,1,1,"Data from the assay component NVS_ENZ_hPKCz was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPKCz_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKCZ. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
519,301,NVS_ENZ_hPKD2,1,1,"Data from the assay component NVS_ENZ_hPKD2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPKD2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKD2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
520,301,NVS_ENZ_hPKD2_Activator,1,1,"Data from the assay component NVS_ENZ_hPKD2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPKD2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PRKD2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
521,302,NVS_ENZ_hPPM1A,1,1,"Data from the assay component NVS_ENZ_hPPM1A was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPPM1A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPM1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'serine/threonine phosphatase'.","enzymatic activity",percent_activity,positive,0,"sodium fluoride",loss,protein,enzyme,phosphatase,"serine/threonine phosphatase",0
522,302,NVS_ENZ_hPPM1A_Activator,1,1,"Data from the assay component NVS_ENZ_hPPM1A was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPPM1A_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPM1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'serine/threonine phosphatase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"sodium fluoride",gain,protein,enzyme,phosphatase,"serine/threonine phosphatase",0
523,303,NVS_ENZ_hPPP1CA,1,1,"Data from the assay component NVS_ENZ_hPPP1CA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPPP1CA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPP1CA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'serine/threonine phosphatase'.","enzymatic activity",percent_activity,positive,0,"calyculin A",loss,protein,enzyme,phosphatase,"serine/threonine phosphatase",0
524,303,NVS_ENZ_hPPP1CA_Activator,1,1,"Data from the assay component NVS_ENZ_hPPP1CA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPPP1CA_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPP1CA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'serine/threonine phosphatase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"calyculin A",gain,protein,enzyme,phosphatase,"serine/threonine phosphatase",0
525,304,NVS_ENZ_hPPP2CA,1,1,"Data from the assay component NVS_ENZ_hPPP2CA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPPP2CA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPP2CA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'serine/threonine phosphatase'.","enzymatic activity",percent_activity,positive,0,"calyculin A",loss,protein,enzyme,phosphatase,"serine/threonine phosphatase",0
526,304,NVS_ENZ_hPPP2CA_Activator,1,1,"Data from the assay component NVS_ENZ_hPPP2CA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPPP2CA_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PPP2CA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'serine/threonine phosphatase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"calyculin A",gain,protein,enzyme,phosphatase,"serine/threonine phosphatase",0
527,305,NVS_ENZ_hPTEN,1,1,"Data from the assay component NVS_ENZ_hPTEN was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTEN, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTEN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'dual-specific phosphatase'.","enzymatic activity",percent_activity,positive,0,"bpV (bipy)",loss,protein,enzyme,phosphatase,"dual-specific phosphatase",0
528,305,NVS_ENZ_hPTEN_Activator,1,1,"Data from the assay component NVS_ENZ_hPTEN was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTEN_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTEN. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'dual-specific phosphatase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"bpV (bipy);Ammonium Molybdate (NH4MoO4)",gain,protein,enzyme,phosphatase,"dual-specific phosphatase",0
529,306,NVS_ENZ_hPTPN1,1,1,"Data from the assay component NVS_ENZ_hPTPN1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'non-receptor tyrosine phosphatase'.","enzymatic activity",percent_activity,positive,0,"Ammonium Molybdate (NH4MoO4)",loss,protein,enzyme,phosphatase,"non-receptor tyrosine phosphatase",0
530,306,NVS_ENZ_hPTPN1_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPN1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'non-receptor tyrosine phosphatase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Ammonium Molybdate (NH4MoO4)",gain,protein,enzyme,phosphatase,"non-receptor tyrosine phosphatase",0
531,307,NVS_ENZ_hPTPN11,1,1,"Data from the assay component NVS_ENZ_hPTPN11 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN11, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN11. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'non-receptor tyrosine phosphatase'.","enzymatic activity",percent_activity,positive,0,"Ammonium Molybdate (NH4MoO4)",loss,protein,enzyme,phosphatase,"non-receptor tyrosine phosphatase",0
532,307,NVS_ENZ_hPTPN11_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPN11 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN11_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN11. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'non-receptor tyrosine phosphatase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Ammonium Molybdate (NH4MoO4)",gain,protein,enzyme,phosphatase,"non-receptor tyrosine phosphatase",0
533,308,NVS_ENZ_hPTPN12,1,1,"Data from the assay component NVS_ENZ_hPTPN12 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN12, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN12. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'non-receptor tyrosine phosphatase'.","enzymatic activity",percent_activity,positive,0,"Ammonium Molybdate (NH4MoO4)",loss,protein,enzyme,phosphatase,"non-receptor tyrosine phosphatase",0
534,308,NVS_ENZ_hPTPN12_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPN12 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN12_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN12. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'non-receptor tyrosine phosphatase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Ammonium Molybdate (NH4MoO4)",gain,protein,enzyme,phosphatase,"non-receptor tyrosine phosphatase",0
535,309,NVS_ENZ_hPTPN13,1,1,"Data from the assay component NVS_ENZ_hPTPN13 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN13, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN13. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'non-receptor tyrosine phosphatase'.","enzymatic activity",percent_activity,positive,0,"Ammonium Molybdate (NH4MoO4)",loss,protein,enzyme,phosphatase,"non-receptor tyrosine phosphatase",0
536,309,NVS_ENZ_hPTPN13_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPN13 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN13_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN13. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'non-receptor tyrosine phosphatase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Ammonium Molybdate (NH4MoO4)",gain,protein,enzyme,phosphatase,"non-receptor tyrosine phosphatase",0
537,310,NVS_ENZ_hPTPN14,1,1,"Data from the assay component NVS_ENZ_hPTPN14 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN14, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN14. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'non-receptor tyrosine phosphatase'.","enzymatic activity",percent_activity,positive,0,"Ammonium Molybdate (NH4MoO4)",loss,protein,enzyme,phosphatase,"non-receptor tyrosine phosphatase",0
538,310,NVS_ENZ_hPTPN14_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPN14 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN14_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN14. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'non-receptor tyrosine phosphatase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Ammonium Molybdate (NH4MoO4)",gain,protein,enzyme,phosphatase,"non-receptor tyrosine phosphatase",0
539,311,NVS_ENZ_hPTPN2,1,1,"Data from the assay component NVS_ENZ_hPTPN2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'non-receptor tyrosine phosphatase'.","enzymatic activity",percent_activity,positive,0,"Ammonium Molybdate (NH4MoO4)",loss,protein,enzyme,phosphatase,"non-receptor tyrosine phosphatase",0
540,311,NVS_ENZ_hPTPN2_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPN2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'non-receptor tyrosine phosphatase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Ammonium Molybdate (NH4MoO4)",gain,protein,enzyme,phosphatase,"non-receptor tyrosine phosphatase",0
541,312,NVS_ENZ_hPTPN4,1,1,"Data from the assay component NVS_ENZ_hPTPN4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'non-receptor tyrosine phosphatase'.","enzymatic activity",percent_activity,positive,0,"Ammonium Molybdate (NH4MoO4)",loss,protein,enzyme,phosphatase,"non-receptor tyrosine phosphatase",0
542,312,NVS_ENZ_hPTPN4_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPN4 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN4_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'non-receptor tyrosine phosphatase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Ammonium Molybdate (NH4MoO4)",gain,protein,enzyme,phosphatase,"non-receptor tyrosine phosphatase",0
543,313,NVS_ENZ_hPTPN6,1,1,"Data from the assay component NVS_ENZ_hPTPN6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN6, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'non-receptor tyrosine phosphatase'.","enzymatic activity",percent_activity,positive,0,"Ammonium Molybdate (NH4MoO4)",loss,protein,enzyme,phosphatase,"non-receptor tyrosine phosphatase",0
544,313,NVS_ENZ_hPTPN6_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPN6 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN6_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'non-receptor tyrosine phosphatase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Ammonium Molybdate (NH4MoO4)",gain,protein,enzyme,phosphatase,"non-receptor tyrosine phosphatase",0
545,314,NVS_ENZ_hPTPN9,1,1,"Data from the assay component NVS_ENZ_hPTPN9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN9, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'non-receptor tyrosine phosphatase'.","enzymatic activity",percent_activity,positive,0,"Ammonium Molybdate (NH4MoO4)",loss,protein,enzyme,phosphatase,"non-receptor tyrosine phosphatase",0
546,314,NVS_ENZ_hPTPN9_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPN9 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPN9_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPN9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'non-receptor tyrosine phosphatase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Ammonium Molybdate (NH4MoO4)",gain,protein,enzyme,phosphatase,"non-receptor tyrosine phosphatase",0
547,315,NVS_ENZ_hPTPRB,1,1,"Data from the assay component NVS_ENZ_hPTPRB was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRB, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'receptor tyrosine phosphatase'.","enzymatic activity",percent_activity,positive,0,"Ammonium Molybdate (NH4MoO4)",loss,protein,enzyme,phosphatase,"receptor tyrosine phosphatase",0
548,315,NVS_ENZ_hPTPRB_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPRB was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRB_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'receptor tyrosine phosphatase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Ammonium Molybdate (NH4MoO4)",gain,protein,enzyme,phosphatase,"receptor tyrosine phosphatase",0
549,316,NVS_ENZ_hPTPRC,1,1,"Data from the assay component NVS_ENZ_hPTPRC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRC, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'receptor tyrosine phosphatase'.","enzymatic activity",percent_activity,positive,0,"Ammonium Molybdate (NH4MoO4)",loss,protein,enzyme,phosphatase,"receptor tyrosine phosphatase",0
550,316,NVS_ENZ_hPTPRC_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPRC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRC_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'receptor tyrosine phosphatase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Ammonium Molybdate (NH4MoO4)",gain,protein,enzyme,phosphatase,"receptor tyrosine phosphatase",0
551,317,NVS_ENZ_hPTPRF,1,1,"Data from the assay component NVS_ENZ_hPTPRF was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRF, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRF. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'receptor tyrosine phosphatase'.","enzymatic activity",percent_activity,positive,0,"Ammonium Molybdate (NH4MoO4)",loss,protein,enzyme,phosphatase,"receptor tyrosine phosphatase",0
552,317,NVS_ENZ_hPTPRF_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPRF was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRF_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRF. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'receptor tyrosine phosphatase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Ammonium Molybdate (NH4MoO4)",gain,protein,enzyme,phosphatase,"receptor tyrosine phosphatase",0
553,318,NVS_ENZ_hPTPRM,1,1,"Data from the assay component NVS_ENZ_hPTPRM was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRM, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRM. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'receptor tyrosine phosphatase'.","enzymatic activity",percent_activity,positive,0,"Ammonium Molybdate (NH4MoO4)",loss,protein,enzyme,phosphatase,"receptor tyrosine phosphatase",0
554,318,NVS_ENZ_hPTPRM_Activator,1,1,"Data from the assay component NVS_ENZ_hPTPRM was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hPTPRM_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTPRM. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'phosphatase' intended target family, where the subfamily is 'receptor tyrosine phosphatase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Ammonium Molybdate (NH4MoO4)",gain,protein,enzyme,phosphatase,"receptor tyrosine phosphatase",0
555,319,NVS_ENZ_hRAF1,1,1,"Data from the assay component NVS_ENZ_hRAF1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hRAF1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene RAF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,SB203580,loss,protein,enzyme,kinase,"serine/threonine kinase",0
556,319,NVS_ENZ_hRAF1_Activator,1,1,"Data from the assay component NVS_ENZ_hRAF1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hRAF1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene RAF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,SB203580,gain,protein,enzyme,kinase,"serine/threonine kinase",0
557,320,NVS_ENZ_hROCK1,1,1,"Data from the assay component NVS_ENZ_hROCK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hROCK1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ROCK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
558,320,NVS_ENZ_hROCK1_Activator,1,1,"Data from the assay component NVS_ENZ_hROCK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hROCK1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ROCK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
559,321,NVS_ENZ_hSGK1,1,1,"Data from the assay component NVS_ENZ_hSGK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSGK1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SGK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"serine/threonine kinase",0
560,321,NVS_ENZ_hSGK1_Activator,1,1,"Data from the assay component NVS_ENZ_hSGK1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSGK1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SGK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'serine/threonine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"serine/threonine kinase",0
561,322,NVS_ENZ_hSIRT1,1,1,"Data from the assay component NVS_ENZ_hSIRT1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSIRT1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'hydrolase' intended target family, where the subfamily is 'protein deacetylase'.","enzymatic activity",percent_activity,positive,0,"Suramin;Ammonium Molybdate (NH4MoO4)",loss,protein,enzyme,hydrolase,"protein deacetylase",0
562,322,NVS_ENZ_hSIRT1_Activator,1,1,"Data from the assay component NVS_ENZ_hSIRT1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSIRT1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'hydrolase' intended target family, where the subfamily is 'protein deacetylase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Suramin;Ammonium Molybdate (NH4MoO4)",gain,protein,enzyme,hydrolase,"protein deacetylase",0
563,323,NVS_ENZ_hSIRT2,1,1,"Data from the assay component NVS_ENZ_hSIRT2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSIRT2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'hydrolase' intended target family, where the subfamily is 'protein deacetylase'.","enzymatic activity",percent_activity,positive,0,Suramin,loss,protein,enzyme,hydrolase,"protein deacetylase",0
564,323,NVS_ENZ_hSIRT2_Activator,1,1,"Data from the assay component NVS_ENZ_hSIRT2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSIRT2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'hydrolase' intended target family, where the subfamily is 'protein deacetylase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Suramin,gain,protein,enzyme,hydrolase,"protein deacetylase",0
565,324,NVS_ENZ_hSIRT3,1,1,"Data from the assay component NVS_ENZ_hSIRT3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSIRT3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'hydrolase' intended target family, where the subfamily is 'protein deacetylase'.","enzymatic activity",percent_activity,positive,0,Nicotinamide,loss,protein,enzyme,hydrolase,"protein deacetylase",0
566,324,NVS_ENZ_hSIRT3_Activator,1,1,"Data from the assay component NVS_ENZ_hSIRT3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSIRT3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SIRT3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'hydrolase' intended target family, where the subfamily is 'protein deacetylase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Nicotinamide,gain,protein,enzyme,hydrolase,"protein deacetylase",0
567,325,NVS_ENZ_hSRC,1,1,"Data from the assay component NVS_ENZ_hSRC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSRC, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SRC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
568,325,NVS_ENZ_hSRC_Activator,1,1,"Data from the assay component NVS_ENZ_hSRC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSRC_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SRC. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
569,326,NVS_ENZ_hSyk,1,1,"Data from the assay component NVS_ENZ_hSyk was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSyk, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SYK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
570,326,NVS_ENZ_hSyk_Activator,1,1,"Data from the assay component NVS_ENZ_hSyk was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hSyk_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene SYK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
571,327,NVS_ENZ_hTie2,1,1,"Data from the assay component NVS_ENZ_hTie2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hTie2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene TEK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,"receptor tyrosine kinase",0
572,327,NVS_ENZ_hTie2_Activator,1,1,"Data from the assay component NVS_ENZ_hTie2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hTie2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene TEK. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,"receptor tyrosine kinase",0
573,328,NVS_ENZ_hTrkA,1,1,"Data from the assay component NVS_ENZ_hTrkA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hTrkA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene NTRK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,"receptor tyrosine kinase",0
574,328,NVS_ENZ_hTrkA_Activator,1,1,"Data from the assay component NVS_ENZ_hTrkA was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hTrkA_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene NTRK1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,"receptor tyrosine kinase",0
575,329,NVS_ENZ_hVEGFR1,1,1,"Data from the assay component NVS_ENZ_hVEGFR1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hVEGFR1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FLT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,"receptor tyrosine kinase",0
576,329,NVS_ENZ_hVEGFR1_Activator,1,1,"Data from the assay component NVS_ENZ_hVEGFR1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hVEGFR1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FLT1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,"receptor tyrosine kinase",0
577,330,NVS_ENZ_hVEGFR2,1,1,"Data from the assay component NVS_ENZ_hVEGFR2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hVEGFR2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene KDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,"receptor tyrosine kinase",0
578,330,NVS_ENZ_hVEGFR2_Activator,1,1,"Data from the assay component NVS_ENZ_hVEGFR2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hVEGFR2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene KDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,"receptor tyrosine kinase",0
579,331,NVS_ENZ_hVEGFR3,1,1,"Data from the assay component NVS_ENZ_hVEGFR3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hVEGFR3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FLT4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,receptor,kinase,"receptor tyrosine kinase",0
580,331,NVS_ENZ_hVEGFR3_Activator,1,1,"Data from the assay component NVS_ENZ_hVEGFR3 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hVEGFR3_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene FLT4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,receptor,kinase,"receptor tyrosine kinase",0
581,332,NVS_ENZ_hZAP70,1,1,"Data from the assay component NVS_ENZ_hZAP70 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hZAP70, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ZAP70. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
582,332,NVS_ENZ_hZAP70_Activator,1,1,"Data from the assay component NVS_ENZ_hZAP70 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hZAP70_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene ZAP70. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'non-receptor tyrosine kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"non-receptor tyrosine kinase",0
583,333,NVS_ENZ_oCOX1,1,1,"Data from the assay component NVS_ENZ_oCOX1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_oCOX1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTGS1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'cyclooxygenase'.","enzymatic activity",percent_activity,positive,0,SC-560,loss,protein,enzyme,oxidoreductase,cyclooxygenase,0
584,333,NVS_ENZ_oCOX1_Activator,1,1,"Data from the assay component NVS_ENZ_oCOX1 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_oCOX1_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTGS1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'cyclooxygenase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,SC-560,gain,protein,enzyme,oxidoreductase,cyclooxygenase,0
585,334,NVS_ENZ_oCOX2,1,1,"Data from the assay component NVS_ENZ_oCOX2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_oCOX2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTGS2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'cyclooxygenase'.","enzymatic activity",percent_activity,positive,0,DuP-697,loss,protein,enzyme,oxidoreductase,cyclooxygenase,0
586,334,NVS_ENZ_oCOX2_Activator,1,1,"Data from the assay component NVS_ENZ_oCOX2 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_oCOX2_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene PTGS2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'cyclooxygenase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,DuP-697,gain,protein,enzyme,oxidoreductase,cyclooxygenase,0
587,335,NVS_ENZ_pMTHFR,1,1,"Data from the assay component NVS_ENZ_pMTHFR was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_pMTHFR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MTHFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'methylenetetrahydrofolate reductase'.","enzymatic activity",percent_activity,positive,0,Sulfasalazine,loss,protein,enzyme,oxidoreductase,"methylenetetrahydrofolate reductase",0
588,335,NVS_ENZ_pMTHFR_Activator,1,1,"Data from the assay component NVS_ENZ_pMTHFR was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_pMTHFR_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene MTHFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'methylenetetrahydrofolate reductase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Sulfasalazine,gain,protein,enzyme,oxidoreductase,"methylenetetrahydrofolate reductase",0
589,336,NVS_ENZ_rabI2C,1,1,"Data from the assay component NVS_ENZ_rabI2C was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rabI2C, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CKB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'imidazoline receptor'.","enzymatic activity",percent_activity,positive,0,2-BFI,loss,protein,receptor,oxidoreductase,"imidazoline receptor",0
590,336,NVS_ENZ_rabI2C_Activator,1,1,"Data from the assay component NVS_ENZ_rabI2C was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rabI2C_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CKB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'imidazoline receptor'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,2-BFI,gain,protein,receptor,oxidoreductase,"imidazoline receptor",0
591,337,NVS_ENZ_rACFSKBinding,1,1,"Data from the assay component NVS_ENZ_rACFSKBinding was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rACFSKBinding, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Adcy5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'lyase' intended target family, where the subfamily is 'adenylyl cyclase'.","enzymatic activity",percent_activity,positive,0,Forskolin,loss,protein,enzyme,lyase,"adenylyl cyclase",0
592,337,NVS_ENZ_rACFSKBinding_Activator,1,1,"Data from the assay component NVS_ENZ_rACFSKBinding was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rACFSKBinding_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Adcy5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'lyase' intended target family, where the subfamily is 'adenylyl cyclase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Forskolin,gain,protein,enzyme,lyase,"adenylyl cyclase",0
593,338,NVS_ENZ_rAChE,1,1,"Data from the assay component NVS_ENZ_rAChE was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rAChE, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Ache. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'esterase' intended target family, where the subfamily is 'acetylcholinesterase'.","enzymatic activity",percent_activity,positive,0,Physostigmine,loss,protein,enzyme,esterase,acetylcholinesterase,0
594,338,NVS_ENZ_rAChE_Activator,1,1,"Data from the assay component NVS_ENZ_rAChE was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rAChE_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Ache. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'esterase' intended target family, where the subfamily is 'acetylcholinesterase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Physostigmine,gain,protein,enzyme,esterase,acetylcholinesterase,0
595,339,NVS_ENZ_rCNOS,1,1,"Data from the assay component NVS_ENZ_rCNOS was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rCNOS, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Nos1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'nitric oxide synthase'.","enzymatic activity",percent_activity,positive,0,Nitro-L-Arginine,loss,protein,enzyme,oxidoreductase,"nitric oxide synthase",0
596,339,NVS_ENZ_rCNOS_Activator,1,1,"Data from the assay component NVS_ENZ_rCNOS was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rCNOS_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Nos1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'nitric oxide synthase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Nitro-L-Arginine,gain,protein,enzyme,oxidoreductase,"nitric oxide synthase",0
597,340,NVS_ENZ_rCOMT,1,1,"Data from the assay component NVS_ENZ_rCOMT was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rCOMT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Comt. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'methyltransferase' intended target family, where the subfamily is 'o-methyltransferase'.","enzymatic activity",percent_activity,positive,0,OR-486,loss,protein,enzyme,methyltransferase,o-methyltransferase,0
598,340,NVS_ENZ_rCOMT_Activator,1,1,"Data from the assay component NVS_ENZ_rCOMT was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rCOMT_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Comt. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'methyltransferase' intended target family, where the subfamily is 'o-methyltransferase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,OR-486,gain,protein,enzyme,methyltransferase,o-methyltransferase,0
599,341,NVS_ENZ_hDYRK1a,1,1,"Data from the assay component NVS_ENZ_hDYRK1a was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hDYRK1a, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DYRK1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'dual-specific kinase'.","enzymatic activity",percent_activity,positive,0,Staurosporine,loss,protein,enzyme,kinase,"dual-specific kinase",0
600,341,NVS_ENZ_hDYRK1a_Activator,1,1,"Data from the assay component NVS_ENZ_hDYRK1a was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_hDYRK1a_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DYRK1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'kinase' intended target family, where the subfamily is 'dual-specific kinase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,Staurosporine,gain,protein,enzyme,kinase,"dual-specific kinase",0
601,342,NVS_ENZ_rMAOAC,1,1,"Data from the assay component NVS_ENZ_rMAOAC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOAC, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maoa. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'monoamine oxidase'.","enzymatic activity",percent_activity,positive,0,"Ro 41-1049;Tetrindole mesylate",loss,protein,enzyme,oxidoreductase,"monoamine oxidase",0
602,342,NVS_ENZ_rMAOAC_Activator,1,1,"Data from the assay component NVS_ENZ_rMAOAC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOAC_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maoa. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'monoamine oxidase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Ro 41-1049;Tetrindole mesylate",gain,protein,enzyme,oxidoreductase,"monoamine oxidase",0
603,343,NVS_ENZ_rMAOAP,1,1,"Data from the assay component NVS_ENZ_rMAOAP was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOAP, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maoa. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'monoamine oxidase'.","enzymatic activity",percent_activity,positive,0,"Ro 41-1049;Tetrindole mesylate",loss,protein,enzyme,oxidoreductase,"monoamine oxidase",0
604,343,NVS_ENZ_rMAOAP_Activator,1,1,"Data from the assay component NVS_ENZ_rMAOAP was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOAP_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maoa. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'monoamine oxidase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Ro 41-1049;Tetrindole mesylate",gain,protein,enzyme,oxidoreductase,"monoamine oxidase",0
605,344,NVS_ENZ_rMAOBC,1,1,"Data from the assay component NVS_ENZ_rMAOBC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOBC, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maob. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'monoamine oxidase'.","enzymatic activity",percent_activity,positive,0,"Ro 16-6491",loss,protein,enzyme,oxidoreductase,"monoamine oxidase",0
606,344,NVS_ENZ_rMAOBC_Activator,1,1,"Data from the assay component NVS_ENZ_rMAOBC was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOBC_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maob. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'monoamine oxidase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Ro 16-6491",gain,protein,enzyme,oxidoreductase,"monoamine oxidase",0
607,345,NVS_ENZ_rMAOBP,1,1,"Data from the assay component NVS_ENZ_rMAOBP was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOBP, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maob. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'monoamine oxidase'.","enzymatic activity",percent_activity,positive,0,"Ro 16-6491",loss,protein,enzyme,oxidoreductase,"monoamine oxidase",0
608,345,NVS_ENZ_rMAOBP_Activator,1,1,"Data from the assay component NVS_ENZ_rMAOBP was analyzed into 2 assay endpoints. This assay endpoint, NVS_ENZ_rMAOBP_Activator, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, gain-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene Maob. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'oxidoreductase' intended target family, where the subfamily is 'monoamine oxidase'. Assay was not developed or optimized to detect gain of signal. Use data with caution.","enzymatic activity",percent_activity,negative,0,"Ro 16-6491",gain,protein,enzyme,oxidoreductase,"monoamine oxidase",0
609,346,NVS_GPCR_bAdoR_NonSelective,1,1,"Data from the assay component NVS_GPCR_bAdoR_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bAdoR_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADORA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"5'-N-ethylcarboxamidoadenosine (NECA)",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
610,347,NVS_GPCR_bAT2,1,1,"Data from the assay component NVS_GPCR_bAT2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bAT2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AGTR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Angiotensin II",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
611,348,NVS_GPCR_bDR_NonSelective,1,1,"Data from the assay component NVS_GPCR_bDR_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bDR_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Spiperone HCl",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
612,349,NVS_GPCR_bH1,1,1,"Data from the assay component NVS_GPCR_bH1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bH1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HRH1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,Tripolidine,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
613,350,NVS_GPCR_bNPY_NonSelective,1,1,"Data from the assay component NVS_GPCR_bNPY_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_bNPY_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NPY. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"porcine neuropeptide Y",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
614,351,NVS_GPCR_g5HT4,1,1,"Data from the assay component NVS_GPCR_g5HT4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_g5HT4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Htr4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,Serotonin,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
615,352,NVS_GPCR_gANPA,1,1,"Data from the assay component NVS_GPCR_gANPA was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gANPA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Nppa. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'lyase' intended target family, where the subfamily is 'guanylyl cyclase'.",binding,percent_activity,positive,0,"rat ANP",loss,protein,receptor,lyase,"guanylyl cyclase",0
616,353,NVS_GPCR_gBK2,1,1,"Data from the assay component NVS_GPCR_gBK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gBK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Bdkrb2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Bradykinin TFA salt",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
617,354,NVS_GPCR_gH2,1,1,"Data from the assay component NVS_GPCR_gH2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gH2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Hrh2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,Tiotidine,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
618,355,NVS_GPCR_gLTB4,1,1,"Data from the assay component NVS_GPCR_gLTB4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gLTB4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Ltb4r. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Leukotriene B4 (LTB4)",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
619,356,NVS_GPCR_gLTD4,1,1,"Data from the assay component NVS_GPCR_gLTD4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gLTD4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cysltr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Leukotriene D4 (LTD4)",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
620,357,NVS_GPCR_gMPeripheral_NonSelective,1,1,"Data from the assay component NVS_GPCR_gMPeripheral_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gMPeripheral_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Chrm3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Atropine sulfate",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
621,358,NVS_GPCR_gOpiateK,1,1,"Data from the assay component NVS_GPCR_gOpiateK was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_gOpiateK, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Oprk1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,U-69593,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
622,359,NVS_GPCR_h5HT2A,1,1,"Data from the assay component NVS_GPCR_h5HT2A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT2A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR2A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,Ketanserin,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
623,360,NVS_GPCR_h5HT5A,1,1,"Data from the assay component NVS_GPCR_h5HT5A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT5A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR5A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Methiothepin mesylate",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
624,361,NVS_GPCR_h5HT6,1,1,"Data from the assay component NVS_GPCR_h5HT6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT6, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Methiothepin mesylate",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
625,362,NVS_GPCR_h5HT7,1,1,"Data from the assay component NVS_GPCR_h5HT7 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_h5HT7, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR7. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,5-carboxamidotryptamine,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
626,363,NVS_GPCR_hAdoRA1,1,1,"Data from the assay component NVS_GPCR_hAdoRA1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdoRA1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADORA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,2-chloroadenosine,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
627,364,NVS_GPCR_hAdoRA2a,1,1,"Data from the assay component NVS_GPCR_hAdoRA2a was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdoRA2a, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADORA2A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"5'-N-ethylcarboxamidoadenosine (NECA)",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
628,365,NVS_GPCR_hAdra2A,1,1,"Data from the assay component NVS_GPCR_hAdra2A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdra2A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRA2A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Oxymetazoline HCl",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
629,366,NVS_GPCR_hAdra2C,1,1,"Data from the assay component NVS_GPCR_hAdra2C was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdra2C, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRA2C. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Oxymetazoline HCl",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
630,367,NVS_GPCR_hAdrb1,1,1,"Data from the assay component NVS_GPCR_hAdrb1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdrb1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Alprenolol HCl",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
631,368,NVS_GPCR_hAdrb2,1,1,"Data from the assay component NVS_GPCR_hAdrb2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdrb2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRB2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Alprenolol HCl",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
632,369,NVS_GPCR_hAdrb3,1,1,"Data from the assay component NVS_GPCR_hAdrb3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAdrb3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ADRB3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Propranolol HCl",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
633,370,NVS_GPCR_hAT1,1,1,"Data from the assay component NVS_GPCR_hAT1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hAT1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AGTR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Angiotensin II",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
634,371,NVS_GPCR_hC5a,1,1,"Data from the assay component NVS_GPCR_hC5a was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hC5a, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene C5AR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"human rC5a",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
635,372,NVS_GPCR_hDRD1,1,1,"Data from the assay component NVS_GPCR_hDRD1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hDRD1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"R(+)-SCH 23390",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
636,373,NVS_GPCR_hDRD2s,1,1,"Data from the assay component NVS_GPCR_hDRD2s was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hDRD2s, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,Haloperidol,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
637,374,NVS_GPCR_hDRD4.4,1,1,"Data from the assay component NVS_GPCR_hDRD4.4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hDRD4.4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene DRD4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,Haloperidol,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
638,375,NVS_GPCR_hETA,1,1,"Data from the assay component NVS_GPCR_hETA was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hETA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene EDNRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,Endothelin-1,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
639,376,NVS_GPCR_hETB,1,1,"Data from the assay component NVS_GPCR_hETB was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hETB, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene EDNRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,Endothelin-1,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
640,377,NVS_GPCR_hH1,1,1,"Data from the assay component NVS_GPCR_hH1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hH1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HRH1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,Tripolidine,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
641,378,NVS_GPCR_hLTB4_BLT1,1,1,"Data from the assay component NVS_GPCR_hLTB4_BLT1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hLTB4_BLT1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene LTB4R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Leukotriene B4 (LTB4)",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
642,379,NVS_GPCR_hM1,1,1,"Data from the assay component NVS_GPCR_hM1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Methylscopolamine bromide",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
643,380,NVS_GPCR_hM2,1,1,"Data from the assay component NVS_GPCR_hM2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Methylscopolamine bromide",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
644,381,NVS_GPCR_hM3,1,1,"Data from the assay component NVS_GPCR_hM3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Methylscopolamine bromide",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
645,382,NVS_GPCR_hM4,1,1,"Data from the assay component NVS_GPCR_hM4 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM4, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Methylscopolamine bromide",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
646,383,NVS_GPCR_hM5,1,1,"Data from the assay component NVS_GPCR_hM5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hM5, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRM5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Methylscopolamine bromide",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
647,384,NVS_GPCR_hNK2,1,1,"Data from the assay component NVS_GPCR_hNK2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNK2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene TACR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Neurokinin A",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
648,385,NVS_GPCR_hNPY1,1,1,"Data from the assay component NVS_GPCR_hNPY1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNPY1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NPY1R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"porcine neuropeptide Y",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
649,386,NVS_GPCR_hNPY2,1,1,"Data from the assay component NVS_GPCR_hNPY2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNPY2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NPY2R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"porcine neuropeptide Y",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
650,387,NVS_GPCR_hNTS,1,1,"Data from the assay component NVS_GPCR_hNTS was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hNTS, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NTSR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,neurotensin,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
651,388,NVS_GPCR_hOpiate_D1,1,1,"Data from the assay component NVS_GPCR_hOpiate_D1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hOpiate_D1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene OPRD1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Naltriben methanesulfonate",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
652,389,NVS_GPCR_hOpiate_mu,1,1,"Data from the assay component NVS_GPCR_hOpiate_mu was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hOpiate_mu, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene OPRM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Naloxone HCl",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
653,390,NVS_GPCR_hORL1,1,1,"Data from the assay component NVS_GPCR_hORL1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hORL1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene OPRL1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,Nociceptin,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
654,391,NVS_GPCR_hPY2,1,1,"Data from the assay component NVS_GPCR_hPY2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hPY2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene P2RY1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,ADPbS,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
655,392,NVS_GPCR_hTXA2,1,1,"Data from the assay component NVS_GPCR_hTXA2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hTXA2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene TBXA2R. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Pinane-thromboxane A2",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
656,393,NVS_GPCR_hV1A,1,1,"Data from the assay component NVS_GPCR_hV1A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_hV1A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AVPR1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"(Phenyl[1]ac, D-Tyr(Me)[2],Arg[6,8],Lys-NH2[9])-vasopressin;Arg8-Vasopressin (AVP)",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
657,394,NVS_GPCR_mCCKAPeripheral,1,1,"Data from the assay component NVS_GPCR_mCCKAPeripheral was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_mCCKAPeripheral, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cckar. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Cholecystokinin 8 (CCK-8) (26-33) sulfated",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
658,395,NVS_GPCR_mCKKBCentral,1,1,"Data from the assay component NVS_GPCR_mCKKBCentral was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_mCKKBCentral, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cckbr. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Cholecystokinin 8 (CCK-8) (26-33) sulfated",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
659,396,NVS_GPCR_p5HT2C,1,1,"Data from the assay component NVS_GPCR_p5HT2C was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_p5HT2C, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR2C. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Mianserin HCl",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
660,397,NVS_GPCR_r5HT_NonSelective,1,1,"Data from the assay component NVS_GPCR_r5HT_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_r5HT_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Htr1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Methysergide maleate",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
661,398,NVS_GPCR_r5HT1_NonSelective,1,1,"Data from the assay component NVS_GPCR_r5HT1_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_r5HT1_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Htr1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,Serotonin,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
662,399,NVS_GPCR_rabPAF,1,1,"Data from the assay component NVS_GPCR_rabPAF was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rabPAF, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PTAFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,C16-PAF,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
663,400,NVS_GPCR_rAdra1_NonSelective,1,1,"Data from the assay component NVS_GPCR_rAdra1_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdra1_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Phentolamine mesylate",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
664,401,NVS_GPCR_rAdra1A,1,1,"Data from the assay component NVS_GPCR_rAdra1A was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdra1A, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Phentolamine mesylate",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
665,402,NVS_GPCR_rAdra1B,1,1,"Data from the assay component NVS_GPCR_rAdra1B was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdra1B, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra1b. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Phentolamine mesylate",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
666,403,NVS_GPCR_rAdra2_NonSelective,1,1,"Data from the assay component NVS_GPCR_rAdra2_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdra2_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra2a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Phentolamine mesylate",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
667,404,NVS_GPCR_rAdrb_NonSelective,1,1,"Data from the assay component NVS_GPCR_rAdrb_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rAdrb_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adrb1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Alprenolol HCl",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
668,405,NVS_GPCR_rCRF,1,1,"Data from the assay component NVS_GPCR_rCRF was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rCRF, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Crhr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'secretin receptor'.",binding,percent_activity,positive,0,Tyr0-oCRF,loss,protein,receptor,gpcr,"secretin receptor",0
669,406,NVS_GPCR_rGABBR,1,1,"Data from the assay component NVS_GPCR_rGABBR was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rGABBR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gabbr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'metabotropic glutamate receptor'.",binding,percent_activity,positive,0,(+/-)-Baclofen,loss,protein,receptor,gpcr,"metabotropic glutamate receptor",0
670,407,NVS_GPCR_rGalanin,1,1,"Data from the assay component NVS_GPCR_rGalanin was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rGalanin, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Galr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"porcine Galanin",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
671,408,NVS_GPCR_rGHB,1,1,"Data from the assay component NVS_GPCR_rGHB was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rGHB, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tspan17. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'metabotropic glutamate receptor'.",binding,percent_activity,positive,0,NCS-382,loss,protein,receptor,gpcr,"metabotropic glutamate receptor",0
672,409,NVS_GPCR_rH3,1,1,"Data from the assay component NVS_GPCR_rH3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rH3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Hrh3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"N-a-methylhistamine (NAMH)",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
673,410,NVS_GPCR_rmAdra2B,1,1,"Data from the assay component NVS_GPCR_rmAdra2B was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rmAdra2B, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Adra2b. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Oxymetazoline HCl;Norepinephrine",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
674,411,NVS_GPCR_rmMGluR1,1,1,"Data from the assay component NVS_GPCR_rmMGluR1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rmMGluR1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grm1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'metabotropic glutamate receptor'.",binding,percent_activity,positive,0,L-Glutamate,loss,protein,receptor,gpcr,"metabotropic glutamate receptor",0
675,412,NVS_GPCR_rmMGluR5,1,1,"Data from the assay component NVS_GPCR_rmMGluR5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rmMGluR5, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grm5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'metabotropic glutamate receptor'.",binding,percent_activity,positive,0,MPEP,loss,protein,receptor,gpcr,"metabotropic glutamate receptor",0
676,413,NVS_GPCR_rNK1,1,1,"Data from the assay component NVS_GPCR_rNK1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rNK1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tacr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Substance P",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
677,414,NVS_GPCR_rNK3,1,1,"Data from the assay component NVS_GPCR_rNK3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rNK3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tacr3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,Eledoisin,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
678,415,NVS_GPCR_rNTS,1,1,"Data from the assay component NVS_GPCR_rNTS was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rNTS, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Ntsr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,Neurotensin,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
679,416,NVS_GPCR_rOpiate_NonSelective,1,1,"Data from the assay component NVS_GPCR_rOpiate_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rOpiate_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Oprm1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Naloxone HCl",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
680,417,NVS_GPCR_rOpiate_NonSelectiveNa,1,1,"Data from the assay component NVS_GPCR_rOpiate_NonSelectiveNa was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rOpiate_NonSelectiveNa, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Oprm1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"Naloxone HCl",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
681,418,NVS_GPCR_rOXT,1,1,"Data from the assay component NVS_GPCR_rOXT was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rOXT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Oxtr. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,Oxytocin,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
682,419,NVS_GPCR_rSST,1,1,"Data from the assay component NVS_GPCR_rSST was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rSST, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Sstr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,Somatostatin,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
683,420,NVS_GPCR_rTRH,1,1,"Data from the assay component NVS_GPCR_rTRH was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rTRH, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Trhr. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,TRH,loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
684,421,NVS_GPCR_rV1,1,1,"Data from the assay component NVS_GPCR_rV1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rV1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Avpr1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'rhodopsin-like receptor'.",binding,percent_activity,positive,0,"(Phenyl[1]ac, D-Tyr(Me)[2],Arg[6,8],Lys-NH2[9])-vasopressin;Arg8-Vasopressin (AVP)",loss,protein,receptor,gpcr,"rhodopsin-like receptor",0
685,422,NVS_GPCR_rVIP_NonSelective,1,1,"Data from the assay component NVS_GPCR_rVIP_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_GPCR_rVIP_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Vipr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'gpcr' intended target family, where the subfamily is 'secretin receptor'.",binding,percent_activity,positive,0,"Vasoactive intestinal peptide (VIP)",loss,protein,receptor,gpcr,"secretin receptor",0
686,423,NVS_IC_hKhERGCh,1,1,"Data from the assay component NVS_IC_hKhERGCh was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_hKhERGCh, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene KCNH2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'ion channel' intended target family, where the subfamily is 'potassium channel'.",binding,percent_activity,positive,0,Terfenadine,loss,protein,receptor,"ion channel","potassium channel",0
687,424,NVS_IC_rCaBTZCHL,1,1,"Data from the assay component NVS_IC_rCaBTZCHL was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rCaBTZCHL, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cacna1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'ion channel' intended target family, where the subfamily is 'calcium channel'.",binding,percent_activity,positive,0,"Diltiazem HCl",loss,protein,receptor,"ion channel","calcium channel",0
688,425,NVS_IC_rCaChN,1,1,"Data from the assay component NVS_IC_rCaChN was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rCaChN, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cacna1b. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'ion channel' intended target family, where the subfamily is 'calcium channel'.",binding,percent_activity,positive,0,"W-Conotoxin GVIA",loss,protein,receptor,"ion channel","calcium channel",0
689,426,NVS_IC_rCaDHPRCh_L,1,1,"Data from the assay component NVS_IC_rCaDHPRCh_L was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rCaDHPRCh_L, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Cacna1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'ion channel' intended target family, where the subfamily is 'calcium channel'.",binding,percent_activity,positive,0,Nifedipine,loss,protein,receptor,"ion channel","calcium channel",0
690,427,NVS_IC_rKAR,1,1,"Data from the assay component NVS_IC_rKAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rKAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grik1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'ion channel' intended target family, where the subfamily is 'ligand-gated ion channel'.",binding,percent_activity,positive,0,"Kainic acid",loss,protein,receptor,"ion channel","ligand-gated ion channel",0
691,428,NVS_IC_rKATPCh,1,1,"Data from the assay component NVS_IC_rKATPCh was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rKATPCh, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Kcnj1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'ion channel' intended target family, where the subfamily is 'potassium channel'.",binding,percent_activity,positive,0,Glibenclamide,loss,protein,receptor,"ion channel","potassium channel",0
692,429,NVS_IC_rKCaCh,1,1,"Data from the assay component NVS_IC_rKCaCh was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rKCaCh, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Kcnn1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'ion channel' intended target family, where the subfamily is 'potassium channel'.",binding,percent_activity,positive,0,Apamin,loss,protein,receptor,"ion channel","potassium channel",0
693,430,NVS_IC_rNaCh_site2,1,1,"Data from the assay component NVS_IC_rNaCh_site2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_IC_rNaCh_site2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Scn1a. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'ion channel' intended target family, where the subfamily is 'sodium channel'.",binding,percent_activity,positive,0,Aconitine,loss,protein,receptor,"ion channel","sodium channel",0
694,431,NVS_LGIC_bGABAR_Agonist,1,1,"Data from the assay component NVS_LGIC_bGABAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_bGABAR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene GABRA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'ion channel' intended target family, where the subfamily is 'ligand-gated ion channel'.",binding,percent_activity,positive,0,GABA,loss,protein,receptor,"ion channel","ligand-gated ion channel",0
695,432,NVS_LGIC_bGABARa1,1,1,"Data from the assay component NVS_LGIC_bGABARa1 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_bGABARa1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene GABRA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'ion channel' intended target family, where the subfamily is 'ligand-gated ion channel'.",binding,percent_activity,positive,0,"Ro 15-1788 (Flumazenil)",loss,protein,receptor,"ion channel","ligand-gated ion channel",0
696,433,NVS_LGIC_bGABARa5,1,1,"Data from the assay component NVS_LGIC_bGABARa5 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_bGABARa5, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene GABRA5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'ion channel' intended target family, where the subfamily is 'ligand-gated ion channel'.",binding,percent_activity,positive,0,"L-655,708",loss,protein,receptor,"ion channel","ligand-gated ion channel",0
697,434,NVS_LGIC_h5HT3,1,1,"Data from the assay component NVS_LGIC_h5HT3 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_h5HT3, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene HTR3A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'ion channel' intended target family, where the subfamily is 'ligand-gated ion channel'.",binding,percent_activity,positive,0,MDL-72222,loss,protein,receptor,"ion channel","ligand-gated ion channel",0
698,435,NVS_LGIC_hNNR_NBungSens,1,1,"Data from the assay component NVS_LGIC_hNNR_NBungSens was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_hNNR_NBungSens, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene CHRNA2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'ion channel' intended target family, where the subfamily is 'ligand-gated ion channel'.",binding,percent_activity,positive,0,(+/-)-Epibatidine,loss,protein,receptor,"ion channel","ligand-gated ion channel",0
699,436,NVS_LGIC_rAMPA,1,1,"Data from the assay component NVS_LGIC_rAMPA was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rAMPA, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gria1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'ion channel' intended target family, where the subfamily is 'ligand-gated ion channel'.",binding,percent_activity,positive,0,"(+/-)-AMPA HBr",loss,protein,receptor,"ion channel","ligand-gated ion channel",0
700,437,NVS_LGIC_rGABAR_NonSelective,1,1,"Data from the assay component NVS_LGIC_rGABAR_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGABAR_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gabra1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'ion channel' intended target family, where the subfamily is 'ligand-gated ion channel'.",binding,percent_activity,positive,0,GABA,loss,protein,receptor,"ion channel","ligand-gated ion channel",0
701,438,NVS_LGIC_rGABARa6,1,1,"Data from the assay component NVS_LGIC_rGABARa6 was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGABARa6, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Gabra6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'ion channel' intended target family, where the subfamily is 'ligand-gated ion channel'.",binding,percent_activity,positive,0,"L-655,708",loss,protein,receptor,"ion channel","ligand-gated ion channel",0
702,439,NVS_LGIC_rGluNMDA_Agonist,1,1,"Data from the assay component NVS_LGIC_rGluNMDA_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGluNMDA_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grin1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'ion channel' intended target family, where the subfamily is 'ligand-gated ion channel'.",binding,percent_activity,positive,0,"N-methyl-D-aspartate (NMDA)",loss,protein,receptor,"ion channel","ligand-gated ion channel",0
703,440,NVS_LGIC_rGluNMDA_MK801_Agonist,1,1,"Data from the assay component NVS_LGIC_rGluNMDA_MK801_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGluNMDA_MK801_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Grin1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'ion channel' intended target family, where the subfamily is 'ligand-gated ion channel'.",binding,percent_activity,positive,0,(+)-MK-801,loss,protein,receptor,"ion channel","ligand-gated ion channel",0
704,441,NVS_LGIC_rGlyRStrySens,1,1,"Data from the assay component NVS_LGIC_rGlyRStrySens was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rGlyRStrySens, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Glra1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'ion channel' intended target family, where the subfamily is 'ligand-gated ion channel'.",binding,percent_activity,positive,0,"Strychnine nitrate",loss,protein,receptor,"ion channel","ligand-gated ion channel",0
705,442,NVS_LGIC_rNNR_BungSens,1,1,"Data from the assay component NVS_LGIC_rNNR_BungSens was analyzed into 1 assay endpoint. This assay endpoint, NVS_LGIC_rNNR_BungSens, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Chrna7. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'ion channel' intended target family, where the subfamily is 'ligand-gated ion channel'.",binding,percent_activity,positive,0,Methyllycaconitine,loss,protein,receptor,"ion channel","ligand-gated ion channel",0
706,443,NVS_MP_hPBR,1,1,"Data from the assay component NVS_MP_hPBR was analyzed into 1 assay endpoint. This assay endpoint, NVS_MP_hPBR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene TSPO. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'transporter' intended target family, where the subfamily is 'cholesterol transporter'.",binding,percent_activity,positive,0,PK11195,loss,protein,transporter,transporter,"cholesterol transporter",0
707,444,NVS_MP_rPBR,1,1,"Data from the assay component NVS_MP_rPBR was analyzed into 1 assay endpoint. This assay endpoint, NVS_MP_rPBR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Tspo. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'transporter' intended target family, where the subfamily is 'cholesterol transporter'.",binding,percent_activity,positive,0,PK11195,loss,protein,transporter,transporter,"cholesterol transporter",0
708,445,NVS_NR_bER,1,1,"Data from the assay component NVS_NR_bER was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_bER, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.",binding,percent_activity,positive,0,17b-estradiol,loss,protein,receptor,"nuclear receptor",steroidal,0
709,446,NVS_NR_bPR,1,1,"Data from the assay component NVS_NR_bPR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_bPR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PGR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.",binding,percent_activity,positive,0,Promegestone,loss,protein,receptor,"nuclear receptor",steroidal,0
710,447,NVS_NR_cAR,1,1,"Data from the assay component NVS_NR_cAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_cAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.",binding,percent_activity,positive,0,Methyltrienolone,loss,protein,receptor,"nuclear receptor",steroidal,0
711,448,NVS_NR_hAR,1,1,"Data from the assay component NVS_NR_hAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.",binding,percent_activity,positive,0,Methyltrienolone,loss,protein,receptor,"nuclear receptor",steroidal,0
712,449,NVS_NR_hCAR_Agonist,1,1,"Data from the assay component NVS_NR_hCAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hCAR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1I3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.",binding,percent_activity,positive,0,CITCO,loss,protein,receptor,"nuclear receptor",non-steroidal,0
713,450,NVS_NR_hCAR_Antagonist,1,1,"Data from the assay component NVS_NR_hCAR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hCAR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1I3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.",binding,percent_activity,positive,0,Clotrimazole,loss,protein,receptor,"nuclear receptor",non-steroidal,0
714,451,NVS_NR_hER,1,1,"Data from the assay component NVS_NR_hER was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hER, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.",binding,percent_activity,positive,0,17b-estradiol,loss,protein,receptor,"nuclear receptor",steroidal,0
715,452,NVS_NR_hFXR_Agonist,1,1,"Data from the assay component NVS_NR_hFXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hFXR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.",binding,percent_activity,positive,0,CDCA,loss,protein,receptor,"nuclear receptor",non-steroidal,0
716,453,NVS_NR_hFXR_Antagonist,1,1,"Data from the assay component NVS_NR_hFXR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hFXR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.",binding,percent_activity,positive,0,Guggulsterone,loss,protein,receptor,"nuclear receptor",non-steroidal,0
717,454,NVS_NR_hGR,1,1,"Data from the assay component NVS_NR_hGR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hGR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR3C1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.",binding,percent_activity,positive,0,"Triamcinolone acetonide",loss,protein,receptor,"nuclear receptor",steroidal,0
718,455,NVS_NR_hPPARa,1,1,"Data from the assay component NVS_NR_hPPARa was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPPARa, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PPARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.",binding,percent_activity,positive,0,GW7647,loss,protein,receptor,"nuclear receptor",non-steroidal,0
719,456,NVS_NR_hPPARg,1,1,"Data from the assay component NVS_NR_hPPARg was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPPARg, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.",binding,percent_activity,positive,0,Ciglitazone,loss,protein,receptor,"nuclear receptor",non-steroidal,0
720,457,NVS_NR_hPR,1,1,"Data from the assay component NVS_NR_hPR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene PGR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.",binding,percent_activity,positive,0,Promegestone,loss,protein,receptor,"nuclear receptor",steroidal,0
721,458,NVS_NR_hPXR,1,1,"Data from the assay component NVS_NR_hPXR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hPXR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.",binding,percent_activity,positive,0,TO901317,loss,protein,receptor,"nuclear receptor",non-steroidal,0
722,459,NVS_NR_hRAR_Antagonist,1,1,"Data from the assay component NVS_NR_hRAR_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hRAR_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene RARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.",binding,percent_activity,positive,0,RO415253,loss,protein,receptor,"nuclear receptor",non-steroidal,0
723,460,NVS_NR_hRARa_Agonist,1,1,"Data from the assay component NVS_NR_hRARa_Agonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hRARa_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene RARA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.",binding,percent_activity,positive,0,TTNPB,loss,protein,receptor,"nuclear receptor",non-steroidal,0
724,461,NVS_NR_hTRa_Antagonist,1,1,"Data from the assay component NVS_NR_hTRa_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hTRa_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene THRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.",binding,percent_activity,positive,0,"Bisphenol A",loss,protein,receptor,"nuclear receptor",non-steroidal,0
725,462,NVS_NR_mERa,1,1,"Data from the assay component NVS_NR_mERa was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_mERa, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Esr1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.",binding,percent_activity,positive,0,17b-estradiol,loss,protein,receptor,"nuclear receptor",steroidal,0
726,463,NVS_NR_rAR,1,1,"Data from the assay component NVS_NR_rAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_rAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Ar. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.",binding,percent_activity,positive,0,Methyltrienolone,loss,protein,receptor,"nuclear receptor",steroidal,0
727,464,NVS_NR_rMR,1,1,"Data from the assay component NVS_NR_rMR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_rMR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Nr3c2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.",binding,percent_activity,positive,0,Spironolactone,loss,protein,receptor,"nuclear receptor",steroidal,0
728,465,NVS_OR_gSIGMA_NonSelective,1,1,"Data from the assay component NVS_OR_gSIGMA_NonSelective was analyzed into 1 assay endpoint. This assay endpoint, NVS_OR_gSIGMA_NonSelective, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Sigmar1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'misc protein' intended target family, where the subfamily is 'chaperone'.",binding,percent_activity,positive,0,Haloperidol,loss,protein,receptor,"misc protein",chaperone,0
729,466,NVS_OR_hFKBP12,1,1,"Data from the assay component NVS_OR_hFKBP12 was analyzed into 1 assay endpoint. This assay endpoint, NVS_OR_hFKBP12, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene FKBP1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'misc protein' intended target family, where the subfamily is 'chaperone'.",binding,percent_activity,positive,0,FK506,loss,protein,enzyme,"misc protein",chaperone,0
730,467,NVS_TR_gDAT,1,1,"Data from the assay component NVS_TR_gDAT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_gDAT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc6a3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'transporter' intended target family, where the subfamily is 'neurotransmitter transporter'.",binding,percent_activity,positive,0,GBR-12909,loss,protein,transporter,transporter,"neurotransmitter transporter",0
731,468,NVS_TR_hAdoT,1,1,"Data from the assay component NVS_TR_hAdoT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hAdoT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC29A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'transporter' intended target family, where the subfamily is 'nucleoside transporter'.",binding,percent_activity,positive,0,"Nitrobenzylthioinosine (NBTI)",loss,protein,transporter,transporter,"nucleoside transporter",0
732,469,NVS_TR_hDAT,1,1,"Data from the assay component NVS_TR_hDAT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hDAT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC6A3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'transporter' intended target family, where the subfamily is 'neurotransmitter transporter'.",binding,percent_activity,positive,0,GBR-12909,loss,protein,transporter,transporter,"neurotransmitter transporter",0
733,470,NVS_TR_hNET,1,1,"Data from the assay component NVS_TR_hNET was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hNET, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC6A2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'transporter' intended target family, where the subfamily is 'neurotransmitter transporter'.",binding,percent_activity,positive,0,Desipramine,loss,protein,transporter,transporter,"neurotransmitter transporter",0
734,471,NVS_TR_hSERT,1,1,"Data from the assay component NVS_TR_hSERT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hSERT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC6A4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'transporter' intended target family, where the subfamily is 'neurotransmitter transporter'.",binding,percent_activity,positive,0,"Imipramine HCl;Clomipramine HCl",loss,protein,transporter,transporter,"neurotransmitter transporter",0
735,472,NVS_TR_rAdoT,1,1,"Data from the assay component NVS_TR_rAdoT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rAdoT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc29a1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'transporter' intended target family, where the subfamily is 'nucleoside transporter'.",binding,percent_activity,positive,0,"Nitrobenzylthioinosine (NBTI)",loss,protein,transporter,transporter,"nucleoside transporter",0
736,473,NVS_TR_rNET,1,1,"Data from the assay component NVS_TR_rNET was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rNET, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc6a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'transporter' intended target family, where the subfamily is 'neurotransmitter transporter'.",binding,percent_activity,positive,0,Desipramine,loss,protein,transporter,transporter,"neurotransmitter transporter",0
737,474,NVS_TR_rSERT,1,1,"Data from the assay component NVS_TR_rSERT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rSERT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc6a4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'transporter' intended target family, where the subfamily is 'neurotransmitter transporter'.",binding,percent_activity,positive,0,"Imipramine HCl",loss,protein,transporter,transporter,"neurotransmitter transporter",0
738,475,NVS_TR_rVMAT2,1,1,"Data from the assay component NVS_TR_rVMAT2 was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_rVMAT2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc18a2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'transporter' intended target family, where the subfamily is 'vesicular transporter'.",binding,percent_activity,positive,0,Reserpine,loss,protein,transporter,transporter,"vesicular transporter",0
739,476,OT_AR_ARELUC_AG_1440,1,1,"Data from the assay component OT_AR_ARELUC_AG_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARELUC_AG_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.","reporter gene",percent_activity,positive,0,6-alpha-Fluorotestosterone,gain,pathway,pathway-specified,"nuclear receptor",steroidal,0
740,477,OT_AR_ARSRC1_0480,1,1,"Data from the assay component OT_AR_ARSRC1_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.",binding,percent_activity,positive,0,"4,5-alpha-Dihydrotestosterone",gain,pathway,pathway-specified,"nuclear receptor",steroidal,0
741,478,OT_AR_ARSRC1_0960,1,1,"Data from the assay component OT_AR_ARSRC1_0960 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARSRC1_0960, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.",binding,percent_activity,positive,0,"4,5-alpha-Dihydrotestosterone",gain,pathway,pathway-specified,"nuclear receptor",steroidal,0
742,479,OT_ER_ERaERa_0480,1,1,"Data from the assay component OT_ER_ERaERa_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERa_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.",binding,percent_activity,positive,0,17b-Estradiol,gain,pathway,pathway-specified,"nuclear receptor",steroidal,0
743,480,OT_ER_ERaERa_1440,1,1,"Data from the assay component OT_ER_ERaERa_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERa_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.",binding,percent_activity,positive,0,17b-Estradiol,gain,pathway,pathway-specified,"nuclear receptor",steroidal,0
744,481,OT_ER_ERaERb_0480,1,1,"Data from the assay component OT_ER_ERaERb_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERb_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.",binding,percent_activity,positive,0,17b-Estradiol,gain,pathway,pathway-specified,"nuclear receptor",steroidal,0
745,482,OT_ER_ERaERb_1440,1,1,"Data from the assay component OT_ER_ERaERb_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERb_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.",binding,percent_activity,positive,0,17b-Estradiol,gain,pathway,pathway-specified,"nuclear receptor",steroidal,0
746,483,OT_ER_ERbERb_0480,1,1,"Data from the assay component OT_ER_ERbERb_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERbERb_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.",binding,percent_activity,positive,0,17b-Estradiol,gain,pathway,pathway-specified,"nuclear receptor",steroidal,0
747,484,OT_ER_ERbERb_1440,1,1,"Data from the assay component OT_ER_ERbERb_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERbERb_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.",binding,percent_activity,positive,0,17b-Estradiol,gain,pathway,pathway-specified,"nuclear receptor",steroidal,0
750,487,OT_ERa_EREGFP_0120,1,1,"Data from the assay component OT_ERa_GFPERaERE_0120 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ERa_EREGFP_0120, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.","reporter gene",percent_activity,positive,0,(Z)-4-Hydroxytamoxifen,gain,pathway,pathway-specified,"nuclear receptor",steroidal,0
751,488,OT_ERa_EREGFP_0480,1,1,"Data from the assay component OT_ERa_GFPERaERE_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ERa_EREGFP_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.","reporter gene",percent_activity,positive,0,(Z)-4-Hydroxytamoxifen,gain,pathway,pathway-specified,"nuclear receptor",steroidal,0
753,490,OT_FXR_FXRSRC1_0480,1,1,"Data from the assay component OT_FXR_FXRSRC1_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_FXR_FXRSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.",binding,percent_activity,positive,0,GW4064,gain,pathway,pathway-specified,"nuclear receptor",non-steroidal,0
754,491,OT_FXR_FXRSRC1_1440,1,1,"Data from the assay component OT_FXR_FXRSRC1_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_FXR_FXRSRC1_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.",binding,percent_activity,positive,0,GW4064,gain,pathway,pathway-specified,"nuclear receptor",non-steroidal,0
755,492,OT_NURR1_NURR1RXRa_0480,1,1,"Data from the assay component OT_NURR1_NURR1RXRa_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_NURR1_NURR1RXRa_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene RXRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.",binding,percent_activity,positive,0,Isoproterenol;Fenoterol,gain,pathway,pathway-specified,"nuclear receptor",non-steroidal,0
756,493,OT_NURR1_NURR1RXRa_1440,1,1,"Data from the assay component OT_NURR1_NURR1RXRa_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_NURR1_NURR1RXRa_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene RXRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.",binding,percent_activity,positive,0,Isoproterenol;Fenoterol,gain,pathway,pathway-specified,"nuclear receptor",non-steroidal,0
757,494,OT_PPARg_PPARgSRC1_0480,1,1,"Data from the assay component OT_PPARg_PPARgSRC1_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_PPARg_PPARgSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.",binding,percent_activity,positive,0,GW1929,gain,pathway,pathway-specified,"nuclear receptor",non-steroidal,0
758,495,OT_PPARg_PPARgSRC1_1440,1,1,"Data from the assay component OT_PPARg_PPARgSRC1_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_PPARg_PPARgSRC1_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.",binding,percent_activity,positive,0,GW1929,gain,pathway,pathway-specified,"nuclear receptor",non-steroidal,0
759,496,TOX21_AR_BLA_Agonist_ch1,1,1,Tox21_AR_BLA_Agonist_ch1,"background control",percent_activity,positive,0,R1881,loss,pathway,pathway-specified,"background measurement","baseline control",0
760,497,TOX21_AR_BLA_Agonist_ch2,1,1,Tox21_AR_BLA_Agonist_ch2,"reporter gene",percent_activity,positive,0,R1881,gain,pathway,pathway-specified,"background measurement","baseline control",0
761,498,TOX21_AR_BLA_Agonist_ratio,1,1,"Data from the assay component Tox21_AR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, Tox21_AR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.","reporter gene",percent_activity,positive,0,R1881,gain,protein,receptor,"nuclear receptor",steroidal,0
762,499,TOX21_AR_BLA_Antagonist_ratio,1,1,"Data from the assay component Tox21_AR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, Tox21_AR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.","reporter gene",percent_activity,positive,0,"Cyproterone acetate",loss,protein,receptor,"nuclear receptor",steroidal,0
763,500,TOX21_AR_BLA_Antagonist_viability,1,1,"Data from the assay component Tox21_AR_BLA_Antagonist_viability was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_AR_BLA_Antagonist_viability, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of ATP for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,1,"Cyproterone acetate",loss,cellular,cellular,"cell cycle",cytotoxicity,0
764,501,TOX21_AR_LUC_MDAKB2_Agonist,1,1,"Data from the assay component Tox21_AR_LUC_MDAKB2_Agonist was analyzed into 1 assay endpoint. This assay endpoint, Tox21_AR_LUC_MDAKB2_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.","reporter gene",percent_activity,positive,0,R1881,gain,protein,receptor,"nuclear receptor",steroidal,0
765,502,TOX21_AR_LUC_MDAKB2_Antagonist,1,1,"Data from the assay component Tox21_AR_LUC_MDAKB2_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, Tox21_AR_LUC_MDAKB2_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.","reporter gene",percent_activity,positive,0,Nilutamide,loss,protein,receptor,"nuclear receptor",steroidal,0
767,504,TOX21_Aromatase_Inhibition,1,1,"Data from the assay component Tox21_Aromatase_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, Tox21_Aromatase_Inhibition, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP19A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'steroidogenesis-related'.","reporter gene",percent_activity,positive,0,Letrozole,loss,protein,enzyme,cyp,steroidogenesis-related,0
769,506,TOX21_AutoFluor_HEK293_Cell_blue,1,1,"Data from the assay component Tox21_AutoFluor_HEK293_Cell_blue was analyzed into 1 assay endpoint. This assay endpoint, Tox21_AutoFluor_HEK293_Cell_blue, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'artifact fluorescence'.","background control",percent_activity,positive,0,"Fluorescein;Rose Bengal Sodium;Triamterene",gain,chemical,"physical feature","background measurement","artifact fluorescence",0
770,507,TOX21_AutoFluor_HEK293_Cell_green,1,1,"Data from the assay component Tox21_AutoFluor_HEK293_Cell_green was analyzed into 1 assay endpoint. This assay endpoint, Tox21_AutoFluor_HEK293_Cell_green, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'artifact fluorescence'.","background control",percent_activity,positive,0,"Fluorescein;Rose Bengal Sodium;Triamterene",gain,chemical,"physical feature","background measurement","artifact fluorescence",0
771,508,TOX21_AutoFluor_HEK293_Cell_red,1,1,"Data from the assay component Tox21_AutoFluor_HEK293_Cell_red was analyzed into 1 assay endpoint. This assay endpoint, Tox21_AutoFluor_HEK293_Cell_red, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'artifact fluorescence'.","background control",percent_activity,positive,0,"Fluorescein;Rose Bengal Sodium;Triamterene",gain,chemical,"physical feature","background measurement","artifact fluorescence",0
772,509,TOX21_AutoFluor_HEK293_Media_blue,1,1,"Data from the assay component Tox21_AutoFluor_HEK293_Media_blue was analyzed into 1 assay endpoint. This assay endpoint, Tox21_AutoFluor_HEK293_Media_blue, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'artifact fluorescence'.","background control",percent_activity,positive,0,"Fluorescein;Rose Bengal Sodium;Triamterene",gain,chemical,"physical feature","background measurement","artifact fluorescence",0
773,510,TOX21_AutoFluor_HEK293_Media_green,1,1,"Data from the assay component Tox21_AutoFluor_HEK293_Media_green was analyzed into 1 assay endpoint. This assay endpoint, Tox21_AutoFluor_HEK293_Media_green, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'artifact fluorescence'.","background control",percent_activity,positive,0,"Fluorescein;Rose Bengal Sodium;Triamterene",gain,chemical,"physical feature","background measurement","artifact fluorescence",0
774,511,TOX21_AutoFluor_HEK293_Media_red,1,1,"Data from the assay component Tox21_AutoFluor_HEK293_Media_red was analyzed into 1 assay endpoint. This assay endpoint, Tox21_AutoFluor_HEK293_Media_red, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'artifact fluorescence'.","background control",percent_activity,positive,0,"Fluorescein;Rose Bengal Sodium;Triamterene",gain,chemical,"physical feature","background measurement","artifact fluorescence",0
775,512,TOX21_AutoFluor_HEPG2_Cell_blue,1,1,"Data from the assay component Tox21_AutoFluor_HEPG2_Cell_blue was analyzed into 1 assay endpoint. This assay endpoint, Tox21_AutoFluor_HEPG2_Cell_blue, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'artifact fluorescence'.","background control",percent_activity,positive,0,"Fluorescein;Rose Bengal Sodium;Triamterene",gain,chemical,"physical feature","background measurement","artifact fluorescence",0
776,513,TOX21_AutoFluor_HEPG2_Cell_green,1,1,"Data from the assay component Tox21_AutoFluor_HEPG2_Cell_green was analyzed into 1 assay endpoint. This assay endpoint, Tox21_AutoFluor_HEPG2_Cell_green, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'artifact fluorescence'.","background control",percent_activity,positive,0,"Fluorescein;Rose Bengal Sodium;Triamterene",gain,chemical,"physical feature","background measurement","artifact fluorescence",0
777,514,TOX21_AutoFluor_HEPG2_Cell_red,1,1,"Data from the assay component Tox21_AutoFluor_HEPG2_Cell_red was analyzed into 1 assay endpoint. This assay endpoint, Tox21_AutoFluor_HEPG2_Cell_red, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'artifact fluorescence'.","background control",percent_activity,positive,0,"Fluorescein;Rose Bengal Sodium;Triamterene",gain,chemical,"physical feature","background measurement","artifact fluorescence",0
778,515,TOX21_AutoFluor_HEPG2_Media_blue,1,1,"Data from the assay component Tox21_AutoFluor_HEPG2_Media_blue was analyzed into 1 assay endpoint. This assay endpoint, Tox21_AutoFluor_HEPG2_Media_blue, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'artifact fluorescence'.","background control",percent_activity,positive,0,"Fluorescein;Rose Bengal Sodium;Triamterene",gain,chemical,"physical feature","background measurement","artifact fluorescence",0
779,516,TOX21_AutoFluor_HEPG2_Media_green,1,1,"Data from the assay component Tox21_AutoFluor_HEPG2_Media_green was analyzed into 1 assay endpoint. This assay endpoint, Tox21_AutoFluor_HEPG2_Media_green, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'artifact fluorescence'.","background control",percent_activity,positive,0,"Fluorescein;Rose Bengal Sodium;Triamterene",gain,chemical,"physical feature","background measurement","artifact fluorescence",0
780,517,TOX21_AutoFluor_HEPG2_Media_red,1,1,"Data from the assay component Tox21_AutoFluor_HEPG2_Media_red was analyzed into 1 assay endpoint. This assay endpoint, Tox21_AutoFluor_HEPG2_Media_red, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of background reporter, gain-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'background measurement' intended target family, where the subfamily is 'artifact fluorescence'.","background control",percent_activity,positive,0,"Fluorescein;Rose Bengal Sodium;Triamterene",gain,chemical,"physical feature","background measurement","artifact fluorescence",0
781,518,TOX21_ELG1_LUC_Agonist,1,1,"Data from the assay component Tox21_ELG1_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, Tox21_ELG1_LUC_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ATAD5. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'hydrolase' intended target family, where the subfamily is 'atpase'.","reporter gene",percent_activity,positive,0,5-Fluorouridine,gain,protein,enzyme,hydrolase,atpase,0
783,520,TOX21_ERa_BLA_Agonist_ch1,1,1,Tox21_ERa_BLA_Agonist_ch1,"background control",percent_activity,positive,0,17b-estradiol,loss,pathway,pathway-specified,"background measurement","baseline control",0
784,521,TOX21_ERa_BLA_Agonist_ch2,1,1,Tox21_ERa_BLA_Agonist_ch2,"reporter gene",percent_activity,positive,0,17b-estradiol,gain,pathway,pathway-specified,"background measurement","baseline control",0
785,522,TOX21_ERa_BLA_Agonist_ratio,1,1,"Data from the assay component Tox21_ERa_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, Tox21_ERa_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.","reporter gene",percent_activity,positive,0,17b-estradiol,gain,protein,receptor,"nuclear receptor",steroidal,0
786,523,TOX21_ERa_BLA_Antagonist_ratio,1,1,"Data from the assay component Tox21_ERa_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, Tox21_ERa_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.","reporter gene",percent_activity,positive,0,4-hydroxytamoxifen,loss,protein,receptor,"nuclear receptor",steroidal,0
787,524,TOX21_ERa_BLA_Antagonist_viability,1,1,"Data from the assay component Tox21_ERa_BLA_Antagonist_viability was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_ERa_BLA_Antagonist_viability, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of ATP for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,1,"tetraoctylammonium bromide",loss,cellular,cellular,"cell cycle",cytotoxicity,0
788,525,TOX21_ERa_LUC_BG1_Agonist,1,1,"Data from the assay component Tox21_ERa_LUC_BG1_Agonist was analyzed into 1 assay endpoint. This assay endpoint, Tox21_ERa_LUC_BG1_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.","reporter gene",percent_activity,positive,0,17b-estradiol,gain,protein,receptor,"nuclear receptor",steroidal,0
789,526,TOX21_ERa_LUC_BG1_Antagonist,1,1,"Data from the assay component Tox21_ERa_LUC_BG1_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, Tox21_ERa_LUC_BG1_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.","reporter gene",percent_activity,positive,0,4-hydroxytamoxifen,loss,protein,receptor,"nuclear receptor",steroidal,0
791,528,TOX21_GR_BLA_Agonist_ch1,1,1,Tox21_GR_BLA_Agonist_ch1,"background control",percent_activity,positive,0,Dexamethasone,loss,pathway,pathway-specified,"background measurement","baseline control",0
792,529,TOX21_GR_BLA_Agonist_ch2,1,1,Tox21_GR_BLA_Agonist_ch2,"reporter gene",percent_activity,positive,0,Dexamethasone,gain,pathway,pathway-specified,"background measurement","baseline control",0
793,530,TOX21_GR_BLA_Agonist_ratio,1,1,"Data from the assay component Tox21_GR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, Tox21_GR_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.","reporter gene",percent_activity,positive,0,Dexamethasone,gain,protein,receptor,"nuclear receptor",steroidal,0
794,531,TOX21_GR_BLA_Antagonist_ratio,1,1,"Data from the assay component Tox21_GR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, Tox21_GR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'steroidal'.","reporter gene",percent_activity,positive,0,Mifeprostone,loss,protein,receptor,"nuclear receptor",steroidal,0
795,532,TOX21_GR_BLA_Antagonist_viability,1,1,"Data from the assay component Tox21_GR_BLA_Antagonist_viability was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_GR_BLA_Antagonist_viability, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of ATP for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,1,"tetraoctylammonium bromide",loss,cellular,cellular,"cell cycle",cytotoxicity,0
797,534,TOX21_MMP_ratio_down,1,1,"Data from the assay component Tox21_MMP_ratio was analyzed into 2 assay endpoints. This assay endpoint, Tox21_MMP_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of 6 membrane potential reporter, gain-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'organelle conformation'.",signaling,percent_activity,positive,0,FCCP,loss,cellular,mitochondria,"cell morphology","organelle conformation",0
799,536,TOX21_MMP_viability,1,1,"Data from the assay component Tox21_MMP_viability was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_MitochondrialToxicity_viability, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of ATP for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,1,"tetraoctylammonium bromide",loss,cellular,cellular,"cell cycle",cytotoxicity,0
800,537,TOX21_PPARg_BLA_Agonist_ch1,1,1,Tox21_PPARg_BLA_Agonist_ch1,"background control",percent_activity,positive,0,Rosiglitazone,loss,protein,receptor,"background measurement","baseline control",0
801,538,TOX21_PPARg_BLA_Agonist_ch2,1,1,Tox21_PPARg_BLA_Agonist_ch2,"reporter gene",percent_activity,positive,0,Rosiglitazone,gain,pathway,pathway-specified,"background measurement","baseline control",0
802,539,TOX21_PPARg_BLA_Agonist_ratio,1,1,"Data from the assay component Tox21_PPARg_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, Tox21_PPARg_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",percent_activity,positive,0,Rosiglitazone,gain,protein,receptor,"nuclear receptor",non-steroidal,0
803,540,TOX21_TR_LUC_GH3_Agonist,1,1,"Data from the assay component Tox21_TR_LUC_GH3_Agonist was analyzed into 1 assay endpoint. This assay endpoint, Tox21_TR_LUC_GH3_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",percent_activity,positive,0,"20mM T3",gain,protein,receptor,"nuclear receptor",non-steroidal,0
804,541,TOX21_TR_LUC_GH3_Antagonist,1,1,"Data from the assay component Tox21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, Tox21_TR_LUC_GH3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",percent_activity,positive,0,"0.001mM T3",loss,protein,receptor,"nuclear receptor",non-steroidal,0
806,543,TOX21_AhR_LUC_Agonist,1,1,"Data from the assay component Tox21_AhR_LUC_Agonist was analyzed into 1 assay endpoint. This assay endpoint, Tox21_AhR_LUC_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AHR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'basic helix-loop-helix protein'.","reporter gene",percent_activity,positive,0,Omeprazole,gain,protein,receptor,"dna binding","basic helix-loop-helix protein",0
890,586,CEETOX_H295R_11DCORT_dn,1,1,NULL,"enzymatic activity",log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,chemical,11-Deoxycortisol,"steroid hormone",glucocorticoids,0
891,586,CEETOX_H295R_11DCORT_up,1,1,NULL,"enzymatic activity",log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,chemical,11-Deoxycortisol,"steroid hormone",glucocorticoids,0
892,587,CEETOX_H295R_OHPREG_dn,1,1,NULL,"enzymatic activity",log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,chemical,17alpha-hydroxypregnenolone,"steroid hormone",progestagens,0
893,587,CEETOX_H295R_OHPREG_up,1,1,NULL,"enzymatic activity",log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,chemical,17alpha-hydroxypregnenolone,"steroid hormone",progestagens,0
894,588,CEETOX_H295R_OHPROG_dn,1,1,NULL,"enzymatic activity",log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,chemical,17alpha-hydroxyprogesterone,"steroid hormone",progestagens,0
895,588,CEETOX_H295R_OHPROG_up,1,1,NULL,"enzymatic activity",log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,chemical,17alpha-hydroxyprogesterone,"steroid hormone",progestagens,0
896,589,CEETOX_H295R_ANDR_dn,1,1,NULL,"enzymatic activity",log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,chemical,Androstenedione,"steroid hormone",androgens,0
897,589,CEETOX_H295R_ANDR_up,1,1,NULL,"enzymatic activity",log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,chemical,Androstenedione,"steroid hormone",androgens,0
900,591,CEETOX_H295R_CORTISOL_dn,1,1,NULL,"enzymatic activity",log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,chemical,Cortisol,"steroid hormone",glucocorticoids,0
901,591,CEETOX_H295R_CORTISOL_up,1,1,NULL,"enzymatic activity",log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,chemical,Cortisol,"steroid hormone",glucocorticoids,0
904,593,CEETOX_H295R_DOC_dn,1,1,NULL,"enzymatic activity",log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,chemical,11-Deoxycorticosterone,"steroid hormone",glucocorticoids,0
905,593,CEETOX_H295R_DOC_up,1,1,NULL,"enzymatic activity",log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,chemical,11-Deoxycorticosterone,"steroid hormone",glucocorticoids,0
906,594,CEETOX_H295R_ESTRADIOL_dn,1,1,NULL,"enzymatic activity",log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,chemical,Estradiol,"steroid hormone",estrogens,0
907,594,CEETOX_H295R_ESTRADIOL_up,1,1,NULL,"enzymatic activity",log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,chemical,Estradiol,"steroid hormone",estrogens,0
908,595,CEETOX_H295R_ESTRONE_dn,1,1,NULL,"enzymatic activity",log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,chemical,Estrone,"steroid hormone",estrogens,0
909,595,CEETOX_H295R_ESTRONE_up,1,1,NULL,"enzymatic activity",log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,chemical,Estrone,"steroid hormone",estrogens,0
912,597,CEETOX_H295R_PROG_dn,1,1,NULL,"enzymatic activity",log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,chemical,Progesterone,"steroid hormone",progestagens,0
913,597,CEETOX_H295R_PROG_up,1,1,NULL,"enzymatic activity",log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,chemical,Progesterone,"steroid hormone",progestagens,0
914,598,CEETOX_H295R_TESTO_dn,1,1,NULL,"enzymatic activity",log2_fold_induction,negative,0,Prochloraz;Forskolin,loss,chemical,Testosterone,"steroid hormone",androgens,0
915,598,CEETOX_H295R_TESTO_up,1,1,NULL,"enzymatic activity",log2_fold_induction,positive,0,Prochloraz;Forskolin,gain,chemical,Testosterone,"steroid hormone",androgens,0
1108,695,TOX21_ARE_BLA_Agonist_ch1,1,1,NULL,"background control",percent_activity,positive,0,Beta-Naphthoflavone,loss,pathway,pathway-specified,"background measurement","baseline control",0
1109,696,TOX21_ARE_BLA_Agonist_ch2,1,1,NULL,"background control",percent_activity,positive,0,Beta-Naphthoflavone,gain,pathway,pathway-specified,"background measurement","baseline control",0
1110,697,TOX21_ARE_BLA_agonist_ratio,1,1,"Data from the assay component Tox21_ARE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_ARE_BLA_agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NFE2L2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'basic leucine zipper'.","reporter gene",percent_activity,positive,0,Beta-Naphthoflavone,gain,pathway,pathway-specified,"dna binding","basic leucine zipper",0
1111,698,TOX21_HSE_BLA_agonist_ch1,1,1,NULL,"background control",percent_activity,positive,0,17-AAG,loss,pathway,pathway-specified,"background measurement","baseline control",0
1112,699,TOX21_HSE_BLA_agonist_ch2,1,1,NULL,"background control",percent_activity,positive,0,17-AAG,gain,pathway,pathway-specified,"background measurement","baseline control",0
1113,700,TOX21_HSE_BLA_agonist_ratio,1,1,"Data from the assay component Tox21_HSE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_HSE_BLA_agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene HSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'heat shock protein'.","reporter gene",percent_activity,positive,0,17-AAG,gain,pathway,pathway-specified,"dna binding","heat shock protein",0
1114,701,TOX21_p53_BLA_p1_ch1,1,1,NULL,"background control",percent_activity,positive,0,"Mitomycin C;Nutlin3",loss,pathway,pathway-specified,"background measurement","baseline control",0
1115,702,TOX21_p53_BLA_p1_ch2,1,1,NULL,"background control",percent_activity,positive,0,"Mitomycin C;Nutlin3",gain,pathway,pathway-specified,"background measurement","baseline control",0
1116,703,TOX21_p53_BLA_p1_ratio,1,1,"Data from the assay component Tox21_p53_BLA_p1_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_p53_BLA_p1_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'tumor suppressor'.","reporter gene",percent_activity,positive,0,"Mitomycin C;Nutlin3",gain,pathway,pathway-specified,"dna binding","tumor suppressor",0
1117,704,TOX21_FXR_BLA_agonist_ch1,1,1,NULL,"background control",percent_activity,positive,0,"Chenodeoxycholic acid",loss,pathway,pathway-specified,"background measurement","baseline control",0
1118,705,TOX21_FXR_BLA_agonist_ch2,1,1,NULL,"background control",percent_activity,positive,0,"Chenodeoxycholic acid",gain,pathway,pathway-specified,"background measurement","baseline control",0
1119,706,TOX21_FXR_BLA_agonist_ratio,1,1,"Data from the assay component Tox21_FXR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_FXR_BLA_agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",percent_activity,positive,0,"Chenodeoxycholic acid",gain,pathway,pathway-specified,"nuclear receptor",non-steroidal,0
1120,707,TOX21_FXR_BLA_antagonist_ratio,1,1,"Data from the assay component Tox21_FXR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_FXR_BLA_antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",percent_activity,positive,0,Guggulsterone,gain,pathway,pathway-specified,"nuclear receptor",non-steroidal,0
1121,708,TOX21_FXR_BLA_antagonist_viability,1,1,"Data from the assay component Tox21_FXR_BLA_Antagonist_viability was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_FXR_BLA_antagonist_viability, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of ATP for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,1,"tetraoctylammonium bromide",loss,cellular,cellular,"cell cycle",cytotoxicity,0
1122,709,TOX21_PPARd_BLA_agonist_ch1,1,1,NULL,"background control",percent_activity,positive,0,"L-165,041",loss,pathway,pathway-specified,"background measurement","baseline control",0
1123,710,TOX21_PPARd_BLA_agonist_ch2,1,1,NULL,"background control",percent_activity,positive,0,"L-165,041",gain,pathway,pathway-specified,"background measurement","baseline control",0
1124,711,TOX21_PPARd_BLA_agonist_ratio,1,1,"Data from the assay component Tox21_PPARd_BLA_Agonist_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_PPARd_BLA_agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene PPARD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",percent_activity,positive,0,"L-165,041",gain,pathway,pathway-specified,"nuclear receptor",non-steroidal,0
1125,712,TOX21_PPARd_BLA_antagonist_ratio,1,1,"Data from the assay component Tox21_PPARd_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_PPARd_BLA_antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene PPARD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",percent_activity,positive,0,MK886,gain,pathway,pathway-specified,"nuclear receptor",non-steroidal,0
1126,713,TOX21_PPARd_BLA_antagonist_viability,1,1,"Data from the assay component Tox21_PPARd_BLA_Antagonist_viability was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_PPARd_BLA_antagonist_viability, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of ATP for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,0,"tetraoctylammonium bromide",loss,cellular,cellular,"cell cycle",cytotoxicity,0
1127,714,TOX21_PPARg_BLA_antagonist_ratio,1,1,"Data from the assay component Tox21_PPARg_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_PPARg_BLA_antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene PPARG. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'nuclear receptor' intended target family, where the subfamily is 'non-steroidal'.","reporter gene",percent_activity,positive,0,GW9662,gain,pathway,pathway-specified,"nuclear receptor",non-steroidal,0
1128,715,TOX21_PPARg_BLA_antagonist_viability,1,1,"Data from the assay component Tox21_PPARg_BLA_Antagonist_viability was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_PPARg_BLA_antagonist_viability, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of ATP for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,1,"tetraoctylammonium bromide",loss,cellular,cellular,"cell cycle",cytotoxicity,0
1129,716,TOX21_VDR_BLA_agonist_ch1,1,1,NULL,"background control",percent_activity,positive,0,Calcitriol,loss,pathway,pathway-specified,"background measurement","baseline control",0
1130,717,TOX21_VDR_BLA_agonist_ch2,1,1,NULL,"background control",percent_activity,positive,0,Calcitriol,gain,pathway,pathway-specified,"background measurement","baseline control",0
1131,718,TOX21_VDR_BLA_agonist_ratio,1,1,"Data from the assay component Tox21_VDR_BLA_Agonist_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_VDR_BLA_agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene CYP24A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","reporter gene",percent_activity,positive,0,Calcitriol,gain,pathway,pathway-specified,cyp,"xenobiotic metabolism",0
1132,719,TOX21_VDR_BLA_antagonist_ratio,1,1,"Data from the assay component Tox21_VDR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_VDR_BLA_antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene CYP24A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cyp' intended target family, where the subfamily is 'xenobiotic metabolism'.","reporter gene",percent_activity,positive,0,NA,gain,pathway,pathway-specified,cyp,"xenobiotic metabolism",0
1133,720,TOX21_VDR_BLA_antagonist_viability,1,1,"Data from the assay component Tox21_VDR_BLA_Antagonist_viability was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_VDR_BLA_antagonist_viability, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of ATP for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,1,"tetraoctylammonium bromide",loss,cellular,cellular,"cell cycle",cytotoxicity,0
1137,723,APR_Hepat_Apoptosis_1hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,cellular,cellular,"cell cycle",proliferation,0
1138,723,APR_Hepat_Apoptosis_1hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,pathway,pathway-specified,"cell cycle",apoptosis,0
1139,724,APR_Hepat_CellLoss_1hr_dn,1,1,NULL,viability,log2_fold_induction,negative,0,NA,loss,cellular,cellular,"cell cycle",cytotoxicity,0
1140,724,APR_Hepat_CellLoss_1hr_up,1,1,NULL,viability,log2_fold_induction,positive,0,NA,gain,cellular,cellular,"cell cycle",proliferation,0
1141,725,APR_Hepat_DNADamage_1hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,cellular,cellular,"cell morphology","dna conformation",0
1142,725,APR_Hepat_DNADamage_1hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,cellular,cellular,"cell morphology","dna conformation",0
1143,726,APR_Hepat_DNATexture_1hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,dna,dna-unspecified,"cell morphology","dna conformation",0
1144,726,APR_Hepat_DNATexture_1hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,dna,dna-unspecified,"cell morphology","dna conformation",0
1145,727,APR_Hepat_LysosomalMass_1hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,cellular,lysosome,"cell morphology","organelle conformation",0
1146,727,APR_Hepat_LysosomalMass_1hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,cellular,lysosome,"cell morphology","organelle conformation",0
1147,728,APR_Hepat_MitoFxnI_1hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,cellular,mitochondria,"cell morphology","organelle conformation",0
1148,728,APR_Hepat_MitoFxnI_1hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,cellular,mitochondria,"cell morphology","organelle conformation",0
1149,729,APR_Hepat_NuclearSize_1hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,cellular,nucleus,"cell morphology","organelle conformation",0
1150,729,APR_Hepat_NuclearSize_1hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,cellular,nucleus,"cell morphology","organelle conformation",0
1151,730,APR_Hepat_Steatosis_1hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,pathway,pathway-specified,"cell morphology","cell conformation",0
1152,730,APR_Hepat_Steatosis_1hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,pathway,pathway-specified,"cell morphology","cell conformation",0
1153,731,APR_Hepat_Apoptosis_24hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,pathway,pathway-specified,"cell cycle",proliferation,0
1154,731,APR_Hepat_Apoptosis_24hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,pathway,pathway-specified,"cell morphology","cell conformation",0
1155,732,APR_Hepat_CellLoss_24hr_dn,1,1,NULL,viability,log2_fold_induction,negative,0,NA,loss,cellular,cellular,"cell cycle",cytotoxicity,0
1156,732,APR_Hepat_CellLoss_24hr_up,1,1,NULL,viability,log2_fold_induction,positive,0,NA,gain,cellular,cellular,"cell cycle",proliferation,0
1157,733,APR_Hepat_DNADamage_24hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,cellular,cellular,"cell morphology","dna conformation",0
1158,733,APR_Hepat_DNADamage_24hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,cellular,cellular,"cell morphology","dna conformation",0
1159,734,APR_Hepat_DNATexture_24hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,dna,dna-unspecified,"cell morphology","dna conformation",0
1160,734,APR_Hepat_DNATexture_24hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,dna,dna-unspecified,"cell morphology","dna conformation",0
1161,735,APR_Hepat_LysosomalMass_24hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,cellular,lysosome,"cell morphology","organelle conformation",0
1162,735,APR_Hepat_LysosomalMass_24hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,cellular,lysosome,"cell morphology","organelle conformation",0
1163,736,APR_Hepat_MitoFxnI_24hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,cellular,mitochondria,"cell morphology","organelle conformation",0
1164,736,APR_Hepat_MitoFxnI_24hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,cellular,mitochondria,"cell morphology","organelle conformation",0
1165,737,APR_Hepat_NuclearSize_24hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,cellular,nucleus,"cell morphology","organelle conformation",0
1166,737,APR_Hepat_NuclearSize_24hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,cellular,nucleus,"cell morphology","organelle conformation",0
1167,738,APR_Hepat_Steatosis_24hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,pathway,pathway-specified,"cell morphology","cell conformation",0
1168,738,APR_Hepat_Steatosis_24hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,pathway,pathway-specified,"cell morphology","cell conformation",0
1169,739,APR_Hepat_Apoptosis_48hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,pathway,pathway-specified,"cell cycle",proliferation,0
1170,739,APR_Hepat_Apoptosis_48hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,pathway,pathway-specified,"cell morphology","cell conformation",0
1171,740,APR_Hepat_CellLoss_48hr_dn,1,1,NULL,viability,log2_fold_induction,negative,0,NA,loss,cellular,cellular,"cell cycle",cytotoxicity,0
1172,740,APR_Hepat_CellLoss_48hr_up,1,1,NULL,viability,log2_fold_induction,positive,0,NA,gain,cellular,cellular,"cell cycle",proliferation,0
1173,741,APR_Hepat_DNADamage_48hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,cellular,cellular,"cell morphology","dna conformation",0
1174,741,APR_Hepat_DNADamage_48hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,cellular,cellular,"cell morphology","dna conformation",0
1175,742,APR_Hepat_DNATexture_48hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,dna,dna-unspecified,"cell morphology","dna conformation",0
1176,742,APR_Hepat_DNATexture_48hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,dna,dna-unspecified,"cell morphology","dna conformation",0
1177,743,APR_Hepat_LysosomalMass_48hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,cellular,lysosome,"cell morphology","organelle conformation",0
1178,743,APR_Hepat_LysosomalMass_48hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,cellular,lysosome,"cell morphology","organelle conformation",0
1179,744,APR_Hepat_MitoFxnI_48hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,cellular,mitochondria,"cell morphology","organelle conformation",0
1180,744,APR_Hepat_MitoFxnI_48hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,cellular,mitochondria,"cell morphology","organelle conformation",0
1181,745,APR_Hepat_NuclearSize_48hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,cellular,nucleus,"cell morphology","organelle conformation",0
1182,745,APR_Hepat_NuclearSize_48hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,cellular,nucleus,"cell morphology","organelle conformation",0
1183,746,APR_Hepat_Steatosis_48hr_dn,1,1,NULL,signaling,log2_fold_induction,negative,0,NA,loss,pathway,pathway-specified,"cell morphology","cell conformation",0
1184,746,APR_Hepat_Steatosis_48hr_up,1,1,NULL,signaling,log2_fold_induction,positive,0,NA,gain,pathway,pathway-specified,"cell morphology","cell conformation",0
1185,747,TOX21_ARE_BLA_agonist_viability,1,1,"Data from the assay component Tox21_ARE_BLA_agonist_viability was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_ARE_BLA_agonist_viability, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of ATP for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,0,"tetraoctylammonium bromide",loss,cellular,cellular,"cell cycle",cytotoxicity,0
1186,748,TOX21_HSE_BLA_agonist_viability,1,1,"Data from the assay component Tox21_HSE_BLA_agonist_viability was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_HSE_BLA_agonist_viability, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of ATP for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,1,"tetraoctylammonium bromide",loss,cellular,cellular,"cell cycle",cytotoxicity,0
1187,749,TOX21_p53_BLA_p1_viability,1,1,"Data from the assay component Tox21_p53_BLA_p1_viability was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_p53_BLA_p1_viability, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of ATP for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,1,"tetraoctylammonium bromide",loss,cellular,cellular,"cell cycle",cytotoxicity,0
1188,750,TOX21_FXR_BLA_agonist_viability,1,1,"Data from the assay component Tox21_FXR_BLA_agonist_viability was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_FXR_BLA_agonist_viability, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of ATP for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,1,"tetraoctylammonium bromide",loss,cellular,cellular,"cell cycle",cytotoxicity,0
1189,751,TOX21_ERa_BLA_Antagonist_ch1,1,1,NULL,"background control",percent_activity,positive,0,4-hydroxytamoxifen,loss,pathway,pathway-specified,"background measurement","baseline control",0
1190,752,TOX21_ERa_BLA_Antagonist_ch2,1,1,NULL,"background control",percent_activity,positive,0,4-hydroxytamoxifen,gain,pathway,pathway-specified,"background measurement","baseline control",0
1191,753,TOX21_FXR_BLA_Antagonist_ch1,1,1,NULL,"background control",percent_activity,positive,0,Guggulsterone,loss,pathway,pathway-specified,"background measurement","baseline control",0
1192,754,TOX21_FXR_BLA_Antagonist_ch2,1,1,NULL,"background control",percent_activity,positive,0,Guggulsterone,gain,pathway,pathway-specified,"background measurement","baseline control",0
1193,755,TOX21_GR_BLA_Antagonist_ch1,1,1,NULL,"background control",percent_activity,positive,0,Mifeprostone,loss,pathway,pathway-specified,"background measurement","baseline control",0
1194,756,TOX21_GR_BLA_Antagonist_ch2,1,1,NULL,"background control",percent_activity,positive,0,Mifeprostone,gain,pathway,pathway-specified,"background measurement","baseline control",0
1195,757,TOX21_PPARd_BLA_Agonist_viability,1,1,"Data from the assay component Tox21_PPARd_BLA_Agonist_viability was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_PPARd_BLA_Agonist_viability, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of ATP for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,1,"tetraoctylammonium bromide",loss,cellular,cellular,"cell cycle",cytotoxicity,0
1196,758,TOX21_PPARd_BLA_Antagonist_ch1,1,1,NULL,"background control",percent_activity,positive,0,"L-165,041",loss,pathway,pathway-specified,"background measurement","baseline control",0
1197,759,TOX21_PPARd_BLA_Antagonist_ch2,1,1,NULL,"background control",percent_activity,positive,0,"L-165,041",gain,pathway,pathway-specified,"background measurement","baseline control",0
1198,760,TOX21_PPARg_BLA_Antagonist_ch1,1,1,NULL,"background control",percent_activity,positive,0,GW9662,loss,pathway,pathway-specified,"background measurement","baseline control",0
1199,761,TOX21_PPARg_BLA_Antagonist_ch2,1,1,NULL,"background control",percent_activity,positive,0,GW9662,gain,pathway,pathway-specified,"background measurement","baseline control",0
1200,762,TOX21_VDR_BLA_Antagonist_ch1,1,1,NULL,"background control",percent_activity,positive,0,NA,loss,pathway,pathway-specified,"background measurement","baseline control",0
1201,763,TOX21_VDR_BLA_Antagonist_ch2,1,1,NULL,"background control",percent_activity,positive,0,NA,gain,pathway,pathway-specified,"background measurement","baseline control",0
1202,764,TOX21_AR_BLA_Antagonist_ch1,1,1,NULL,"background control",percent_activity,positive,0,"Cyproterone acetate",loss,pathway,pathway-specified,"background measurement","baseline control",0
1203,765,TOX21_AR_BLA_Antagonist_ch2,1,1,NULL,"background control",percent_activity,positive,0,"Cyproterone acetate",gain,pathway,pathway-specified,"background measurement","baseline control",0
1204,766,ATG_XTT_Cytotoxicity_up,1,1,"Data from the assay component ATG_XTT_Cytotoxicity was analyzed into 1 assay endpoint. This assay endpoint, ATG_XTT_Cytotoxicity_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,0,NA,loss,cellular,cellular,"cell cycle",cytotoxicity,0
1315,890,TOX21_p53_BLA_p2_ch1,1,1,NULL,"background control",percent_activity,positive,0,"Mitomycin C;Nutlin3",loss,pathway,pathway-specified,"background measurement","baseline control",0
1316,891,TOX21_p53_BLA_p2_ch2,1,1,NULL,"background control",percent_activity,positive,0,"Mitomycin C;Nutlin3",gain,pathway,pathway-specified,"background measurement","baseline control",0
1317,892,TOX21_p53_BLA_p2_ratio,1,1,"Data from the assay component Tox21_p53_BLA_p2_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_p53_BLA_p2_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'tumor suppressor'.","reporter gene",percent_activity,positive,0,"Mitomycin C;Nutlin3",gain,pathway,pathway-specified,"dna binding","tumor suppressor",0
1318,893,TOX21_p53_BLA_p2_viability,1,1,"Data from the assay component Tox21_p53_BLA_p2_viability was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_p53_BLA_p2_viability, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of ATP for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,1,"tetraoctylammonium bromide",loss,cellular,cellular,"cell cycle",cytotoxicity,0
1319,894,TOX21_p53_BLA_p3_ch1,1,1,NULL,"background control",percent_activity,positive,0,"Mitomycin C;Nutlin3",loss,pathway,pathway-specified,"background measurement","baseline control",0
1320,895,TOX21_p53_BLA_p3_ch2,1,1,NULL,"background control",percent_activity,positive,0,"Mitomycin C;Nutlin3",gain,pathway,pathway-specified,"background measurement","baseline control",0
1321,896,TOX21_p53_BLA_p3_ratio,1,1,"Data from the assay component Tox21_p53_BLA_p3_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_p53_BLA_p3_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'tumor suppressor'.","reporter gene",percent_activity,positive,0,"Mitomycin C;Nutlin3",gain,pathway,pathway-specified,"dna binding","tumor suppressor",0
1322,897,TOX21_p53_BLA_p3_viability,1,1,"Data from the assay component Tox21_p53_BLA_p3_viability was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_p53_BLA_p3_viability, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of ATP for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,1,"tetraoctylammonium bromide",loss,cellular,cellular,"cell cycle",cytotoxicity,0
1323,898,TOX21_p53_BLA_p4_ch1,1,1,NULL,"background control",percent_activity,positive,0,"Mitomycin C;Nutlin3",loss,pathway,pathway-specified,"background measurement","baseline control",0
1324,899,TOX21_p53_BLA_p4_ch2,1,1,NULL,"background control",percent_activity,positive,0,"Mitomycin C;Nutlin3",gain,pathway,pathway-specified,"background measurement","baseline control",0
1325,900,TOX21_p53_BLA_p4_ratio,1,1,"Data from the assay component Tox21_p53_BLA_p4_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_p53_BLA_p4_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'tumor suppressor'.","reporter gene",percent_activity,positive,0,"Mitomycin C;Nutlin3",gain,pathway,pathway-specified,"dna binding","tumor suppressor",0
1326,901,TOX21_p53_BLA_p4_viability,1,1,"Data from the assay component Tox21_p53_BLA_p4_viability was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_p53_BLA_p4_viability, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of ATP for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,1,"tetraoctylammonium bromide",loss,cellular,cellular,"cell cycle",cytotoxicity,0
1327,902,TOX21_p53_BLA_p5_ch1,1,1,NULL,"background control",percent_activity,positive,0,"Mitomycin C;Nutlin3",loss,pathway,pathway-specified,"background measurement","baseline control",0
1328,903,TOX21_p53_BLA_p5_ch2,1,1,NULL,"background control",percent_activity,positive,0,"Mitomycin C;Nutlin3",gain,pathway,pathway-specified,"background measurement","baseline control",0
1329,904,TOX21_p53_BLA_p5_ratio,1,1,"Data from the assay component Tox21_p53_BLA_p5_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_p53_BLA_p5_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'tumor suppressor'.","reporter gene",percent_activity,positive,0,"Mitomycin C;Nutlin3",gain,pathway,pathway-specified,"dna binding","tumor suppressor",0
1330,905,TOX21_p53_BLA_p5_viability,1,1,"Data from the assay component Tox21_p53_BLA_p5_viability was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_p53_BLA_p5_viability, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of ATP for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,1,"tetraoctylammonium bromide",loss,cellular,cellular,"cell cycle",cytotoxicity,0
1331,906,TOX21_VDR_BLA_Agonist_viability,1,1,"Data from the assay component Tox21_VDR_BLA_Agonist_viability was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_VDR_BLA_Agonist_viability, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of ATP for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,1,"tetraoctylammonium bromide",loss,cellular,cellular,"cell cycle",cytotoxicity,0
1340,907,TOX21_ESRE_BLA_ch1,1,1,NULL,"background control",percent_activity,positive,0,17-AAG,loss,pathway,pathway-specified,"background measurement","baseline control",0
1341,908,TOX21_ESRE_BLA_ch2,1,1,NULL,"background control",percent_activity,positive,0,17-AAG,gain,pathway,pathway-specified,"background measurement","baseline control",0
1342,909,TOX21_ESRE_BLA_ratio,1,1,"Data from the assay component Tox21_ESRE_BLA_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_ESRE_BLA_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ATF6. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'basic leucine zipper'.","reporter gene",percent_activity,positive,0,17-AAG,gain,pathway,pathway-specified,"dna binding","basic leucine zipper",0
1343,910,TOX21_ESRE_BLA_viability,1,1,"Data from the assay component Tox21_ESRE_BLA_viability was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_ESRE_BLA_viability, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of ATP for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,1,"tetraoctylammonium bromide",loss,cellular,cellular,"cell cycle",cytotoxicity,0
1344,911,TOX21_NFkB_BLA_agonist_ch1,1,1,NULL,"background control",percent_activity,positive,0,TNFa,loss,pathway,pathway-specified,"background measurement","baseline control",0
1345,912,TOX21_NFkB_BLA_agonist_ch2,1,1,NULL,"background control",percent_activity,positive,0,TNFa,gain,pathway,pathway-specified,"background measurement","baseline control",0
1346,913,TOX21_NFkB_BLA_agonist_ratio,1,1,"Data from the assay component Tox21_NFkB_BLA_agonist_ratio was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_NFkB_BLA_agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NFKB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dna binding' intended target family, where the subfamily is 'NF-kappa B'.","reporter gene",percent_activity,positive,0,TNFa,gain,pathway,pathway-specified,"dna binding","NF-kappa B",0
1347,914,TOX21_NFkB_BLA_agonist_viability,1,1,"Data from the assay component Tox21_NFkB_BLA_agonist_viability was analyzed into 1 assay endpoint. 
This assay endpoint, Tox21_NFkB_BLA_agonist_viability, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of ATP for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell cycle' intended target family, where the subfamily is 'cytotoxicity'.",viability,percent_activity,positive,1,"tetraoctylammonium bromide",loss,cellular,cellular,"cell cycle",cytotoxicity,0
1348,915,ATG_NUR77_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
1349,916,ATG_GCNF_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
1350,917,ATG_COUP_TF2_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
1351,918,ATG_PNR_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
1352,919,ATG_LRH1_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
1353,920,ATG_Rev_ERB_A_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
1354,921,ATG_HNF4g_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
1355,922,ATG_ERRb_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",steroidal,0
1356,923,ATG_MR_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",steroidal,0
1357,924,ATG_COUP_TF1_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
1358,925,ATG_NOR1_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
1359,926,ATG_TR4_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
1360,927,ATG_DAX1_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
1361,928,ATG_Rev_ERB_B_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
1362,929,ATG_RORa_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
1363,930,ATG_PR_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",steroidal,0
1364,931,ATG_RXRg_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
1365,932,ATG_SF_1_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
1366,933,ATG_SHP_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
1367,934,ATG_ERb_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",steroidal,0
1368,935,ATG_TLX_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
1369,936,ATG_THRb_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",non-steroidal,0
1370,937,ATG_EAR2_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
1371,938,ATG_TR2_TRANS2_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,protein,"transcription factor","nuclear receptor",orphan,0
1372,939,Tanguay_ZF_120hpf_MORT_up,1,1,NULL,"developmental defect",percent_activity,positive,0,NA,gain,limb,malformation,NULL,NULL,0
1373,940,Tanguay_ZF_120hpf_YSE_up,1,1,NULL,"developmental defect",percent_activity,positive,0,NA,gain,organ,malformation,NULL,NULL,0
1374,941,Tanguay_ZF_120hpf_AXIS_up,1,1,NULL,"developmental defect",percent_activity,positive,0,NA,gain,limb,malformation,NULL,NULL,0
1375,942,Tanguay_ZF_120hpf_EYE_up,1,1,NULL,"developmental defect",percent_activity,positive,0,NA,gain,limb,malformation,NULL,NULL,0
1376,943,Tanguay_ZF_120hpf_SNOU_up,1,1,NULL,"developmental defect",percent_activity,positive,0,NA,gain,limb,malformation,NULL,NULL,0
1377,944,Tanguay_ZF_120hpf_JAW_up,1,1,NULL,"developmental defect",percent_activity,positive,0,NA,gain,limb,malformation,NULL,NULL,0
1378,945,Tanguay_ZF_120hpf_OTIC_up,1,1,NULL,"developmental defect",percent_activity,positive,0,NA,gain,limb,malformation,NULL,NULL,0
1379,946,Tanguay_ZF_120hpf_PE_up,1,1,NULL,"developmental defect",percent_activity,positive,0,NA,gain,limb,malformation,NULL,NULL,0
1380,947,Tanguay_ZF_120hpf_BRAI_up,1,1,NULL,"developmental defect",percent_activity,positive,0,NA,gain,limb,malformation,NULL,NULL,0
1381,948,Tanguay_ZF_120hpf_SOMI_up,1,1,NULL,"developmental defect",percent_activity,positive,0,NA,gain,limb,malformation,NULL,NULL,0
1382,949,Tanguay_ZF_120hpf_PFIN_up,1,1,NULL,"developmental defect",percent_activity,positive,0,NA,gain,limb,malformation,NULL,NULL,0
1383,950,Tanguay_ZF_120hpf_CFIN_up,1,1,NULL,"developmental defect",percent_activity,positive,0,NA,gain,limb,malformation,NULL,NULL,0
1384,951,Tanguay_ZF_120hpf_PIG_up,1,1,NULL,"developmental defect",percent_activity,positive,0,NA,gain,limb,malformation,NULL,NULL,0
1385,952,Tanguay_ZF_120hpf_CIRC_up,1,1,NULL,"developmental defect",percent_activity,positive,0,NA,gain,limb,malformation,NULL,NULL,0
1386,953,Tanguay_ZF_120hpf_TRUN_up,1,1,NULL,"developmental defect",percent_activity,positive,0,NA,gain,limb,malformation,NULL,NULL,0
1387,954,Tanguay_ZF_120hpf_SWIM_up,1,1,NULL,"developmental defect",percent_activity,positive,0,NA,gain,limb,malformation,NULL,NULL,0
1388,955,Tanguay_ZF_120hpf_NC_up,1,1,NULL,"developmental defect",percent_activity,positive,0,NA,gain,limb,malformation,NULL,NULL,0
1389,956,Tanguay_ZF_120hpf_TR_up,1,1,NULL,"developmental defect",percent_activity,positive,0,NA,gain,limb,malformation,NULL,NULL,0
1400,32,ATG_Ahr_CIS_dn,1,1,"ATG_Ahr_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,"6-formylindolo carbazole",loss,protein,"transcription factor","dna binding","basic helix-loop-helix protein",0
1401,33,ATG_AP_1_CIS_dn,1,1,"ATG_AP_1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,4-Hydroxynonenal,loss,protein,"transcription factor","dna binding","basic leucine zipper",0
1402,34,ATG_AP_2_CIS_dn,1,1,"ATG_AP_2_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","basic helix-turn-helix leucine zipper",0
1403,84,ATG_AR_TRANS_dn,1,1,"ATG_AR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",steroidal,0
1404,35,ATG_BRE_CIS_dn,1,1,"ATG_BRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","Smad protein",0
1405,85,ATG_CAR_TRANS_dn,1,1,"ATG_CAR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1406,37,ATG_CMV_CIS_dn,1,1,"ATG_CMV_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","background control",log2_fold_induction,negative,0,4-Hydroxynonenal,loss,protein,"transcription factor","background measurement","internal marker",0
1407,924,ATG_COUP_TF1_TRANS2_dn,1,1,"ATG_COUP_TF1_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1408,917,ATG_COUP_TF2_TRANS2_dn,1,1,"ATG_COUP_TF2_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1409,38,ATG_CRE_CIS_dn,1,1,"ATG_CRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,Forskolin,loss,protein,"transcription factor","dna binding","basic leucine zipper",0
1410,36,ATG_C_EBP_CIS_dn,1,1,"ATG_C_EBP_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","basic leucine zipper",0
1411,927,ATG_DAX1_TRANS2_dn,1,1,"ATG_DAX1_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1412,39,ATG_DR4_LXR_CIS_dn,1,1,"ATG_DR4_LXR_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1413,40,ATG_DR5_CIS_dn,1,1,"ATG_DR5_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,"9-cis-Retinoic Acid",loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1414,42,ATG_E2F_CIS_dn,1,1,"ATG_E2F_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","E2F transcription factor",0
1415,937,ATG_EAR2_TRANS2_dn,1,1,"ATG_EAR2_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1416,43,ATG_EGR_CIS_dn,1,1,"ATG_EGR_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","zinc finger",0
1417,86,ATG_ERa_TRANS_dn,1,1,"ATG_ERa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,17b-estradiol,loss,protein,"transcription factor","nuclear receptor",steroidal,0
1418,934,ATG_ERb_TRANS2_dn,1,1,"ATG_ERb_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",steroidal,0
1419,44,ATG_ERE_CIS_dn,1,1,"ATG_ERE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,17b-estradiol,loss,protein,"transcription factor","nuclear receptor",steroidal,0
1420,87,ATG_ERRa_TRANS_dn,1,1,"ATG_ERRa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",steroidal,0
1421,922,ATG_ERRb_TRANS2_dn,1,1,"ATG_ERRb_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",steroidal,0
1422,88,ATG_ERRg_TRANS_dn,1,1,"ATG_ERRg_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",steroidal,0
1423,45,ATG_Ets_CIS_dn,1,1,"ATG_Ets_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,4-Hydroxynonenal,loss,protein,"transcription factor","dna binding","winged helix-turn-helix",0
1424,41,ATG_E_Box_CIS_dn,1,1,"ATG_E_Box_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,4-Hydroxynonenal,loss,protein,"transcription factor","dna binding","basic helix-loop-helix protein",0
1425,46,ATG_FoxA2_CIS_dn,1,1,"ATG_FoxA2_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","forkhead box protein",0
1426,47,ATG_FoxO_CIS_dn,1,1,"ATG_FoxO_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","forkhead box protein",0
1427,89,ATG_FXR_TRANS_dn,1,1,"ATG_FXR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,CDCA,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1428,90,ATG_GAL4_TRANS_dn,1,1,"ATG_GAL4_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","background control",log2_fold_induction,negative,0,4-Hydroxynonenal,loss,protein,"transcription factor","background measurement","baseline control",0
1429,48,ATG_GATA_CIS_dn,1,1,"ATG_GATA_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","GATA proteins",0
1430,916,ATG_GCNF_TRANS2_dn,1,1,"ATG_GCNF_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1431,49,ATG_GLI_CIS_dn,1,1,"ATG_GLI_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,4-Hydroxynonenal,loss,protein,"transcription factor","dna binding","zinc finger",0
1432,50,ATG_GRE_CIS_dn,1,1,"ATG_GRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,Dexamethasone,loss,protein,"transcription factor","nuclear receptor",steroidal,0
1433,91,ATG_GR_TRANS_dn,1,1,"ATG_GR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",steroidal,0
1434,51,ATG_HIF1a_CIS_dn,1,1,"ATG_HIF1a_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","basic helix-loop-helix protein",0
1435,92,ATG_HNF4a_TRANS_dn,1,1,"ATG_HNF4a_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1436,921,ATG_HNF4g_TRANS2_dn,1,1,"ATG_HNF4g_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1437,52,ATG_HNF6_CIS_dn,1,1,"ATG_HNF6_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","homeobox protein",0
1438,93,ATG_Hpa5_TRANS_dn,1,1,"ATG_Hpa5_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","background control",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","background measurement","internal marker",0
1439,53,ATG_HSE_CIS_dn,1,1,"ATG_HSE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,4-Hydroxynonenal,loss,protein,"transcription factor","dna binding","heat shock protein",0
1440,54,ATG_IR1_CIS_dn,1,1,"ATG_IR1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1441,55,ATG_ISRE_CIS_dn,1,1,"ATG_ISRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","interferon regulatory factors",0
1442,919,ATG_LRH1_TRANS2_dn,1,1,"ATG_LRH1_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1443,94,ATG_LXRa_TRANS_dn,1,1,"ATG_LXRa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,T9,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1444,95,ATG_LXRb_TRANS_dn,1,1,"ATG_LXRb_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,T9;4-Hydroxynonenal,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1445,60,ATG_MRE_CIS_dn,1,1,"ATG_MRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","zinc finger",0
1446,923,ATG_MR_TRANS2_dn,1,1,"ATG_MR_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",steroidal,0
1447,61,ATG_Myb_CIS_dn,1,1,"ATG_Myb_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,4-Hydroxynonenal,loss,protein,"transcription factor","dna binding","MYB proteins",0
1448,62,ATG_Myc_CIS_dn,1,1,"ATG_Myc_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","basic helix-loop-helix leucine zipper",0
1449,56,ATG_M_06_CIS_dn,1,1,"ATG_M_06_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","background control",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","background measurement","internal marker",0
1450,96,ATG_M_06_TRANS_dn,1,1,"ATG_M_06_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","background control",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","background measurement","internal marker",0
1451,57,ATG_M_19_CIS_dn,1,1,"ATG_M_19_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","background control",log2_fold_induction,negative,0,4-Hydroxynonenal,loss,protein,"transcription factor","background measurement","internal marker",0
1452,97,ATG_M_19_TRANS_dn,1,1,"ATG_M_19_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","background control",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","background measurement","internal marker",0
1453,58,ATG_M_32_CIS_dn,1,1,"ATG_M_32_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","background control",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","background measurement","internal marker",0
1454,98,ATG_M_32_TRANS_dn,1,1,"ATG_M_32_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","background control",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","background measurement","internal marker",0
1455,59,ATG_M_61_CIS_dn,1,1,"ATG_M_61_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","background control",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","background measurement","internal marker",0
1456,99,ATG_M_61_TRANS_dn,1,1,"ATG_M_61_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","background control",log2_fold_induction,negative,0,4-Hydroxynonenal,loss,protein,"transcription factor","background measurement","internal marker",0
1457,64,ATG_NFI_CIS_dn,1,1,"ATG_NFI_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","nuclear factor I",0
1458,63,ATG_NF_kB_CIS_dn,1,1,"ATG_NF_kB_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","NF-kappa B",0
1459,925,ATG_NOR1_TRANS2_dn,1,1,"ATG_NOR1_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1460,65,ATG_NRF1_CIS_dn,1,1,"ATG_NRF1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","nuclear respiratory factors",0
1461,66,ATG_NRF2_ARE_CIS_dn,1,1,"ATG_NRF2_ARE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,4-Hydroxynonenal,loss,protein,"transcription factor","dna binding","basic leucine zipper",0
1462,915,ATG_NUR77_TRANS2_dn,1,1,"ATG_NUR77_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1463,100,ATG_NURR1_TRANS_dn,1,1,"ATG_NURR1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1464,67,ATG_Oct_MLP_CIS_dn,1,1,"ATG_Oct_MLP_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","POU domain protein",0
1465,68,ATG_p53_CIS_dn,1,1,"ATG_p53_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","tumor suppressor",0
1466,69,ATG_Pax6_CIS_dn,1,1,"ATG_Pax6_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","paired box protein",0
1467,70,ATG_PBREM_CIS_dn,1,1,"ATG_PBREM_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,4-Hydroxynonenal,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1468,918,ATG_PNR_TRANS2_dn,1,1,"ATG_PNR_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1469,101,ATG_PPARa_TRANS_dn,1,1,"ATG_PPARa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,GW7647,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1470,102,ATG_PPARd_TRANS_dn,1,1,"ATG_PPARd_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,GW7647,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1471,103,ATG_PPARg_TRANS_dn,1,1,"ATG_PPARg_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,GW7647,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1472,71,ATG_PPRE_CIS_dn,1,1,"ATG_PPRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,Rosiglitazone,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1473,930,ATG_PR_TRANS2_dn,1,1,"ATG_PR_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",steroidal,0
1474,72,ATG_PXRE_CIS_dn,1,1,"ATG_PXRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,Rifampicin,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1475,104,ATG_PXR_TRANS_dn,1,1,"ATG_PXR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,4-Hydroxynonenal,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1476,105,ATG_RARa_TRANS_dn,1,1,"ATG_RARa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1477,106,ATG_RARb_TRANS_dn,1,1,"ATG_RARb_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1478,107,ATG_RARg_TRANS_dn,1,1,"ATG_RARg_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1479,920,ATG_Rev_ERB_A_TRANS2_dn,1,1,"ATG_Rev_ERB_A_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1480,928,ATG_Rev_ERB_B_TRANS2_dn,1,1,"ATG_Rev_ERB_B_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1481,929,ATG_RORa_TRANS2_dn,1,1,"ATG_RORa_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1482,108,ATG_RORb_TRANS_dn,1,1,"ATG_RORb_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,4-Hydroxynonenal,loss,protein,"transcription factor","nuclear receptor",orphan,0
1483,73,ATG_RORE_CIS_dn,1,1,"ATG_RORE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1484,109,ATG_RORg_TRANS_dn,1,1,"ATG_RORg_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1485,110,ATG_RXRa_TRANS_dn,1,1,"ATG_RXRa_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1486,111,ATG_RXRb_TRANS_dn,1,1,"ATG_RXRb_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1487,931,ATG_RXRg_TRANS2_dn,1,1,"ATG_RXRg_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1488,932,ATG_SF_1_TRANS2_dn,1,1,"ATG_SF_1_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1489,933,ATG_SHP_TRANS2_dn,1,1,"ATG_SHP_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1490,74,ATG_Sox_CIS_dn,1,1,"ATG_Sox_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,4-Hydroxynonenal,loss,protein,"transcription factor","dna binding","HMG box protein",0
1491,75,ATG_Sp1_CIS_dn,1,1,"ATG_Sp1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","zinc finger",0
1492,76,ATG_SREBP_CIS_dn,1,1,"ATG_SREBP_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","basic helix-loop-helix leucine zipper",0
1493,77,ATG_STAT3_CIS_dn,1,1,"ATG_STAT3_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","stat protein",0
1494,79,ATG_TAL_CIS_dn,1,1,"ATG_TAL_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","background control",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","background measurement","internal marker",0
1495,78,ATG_TA_CIS_dn,1,1,"ATG_TA_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","background control",log2_fold_induction,negative,0,4-Hydroxynonenal,loss,protein,"transcription factor","background measurement","internal marker",0
1496,80,ATG_TCF_b_cat_CIS_dn,1,1,"ATG_TCF_b_cat_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","HMG box protein",0
1497,81,ATG_TGFb_CIS_dn,1,1,"ATG_TGFb_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","growth factor","transforming growth factor beta",0
1498,112,ATG_THRa1_TRANS_dn,1,1,"ATG_THRa1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,4-Hydroxynonenal,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1499,936,ATG_THRb_TRANS2_dn,1,1,"ATG_THRb_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1500,935,ATG_TLX_TRANS2_dn,1,1,"ATG_TLX_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1501,938,ATG_TR2_TRANS2_dn,1,1,"ATG_TR2_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1502,926,ATG_TR4_TRANS2_dn,1,1,"ATG_TR4_TRANS2_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",orphan,0
1503,82,ATG_VDRE_CIS_dn,1,1,"ATG_VDRE_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,4-Hydroxynonenal,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1504,113,ATG_VDR_TRANS_dn,1,1,"ATG_VDR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","nuclear receptor",non-steroidal,0
1505,83,ATG_Xbp1_CIS_dn,1,1,"ATG_Xbp1_CIS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NA,loss,protein,"transcription factor","dna binding","basic leucine zipper",0
1507,962,NHEERL_ZF_144hpf_TERATOSCORE_up,1,1,NULL,"developmental defect",percent_activity,positive,0,NA,gain,NULL,NULL,NULL,NULL,0
1508,963,NCCT_TPO_AUR_dn,1,1,NULL,binding,percent_activity,positive,0,"methimazole (MMI)",loss,protein,enzyme,oxidoreductase,peroxidase,0
1509,964,NCCT_HEK293T_CellTiterGLO,1,1,NULL,viability,percent_activity,positive,0,LUCINH1;LUCINH2,loss,cellular,cellular,"cell cycle",cytotoxicity,0
1510,965,NCCT_QuantiLum_inhib_dn,1,1,NULL,binding,percent_activity,positive,0,b-naphthoquinone,loss,protein,enzyme,oxidoreductase,monooxygenase,0
1611,838,CLD_ABCB1_6hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transporter,"ABC transporter",0
1612,839,CLD_ABCB11_6hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transporter,"ABC transporter",0
1613,840,CLD_ABCG2_6hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transporter,"ABC transporter",0
1614,841,CLD_ACTIN_6hr,1,1,NULL,"background control",log2_fold_induction,positive,0,NA,gain,rna,mRNA,"background measurement","baseline control",0
1615,842,CLD_CYP1A1_6hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,cyp,"xenobiotic metabolism",0
1616,843,CLD_CYP1A2_6hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,cyp,"xenobiotic metabolism",0
1617,844,CLD_CYP2B6_6hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,cyp,"xenobiotic metabolism",0
1618,845,CLD_CYP2C19_6hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,cyp,"xenobiotic metabolism",0
1619,846,CLD_CYP2C9_6hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,cyp,"xenobiotic metabolism",0
1620,847,CLD_CYP3A4_6hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,cyp,"xenobiotic metabolism",0
1621,848,CLD_GAPDH_6hr,1,1,NULL,"background control",log2_fold_induction,positive,0,NA,gain,rna,mRNA,"background measurement","baseline control",0
1622,849,CLD_GSTA2_6hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transferase,"alkyl and aryl transferase",0
1623,850,CLD_HMGCS2_6hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,lyase,"HMG-CoA synthase",0
1624,851,CLD_SLCO1B1_6hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transporter,"organic anion transporter",0
1625,852,CLD_SULT2A_6hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transferase,sulfotransferase,0
1626,853,CLD_UGT1A1_6hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transferase,glucuronosyltransferase,0
1627,854,CLD_ABCB1_24hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transporter,"ABC transporter",0
1628,855,CLD_ABCB11_24hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transporter,"ABC transporter",0
1629,856,CLD_ABCG2_24hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transporter,"ABC transporter",0
1630,857,CLD_ACTIN_24hr,1,1,NULL,"background control",log2_fold_induction,positive,0,NA,gain,rna,mRNA,"background measurement","baseline control",0
1631,858,CLD_CYP1A1_24hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,cyp,"xenobiotic metabolism",0
1632,859,CLD_CYP1A2_24hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,cyp,"xenobiotic metabolism",0
1633,860,CLD_CYP2B6_24hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,cyp,"xenobiotic metabolism",0
1634,861,CLD_CYP2C19_24hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,cyp,"xenobiotic metabolism",0
1635,862,CLD_CYP2C9_24hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,cyp,"xenobiotic metabolism",0
1636,863,CLD_CYP3A4_24hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,cyp,"xenobiotic metabolism",0
1637,864,CLD_GAPDH_24hr,1,1,NULL,"background control",log2_fold_induction,positive,0,NA,gain,rna,mRNA,"background measurement","baseline control",0
1638,865,CLD_GSTA2_24hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transferase,"alkyl and aryl transferase",0
1639,866,CLD_HMGCS2_24hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,lyase,"HMG-CoA synthase",0
1640,867,CLD_SLCO1B1_24hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transporter,"organic anion transporter",0
1641,868,CLD_SULT2A_24hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transferase,sulfotransferase,0
1642,869,CLD_UGT1A1_24hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transferase,glucuronosyltransferase,0
1643,870,CLD_ABCB1_48hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transporter,"ABC transporter",0
1644,871,CLD_ABCB11_48hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transporter,"ABC transporter",0
1645,872,CLD_ABCG2_48hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transporter,"ABC transporter",0
1646,873,CLD_ACTIN_48hr,1,1,NULL,"background control",log2_fold_induction,positive,0,NA,gain,rna,mRNA,"background measurement","baseline control",0
1647,874,CLD_CYP1A1_48hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,cyp,"xenobiotic metabolism",0
1648,875,CLD_CYP1A2_48hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,cyp,"xenobiotic metabolism",0
1649,876,CLD_CYP2B6_48hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,cyp,"xenobiotic metabolism",0
1650,877,CLD_CYP2C19_48hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,cyp,"xenobiotic metabolism",0
1651,878,CLD_CYP2C9_48hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,cyp,"xenobiotic metabolism",0
1652,879,CLD_CYP3A4_48hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,cyp,"xenobiotic metabolism",0
1653,880,CLD_GAPDH_48hr,1,1,NULL,"background control",log2_fold_induction,positive,0,NA,gain,rna,mRNA,"background measurement","baseline control",0
1654,881,CLD_GSTA2_48hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transferase,"alkyl and aryl transferase",0
1655,882,CLD_HMGCS2_48hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,lyase,"HMG-CoA synthase",0
1656,883,CLD_SLCO1B1_48hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transporter,"organic anion transporter",0
1657,884,CLD_SULT2A_48hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transferase,sulfotransferase,0
1658,885,CLD_UGT1A1_48hr,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NA,gain,rna,mRNA,transferase,glucuronosyltransferase,0
1745,1035,ATG_GPCR_ADORA2A_TRANS_dn,1,1,"ATG_GPCR_ADORA2A_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1746,1035,ATG_GPCR_ADORA2A_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1747,1036,ATG_GPCR_ADORA2B_TRANS_dn,1,1,"ATG_GPCR_ADORA2B_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1748,1036,ATG_GPCR_ADORA2B_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1749,1037,ATG_GPCR_ADRA1A_TRANS_dn,1,1,"ATG_GPCR_ADRA1A_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1750,1037,ATG_GPCR_ADRA1A_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1751,1038,ATG_GPCR_ADRA2B_TRANS_dn,1,1,"ATG_GPCR_ADRA2B_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1752,1038,ATG_GPCR_ADRA2B_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1753,1039,ATG_GPCR_ADRB2_TRANS_dn,1,1,"ATG_GPCR_ADRB2_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1754,1039,ATG_GPCR_ADRB2_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1755,1040,ATG_GPCR_ADRB3_TRANS_dn,1,1,"ATG_GPCR_ADRB3_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1756,1040,ATG_GPCR_ADRB3_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1757,1041,ATG_GPCR_CHRM3_TRANS_dn,1,1,"ATG_GPCR_CHRM3_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1758,1041,ATG_GPCR_CHRM3_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1759,1042,ATG_GPCR_DRD1_TRANS_dn,1,1,"ATG_GPCR_DRD1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1760,1042,ATG_GPCR_DRD1_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1761,1043,ATG_GPCR_DRD5_TRANS_dn,1,1,"ATG_GPCR_DRD5_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1762,1043,ATG_GPCR_DRD5_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1763,1044,ATG_GPCR_EDNRA_TRANS_dn,1,1,"ATG_GPCR_EDNRA_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1764,1044,ATG_GPCR_EDNRA_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1765,1045,ATG_GPCR_GCGR_TRANS_dn,1,1,"ATG_GPCR_GCGR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1766,1045,ATG_GPCR_GCGR_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1767,1046,ATG_GPCR_GPBAR1_TRANS_dn,1,1,"ATG_GPCR_GPBAR1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1768,1046,ATG_GPCR_GPBAR1_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1769,1047,ATG_GPCR_GPR40_TRANS_dn,1,1,"ATG_GPCR_GPR40_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1770,1047,ATG_GPCR_GPR40_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1771,1048,ATG_GPCR_GQ_TRANS_dn,1,1,"ATG_GPCR_GQ_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,protein,"transcription factor","background measurement","internal marker",0
1772,1048,ATG_GPCR_GQ_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,protein,"transcription factor","background measurement","internal marker",0
1773,1049,ATG_GPCR_GS1_TRANS_dn,1,1,"ATG_GPCR_GS1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,protein,"transcription factor","background measurement","internal marker",0
1774,1049,ATG_GPCR_GS1_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,protein,"transcription factor","background measurement","internal marker",0
1775,1050,ATG_GPCR_GS_TRANS_dn,1,1,"ATG_GPCR_GS_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,protein,"transcription factor","background measurement","internal marker",0
1776,1050,ATG_GPCR_GS_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,protein,"transcription factor","background measurement","internal marker",0
1777,1051,ATG_GPCR_HRH1_TRANS_dn,1,1,"ATG_GPCR_HRH1_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,protein,"transcription factor","background measurement","internal marker",0
1778,1051,ATG_GPCR_HRH1_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1779,1052,ATG_GPCR_HTR6_TRANS_dn,1,1,"ATG_GPCR_HTR6_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1780,1052,ATG_GPCR_HTR6_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1781,1053,ATG_GPCR_HTR7_TRANS_dn,1,1,"ATG_GPCR_HTR7_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1782,1053,ATG_GPCR_HTR7_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1783,1054,ATG_GPCR_LPAR4_TRANS_dn,1,1,"ATG_GPCR_LPAR4_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1784,1054,ATG_GPCR_LPAR4_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1785,1055,ATG_GPCR_MC1R_TRANS_dn,1,1,"ATG_GPCR_MC1R_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1786,1055,ATG_GPCR_MC1R_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1787,1056,ATG_GPCR_MC2R_TRANS_dn,1,1,"ATG_GPCR_MC2R_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1788,1056,ATG_GPCR_MC2R_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1789,1057,ATG_GPCR_MC3R_TRANS_dn,1,1,"ATG_GPCR_MC3R_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1790,1057,ATG_GPCR_MC3R_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1791,1058,ATG_GPCR_MC4R_TRANS_dn,1,1,"ATG_GPCR_MC4R_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1792,1058,ATG_GPCR_MC4R_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1793,1059,ATG_GPCR_PTGDR_TRANS_dn,1,1,"ATG_GPCR_PTGDR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1794,1059,ATG_GPCR_PTGDR_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1795,1060,ATG_GPCR_PTGIR_TRANS_dn,1,1,"ATG_GPCR_PTGIR_TRANS_dn was not developed or optimized to detect loss of signal. Use data with caution.","reporter gene",log2_fold_induction,negative,0,NULL,loss,NULL,NULL,NULL,NULL,0
1796,1060,ATG_GPCR_PTGIR_TRANS_up,1,1,NULL,"reporter gene",log2_fold_induction,positive,0,NULL,gain,NULL,NULL,NULL,NULL,0
1797,1061,Tanguay_ZF_120hpf_ActivityScore,1,1,Tanguay_ZF_120hpf_ActivityScore,NULL,percent_activity,NULL,0,NULL,NULL,NULL,NULL,NULL,NULL,0
1816,1120,TOX21_AR_LUC_MDAKB2_Antagonist2,1,1,Tox21_AR_LUC_MDAKB2_Antagonist2,signaling,percent_activity,NULL,0,NULL,NULL,NULL,NULL,NULL,NULL,0
1824,1128,NCCT_TPO_GUA_dn,1,1,NULL,binding,percent_activity,positive,0,NULL,loss,protein,enzyme,oxidoreductase,peroxidase,0
1848,1146,NCCT_QuantiLum_inhib_2_dn,1,1,NULL,binding,percent_activity,positive,0,b-naphthoquinone,loss,protein,enzyme,oxidoreductase,monooxygenase,0
1854,534,TOX21_MMP_ratio_up,1,1,"Data from the assay component Tox21_MMP_ratio_up was analyzed into 2 assay endpoint. The assay endpoin, Tox21_MMP_ratio_up, was analyzed in thenegative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of membrane potential reportloss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'cell morphology' intended target family, where the subfamily is 'organelle conformation'.",signaling,percent_activity,negative,0,FCCP,gain,cellular,mitochondria,"cell morphology","organelle conformation",0
